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Abstract 
 
 
There is increasing detection of renal tumours, especially small renal masses largely due to 
widespread availability of radiological imaging modalities. However, imaging techniques and 
renal lesion biopsies cannot accurately define malignant from benign renal tumours. 
Therefore such indeterminate renal tumours undergo surgical resection. Unfortunately a 
significant proportion of resected renal tumours turn out to be benign on histopathological 
diagnosis. The impact of this scenario is the morbidities of unnecessary surgery and loss of 
valuable nephrons with the associated increased risk of chronic kidney disease and 
cardiovascular complications. Reduction of unnecessary surgeries would also translate into 
decreased costs, and allow for more efficient utilisation of health budgets. 
 
Another diagnostic dilemma faced by pathologists is the occasional difficulty in 
distinguishing some renal tumour subtypes, due to overlapping morphological and 
histological features. Differentiating malignant chromophobe renal cell carcinoma (chRCC) 
from benign renal oncocytoma (RO) is one such dilemma. Their correct diagnosis is crucial 
as prognosis, management and surveillance protocols differ between the two tumour 
subtypes. Therefore effective and reproducible immunohistochemistry (IHC) biomarkers 
need to be identified, together with novel biomarkers, through molecular profiling of these 
tumour subtypes. 
 
 In Chapter 1, the relevant background, significance of the research topic, literature review, 
hypothesis and aims of this PhD research were presented. Contents of this chapter have also 
been published as a review article. The review article provided the clinical presentation, 
ii 
 
explained the diagnostic dilemma, and described the value of current molecular markers to 
assist in differentiation between chRCC and RO.  
 
The aims of this research project were to: 1) identify a panel of IHC biomarkers which can 
effectively differentiate chRCC from RO through a comprehensive literature search and 
meta-analysis approach, as well as using some of the research results from my laboratory; 2) 
analyse the molecular profiles of renal cancers via IHC and morphometry techniques using 
selected biomarkers on renal tumour and normal renal tissue samples; 3) specifically, to 
investigate IHC biomarkers that are useful in differentiating chRCC from RO via IHC and 
morphometry; and 4) initiate and develop a comprehensive Renal Tumour Biobank (clinical 
data, urine, sera, renal tumour and normal tissue) from patients with renal tumours 
undergoing nephrectomy. 
 
In Chapter 2, the general materials and methods were presented, including the use of 
prospective RCC patient samples, IHC of archived RCC tissue blocks, morphometry and 
statistical analyses. The methodology of IHC of the biomarkers on the tissue slides and 
morphometric analyses were discussed. Prospective RCC patient samples which included 
renal tumour, normal renal tissue, sera and urine were collected, processed and stored in the 
Centre for Kidney Disease Research (CKDR) leading to the creation of the Renal Tumour 
Biobank. This work involved a significant amount of time and resources throughout the PhD 
research project, achieved Aim 4 of the thesis, and will be a legacy of this PhD research.  
 
Chapter 3 examined the existing IHC biomarkers that have been reported as useful in 
differentiating chRCC from RO. A meta-analysis and systematic review was conducted in 
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this chapter to assess the most effective IHC biomarkers, and it has been published. In 
summary, we recommended a selection from a panel of IHC biomarkers, namely, amylase 
α1A, Wnt-5a, FXYD2, ARPP, CD63, TGFβ1, CK7, S100A1, caveolin-1 and claudin-7 to aid 
in the differentiation of chRCC and RO. 
 
In Chapter 4, we investigated the molecular profiles of nuclear factor-κB (NF-κB) subunits 
in RCC disease. Our results represent the first and largest study to report on the IHC 
expression of NF-κB subunits (p65, p50, p52, cRel) and their associated prognostic cancer 
specific survival outcome in RCC patients. Although there were no associations with RCC 
subtypes, overexpression of p65 and decreased expression of other subunits were noted in 
renal tumours compared with normal renal tissue. Moreover, p65 overexpression was 
correlated to a poorer cancer survival outcome.  
 
In Chapter 5, the IHC of various established and novel biomarkers: CK7, Cav-1, S100A1, 
leptin and its receptor (Ob and ObR) and kidney injury molecule-1 (KIM-1) were 
investigated in archived renal tumour specimens and paired normal kidney. The utility of 
selected IHC biomarkers to differentiate clear cell RCC, chRCC and RO was analysed using 
morphometry. We demonstrated that chRCC had higher CK7 overall expression intensity 
compared to RO, presented the difference in Cav-1 staining patterns between the two 
subtypes, and demonstrated that higher Ob nuclear expression and higher KIM-1 overall 
expression were seen in RO compared with chRCC. 
 
In Chapter 6, the summary of major results and future directions gained from this research 
were presented. The results will spur further research into the possible diagnostic roles of 
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these biomarkers through non-invasive methods of sera and urine analyses. The results from 
this PhD will no doubt add to the better understanding of the molecular signatures of renal 
tumours and hopefully be translated into clinical practice to improve the quality of life of 
renal tumour patients. 
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CHAPTER 1 
 
 
LITERATURE REVIEW, HYPOTHESIS AND AIMS 
 
1.1 GENERAL INTRODUCTION 
 
The incidence of renal tumours has been increasing steadily in Europe, United States and 
Australia for the past three decades (Ljungberg et al. 2011). The widespread use of cross-
sectional imaging has increased the detection of incidental smaller tumours (Duchene et al. 
2003), while the 20-30% incidence of advanced metastatic tumours has remained relatively 
constant (Gupta et al. 2008). Small renal masses are usually defined as less than 4 cm in 
diameter (Jayson and Sanders 1998).   Despite current imaging techniques and the availability 
of renal lesion biopsy, the current clinical paradigm is to regard all solid renal lesions 
suspicious for renal cell carcinoma as malignant and most contemporary surgical series 
continue to report significant rates (approximately 26%) of benign lesions amongst resected 
small renal masses (Duchene et al. 2003; Schachter et al. 2007). Preoperative biopsy of small 
lesions is not widely utilized. A key issue for biopsy is the limited reliability of a negative or 
benign result. A recent systematic review of over 3000 renal lesion biopsies identified a 
negative predictive value of only 72% (Patel et al. 2016). One contributing factor is potential 
diagnostic uncertainty in the differentiation of benign renal oncocytoma (RO) from malignant 
chromophobe renal cell carcinoma (chRCC) (Yusenko 2010b) and, as an added difficulty, 
eosinophilic ccRCC. Consequently, there is a group of small renal lesions where increased 
confidence in characterization may defer or obviate the need for surgical intervention. RO 
and small chRCC are two such lesions. 
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ChRCC, although having a more favorable prognosis than other RCC subtypes, is a 
malignant tumor with the potential for metastatic spread and death. In comparison, there 
appears to be only one confirmed case report of metastases from RO (Oxley et al. 2007). 
Thus, due to its benign nature, RO can usually be monitored and treated expectantly. 
Similarly, small renal masses found to be chRCC may, in some situations, be suitable for 
active surveillance rather than immediate resection or ablation. RO and chRCC are often 
considered to be extremities of the same morphological spectrum (Delongchamps et al. 
2009). Proper differentiation largely relies on haematoxylin and eosin (H&E) histochemistry 
of sections, and an experienced histopathologist to discern the characteristic 
histomorphologic features that separate the two entities. Immunohistochemistry (IHC) is used 
in selected instances with various biomarker antibodies. Electron microscopy was commonly 
performed in the past, but is done only in rare cases now, as these techniques are not widely 
available and costs of sample preparation and analyses are high. There is also the coexistence 
of RO with chRCC seen in sporadic cases of hybrid tumours, renal oncocytosis and Birt-
Hogg-Dube (BHD) syndrome. Differentiation of RO and chRCC especially as small renal 
masses, from other more sinister forms of RCC like clear cell RCC (ccRCC), is also 
important for the appropriate management of these patients.  
 
Currently, malignant chRCC and benign RO are two renal tumours that often are difficult to 
differentiate clinically, both at pre-operative diagnostic and post-operative histopathological 
stages. Current imaging modalities and pre-operative renal mass biopsy techniques cannot 
accurately differentiate chRCC and RO. Therefore, due to this diagnostic dilemma, these 
renal lesions undergo nephrectomy, with subsequent pathological reports revealing that 
approximately 20% of these small renal lesions (≤4 cm) were benign (Schachter et al. 2007). 
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With reliable characterisation of benign renal tumours, the rate of unnecessary renal surgery 
can be reduced with significant economic and health outcome benefits. Nephron preservation 
is an important strategy in reducing the incidence of end stage kidney disease and its 
associated cardiovascular mortality. Accurate diagnosis of pathological specimens also 
dictates long term surveillance requirements for malignant chRCC as compared to benign RO 
cases, where an expectant approach is sufficient. Improved accuracy and confidence in 
characterisation of benign and low malignant potential lesions will decrease unnecessary 
intervention and help curb expanding healthcare costs by avoiding overtreatment of benign 
and indolent lesions. 
 
Better understanding of the molecular profiles of kidney cancers will help solve some of the 
diagnostic dilemma mentioned above. Therefore identification of such molecular biomarkers 
which can aid in the differentiation of chRCC and RO is crucial and forms the basis of this 
research project. “Biomarker” refers to a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention (Biomarkers Definitions Working 
Group 2001). In this study, established and novel IHC biomarkers were analysed. This 
research result will hopefully be translated to provide useful intervention into day to day 
practice of clinical urology.   
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1.2 LITERATURE REVIEW 
1.2.1 History 
RO was first described by Zippel in 1942 as a neoplasm entirely composed of large 
eosinophilic cells called oncocytes (Zippel 1942). Later, in 1976, Klein and Valensi (Klein 
and Valensi 1976) identified another 13 cases as a distinct clinical pathological entity with a 
typical benign histological appearance  and clinical course. RO was originally thought to 
derive from renal proximal tubules but most pathologists now suggest a distal tubular origin, 
(Storkel et al. 1988) most likely arising from intercalated cells of collecting ducts. The first 
description of chRCC, as distinct from ccRCC, was made by Thoenes et al in 1985 (Thoenes 
et al. 1985) and a year later, they added the chRCC subtype to the classification of renal 
tumours (Thoenes et al. 1986). The cell characteristic had been described prior to the 1985 
publication but only in experimentally-induced adenomas in animals. The chromophobe cells 
had slightly opaque or finely reticular cytoplasm that resisted staining with H&E. They were 
able to be distinguished from ccRCC by a strongly-positive reaction within their cytoplasm to 
Hale's colloidal iron, and a weaker positive reaction with Alcian Blue, a distinction that has 
since been found to be unreliable. The authors, however, made a step forward for 
classification of RCC by suggesting that the descriptive term "light cell" RCC should be 
discarded and replaced by either "clear cell" or "chromophobe cell" as appropriate. They 
pointed out that chromophobe cell tumours were likely to have a different derivation from 
ccRCC and other RCC, and that they may also have a different prognosis, a fact that has 
since been established. Since the description of chRCC came a decade later than RO, there 
were many instances in that era where renal tumours, which were likely to be chRCC, were 
described as RO. This may have contributed to the confusion surrounding the original 
recognition of the benign nature of RO.  
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1.2.2 Epidemiology 
Renal tumours are highly heterogeneous with at least 16 known subtypes, of which four 
subtypes predominate (Amin and Anthony 1999; Chawla et al. 2006). Recent 
recommendations from the classification working group of the International Society of 
Urological Pathology (ISUP) consensus conference on renal neoplasia stated that 5 entities 
should be recognized as new distinct epithelial tumours within the classification system: 
tubulocystic RCC, acquired cystic disease-associated RCC, clear cell (tubulo) papillary RCC, 
the MiT family translocation RCC (in particular t(6;11) RCC), and hereditary leiomyomatosis 
RCC syndrome-associated RCC. In addition, there are 3 rare carcinomas that were considered 
as emerging or provisional new entities: thyroid-like follicular RCC; succinate 
dehydrogenase B deficiency-associated RCC; and ALK translocation RCC (Srigley et al. 
2013), as shown in Table 1.1 and 1.2.  
 
Table 1.1: Proposed New Renal Epithelial Tumours and Emerging/Provisional Tumour 
Entities 
New epithelial tumours 
Tubulocystic renal cell carcinoma 
Acquired cystic disease associated renal cell carcinoma 
Clear cell (tubulo) papillary renal cell carcinoma 
MiT family translocation renal cell carcinoma (including t(6;11) renal cell carcinoma) 
Hereditary leiomyomatosis renal cell carcinoma syndrome associated renal cell carcinoma 
Emerging/provisional entities 
Thyroid-like follicular renal cell carcinoma 
Succinic dehydrogenase B deficiency associated renal cell carcinoma 
ALK-translocation renal cell carcinoma 
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Table 1.2: ISUP Vancouver Modification of WHO (2004) Histologic Classification of 
Kidney Tumours 
Renal cell tumours 
Papillary adenoma 
Oncocytoma 
Clear cell renal cell carcinoma 
Multilocular cystic clear cell renal cell neoplasm of low malignant potential 
Papillary renal cell carcinoma 
Chromophobe renal cell carcinoma 
Hybrid oncocytic chromophobe tumour 
Carcinoma of the collecting ducts of Bellini 
Renal medullary carcinoma 
MiT family translocation renal cell carcinoma 
Xp11 translocation renal cell carcinoma 
t(6;11) renal cell carcinoma 
Carcinoma associated with neuroblastoma 
Mucinous tubular and spindle cell carcinoma 
Tubulocystic renal cell carcinoma 
Acquired cystic disease associated renal cell carcinoma 
Clear cell (tubulo) papillary renal cell carcinoma 
Hereditary leiomyomatosis renal cell carcinoma syndrome-associated renal cell carcinoma 
Renal cell carcinoma, unclassified 
Metanephric tumours 
Metanephric adenoma 
Metanephric adenofibroma 
Metanephric stromal tumour 
Nephroblastic tumours 
Nephrogenic rests 
Nephroblastoma 
Cystic partially differentiated nephroblastoma 
Mesenchymal tumours 
Clear cell sarcoma 
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Rhabdoid tumour 
Congenital mesoblastic nephroma 
Ossifying renal tumour of infants 
Leiomyosarcoma (including renal vein) 
Angiosarcoma 
Rhabdomyosarcoma 
Malignant fibrous histiocytoma 
Hemangiopericytoma 
Osteosarcoma 
Synovial sarcoma 
Angiomyolipoma 
Epithelioid angiomyolipoma 
Leiomyoma 
Hemangioma 
Lymphangioma 
Juxtaglomerular cell tumour 
Renomedullary interstitial cell tumour 
Schwannoma 
Solitary fibrous tumour 
Mixed mesenchymal and epithelial tumours 
Cystic nephroma/mixed epithelial stromal tumour 
Neuroendocrine tumours 
Carcinoid (low-grade neuroendocrine tumour) 
Neuroendocrine carcinoma (high-grade neuroendocrine tumour) 
Primitive neuroectodermal tumour 
Neuroblastoma 
Phaeochromocytoma 
Hematopoietic and lymphoid tumours 
Lymphoma 
Leukaemia 
Plasmacytoma 
Germ cell tumors 
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Teratoma 
Choriocarcinoma 
Metastatic tumours 
Other tumours 
 
ccRCC, arising from the proximal tubular epithelial cells, is the most common subtype 
constituting 70-80% of RCC, followed by papillary RCC (pRCC) (10-15%), chRCC (5%) 
and collecting duct RCC (<1%) (Kawaguchi et al. 2011; Kurup et al. 2012). RO accounts for 
approximately 3-7% of all adult renal neoplasms. The peak age of incidence for detection of 
RO tends to be in the 7
th
 decade of life. For chRCC, the peak incidence occurs in the 6
th
 
decade. For cases of RO, men seem to be affected twice as often as females; for chRCC, the 
disease tends to affect men and women equally (Cindolo et al. 2005).RO and chRCC develop 
as either sporadic or familial forms, and both can be associated with distinct genetic 
mutations. The majority of RO and chRCC occur as sporadic cases (Lopez-Beltran et al. 
2006; Vera-Badillo et al. 2012). There is also the occasional occurrence of familial renal 
cancers of oncocytoma with BHD syndrome. Familial oncocytoma is due to partial or 
complete loss of multiple chromosomes. BHD syndrome is an autosomal dominant inherited 
syndrome with the BHD gene locus located in the short arm of chromosome 17 (Khoo et al. 
2001; Nickerson et al. 2002). This syndrome is characterised by fibrofolliculomas, lung cysts 
that can lead to spontaneous pneumothoraxes, and various subtypes of renal tumours 
including hybrid tumours, RO, chRCC and ccRCC. 
 
In rare instances, patients can present with renal oncocytosis. Renal oncocytosis was first 
described in 1982 (Warfel and Eble 1982): multiple and bilateral oncocytic nodules and a 
spectrum of oncocytic changes are found diffusely throughout the renal parenchyma. A large 
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series investigating renal oncocytosis revealed that hybrid development of RO and chRCC 
was most common (Adamy et al. 2011). Hybrid oncocytic chromophobe tumours are tumours 
which display histological features of both chRCC and RO. They can occur in three 
clinicopathological scenarios: sporadic; in association with BHD syndrome; and in 
association with renal oncocytosis. All scenarios demonstrate indolent clinical behaviour 
(Hes et al. 2013).  
 
1.2.3 Clinical presentation 
Generally, patients with RO tend to be asymptomatic and present incidentally following 
cross-sectional imaging for an unrelated complaint. Similarly, the majority of patients with 
chRCC present incidentally with asymptomatic renal masses (Volpe et al. 2012). Less 
commonly chRCC may present with local symptoms of haematuria, flank mass and loin pain, 
and constitutional symptoms of weight loss and loss of appetite (Vera-Badillo et al. 2012). 
ChRCC can also present with paraneoplastic syndrome and metastases with predilection to 
the liver (Klatte et al. 2008). In the largest published series to date, chRCC present with 
metastases at a rate of 1.3% (Volpe et al. 2012). Generally, patients with chRCC tend to 
present in less advanced stages, less frequently with metastases and are usually of better 
performance status (Klatte et al. 2008) compared with other subtypes of RCC. It should be 
noted, however, that the local and constitutional symptoms for chRCC are similar to those 
seen for other RCC.Malignant chRCC have the propensity to metastasise whereas RO will 
almost always follow a benign clinical course with no significant risk of metastases. Previous 
published  isolated case reports of metastatic RO on initial presentation or following resection 
of the RO (Amin and Anthony 1999; PerezOrdonez et al. 1997) have been noted, but these 
case reports have not been substantiated with proper histopathological confirmation of the 
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metastatic deposits, except for one liver metastasis (Oxley et al. 2007). In that case report by 
Oxley et al (2007), the patient presented with a large symptomatic left RO and subsequently 
developed liver metastases which were confirmed on histopathology from the liver biopsies. 
Therefore, accurate diagnosis of the benign nature of RO is crucial as no further surveillance 
or treatment will be required.  
 
Renal tumours can be detected by radiological imaging using ultrasonography, computed 
tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography 
(PET). Usually following the suspicion of a renal mass, either clinically or via ultrasound, a 
multiphase CT scan will be performed to delineate its nature (Szolar et al. 1997). Multiphase 
CT scans can clearly delineate the renal tumour, its local extension to surrounding tissues and 
detect any metastases to regional lymph nodes or other organs. Cases of small renal masses 
(lesions < 4cm) detected incidentally are increasing in incidence largely owing to the 
widespread utilisation of ultrasound and CT scans. Generally, there is no accurate 
differentiation between benign and malignant renal lesions using CT scans (except for 
angiomyolipoma), but retrospectively about 20% of these small renal masses will be found to 
be benign lesions (Remzi et al. 2006). Percutaneous biopsy of these small renal masses 
provides an enticing strategy to identify lesions of no or low malignant potential however 
widespread uptake of biopsy into clinical practice has been limited, at least in part due to the 
limited reliability of a negative or benign biopsy result. Predicting whether a small renal mass 
is malignant, based on its growth velocity, has been reported, but there is no good correlation 
of malignancy with growth rate (Kurup et al. 2012). A recent meta-analysis of small renal 
masses which included benign and malignant lesions, showed a mean growth rate of 0.28cm 
annually (range 0.09 to 0.86) for small renal masses followed with imaging (Chawla et al. 
2006). RO increase in size with variable velocity, with one case series reporting an observed 
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growth rate of 0.20cm annually (Kawaguchi et al. 2011). The largest pool of 33 biopsy-
proven benign RO demonstrated a growth rate similar to reported growth rates for RCC, thus 
highlighting again that observation of growth cannot distinguish between the benign or 
malignant nature of such lesions (Kurup et al. 2012). The locality and size of tumours may 
also be variable. Uncommonly, there have been case reports of large RO (25 x 15 x 12cm) 
(Akbulut et al. 2010), but the average size is normally around 4.9±2.7cm (Romis et al. 2004). 
Published reports worldwide show that RO can be multifocal in 6-11% (Dechet et al. 1999; 
Trpkov et al. 2010) and bilaterality was reported in about 3-5% (Davis CJ 1991; Dechet et al. 
1999). In comparison, the median size of chRCC is about 6.0cm (Vera-Badillo et al. 2012), 
which is larger compared to other subtypes of RCC (Cheville et al. 2003). Multifocality of 
chRCC is usually around 10-12% (Yusenko 2010a). 
1.2.4 Diagnostic dilemma 
Following diagnosis of suspected renal tumours on ultrasound or other radiological 
modalities, a multiphase CT scan of the abdomen pelvis together with CT thorax or chest 
Xray or bone scan are usually performed to clinically stage these patients. For renal tumours, 
the current 2010 Tumour Node Metastasis (TNM) staging classification (Edge and Compton 
2010) is as follows: 
Table 1.3: 2010 Tumour Node Metastasis (TNM) staging classification 
Primary tumours (T) 
 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
T1 Tumour ≤7 cm in greatest dimension, limited to the kidney 
T1a Tumour ≤4 cm in greatest dimension, limited to the kidney 
T1b Tumour >4 cm but ≤7 cm in greatest dimension, limited to the kidney 
T2 Tumour >7 cm in greatest dimension, limited to the kidney 
T2a Tumour >7 cm but ≤10 cm in greatest dimension, limited to the kidney 
T2b Tumour >10 cm, limited to the kidney 
T3 Tumour extends into major veins or perinephric tissues but not into the ipsilateral 
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adrenal gland and not beyond the Gerota fascia 
T3a 
Tumour grossly extends into the renal vein or its segmental (muscle-containing) 
branches, or tumour invades perirenal and/or renal sinus fat but not beyond the Gerota 
fascia 
T3b Tumour grossly extends into the vena cava below the diaphragm 
T3c 
Tumour grossly extends into the vena cava above the diaphragm or invades the wall of 
the vena cava 
T4 
Tumour invades beyond the Gerota fascia (including contiguous extension into the 
ipsilateral adrenal gland) 
 
Regional lymph node (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in regional lymph node(s) 
 
Distant metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis 
  
The increasing use of CT scans for small renal masses has led to a diagnostic dilemma of 
accurately characterising the nature of these renal lesions and their subsequent management. 
Typically on CT scans, RCC are solid heterogeneous masses with contrast enhancement 
showing areas of patchy uptake of contrast. Locally advanced tumours may directly invade 
the adrenal gland, renal vein, inferior vena cava and regional lymph nodes. ChRCC usually 
demonstrate homogenous enhancement, whereas ccRCC, papillary and collecting duct RCC 
tended to show heterogeneous or predominantly peripheral enhancement. Even though 
calcification was seen more commonly in chRCC (38%) than in papillary (32%) or 
conventional (cc)RCC (11%) (Kim et al. 2002), the differences between some subtypes were 
relatively small, and this feature was not reliable and not useful as a diagnostic criterion. On 
MRI, chRCC typically have heterogeneous T2 signal intensity and enhancement.In contrast, 
on CT scanning, RO typically show a well-defined, smooth, relatively homogeneous solid 
mass with a central area of hypo-attenuation due to the presence of a central stellate scar, and 
rarely show any extension to the renal vein, inferior vena cava or the adrenals. MRI scan will 
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typically reveal low to moderate homogeneous intensity on T1-weighted images and 
relatively high signal intensity on T2-weighted images (Remark et al. 1988). Classically, if 
renal angiography on RO were performed, it would show a typical spoke-wheel pattern, 
highlighting the marked peripheral vascularity in contrast with the relatively hypovascular 
central part of the tumour. However, classical hypo-attenuation of the central stellate scar on 
CT scan is seen in less than one third of RO, and although characteristic of RO, it is not 
diagnostic (Chawla et al. 2006; Khoo et al. 2001). Moreover, there are no consistently 
reliable pathognomic CT scan features that can safely differentiate RO from RCC 
(Choudhary et al. 2009). Therefore, most RO are treated as suspicious of RCC based on 
imaging, and thereafter are subjected to surgical resection. Examples of multiphase CT scans 
of chRCC and RO from our prospective cohort of patients are shown in Figures1.1 A-D. As 
can be seen on these CT scans, chRCC and RO lesions cannot be accurately differentiated 
based on features on multiphase CT scan alone. 
 
A recent study on the ability of MRI to discriminate RO from chRCC showed that these two 
entities exhibited similar findings, and no MRI features were reliable in distinguishing 
between the two (Rosenkrantz et al. 2010). The ability of any renal lesion to uptake 18-
fluorodeoxyglucose (FDG) is the basis of 18-FDG positron emission tomography/computed 
tomography (PET/CT) scans. However, in detection of renal tumours, the role of FDG PET is 
limited as there are high false negative rates (Aide et al. 2003). Benign ROs are also often 
FDG-avid, and thus this cannot be used in separating them from malignant renal tumours 
(Ramdave et al. 2001). Recently, multiphasic multi-detector CT scans have helped to 
discriminate ccRCC from RO, papillary RCC and chRCC by utilising the different 
enhancements at various phases of the scans (Young et al. 2013). This will aid somewhat to 
the distinction of ccRCC from RO, but not the discrimination of RO from chRCC. Arterial 
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phase enhancements >500% and washout values >50% in Hounsfield units obtained in 
multiphasic CT scans can be seen exclusively in RO and can aid in distinguishing RO from 
other subtypes of RCC (Bird et al. 2011).
Figure 1.1: CT scan of renal tumourA. Axial CT scan (corticomedullary phase) of right 
chRCC; B. Axial CT scan (nephrographic phase) of left RO; C. Coronal CT scan 
(corticomedullary phase) of left chRCC; D. Coronal CT scan (nephrographic phase) of left 
RO (renal tumours shown with red arrows) 
 
1.2.5 Pathology 
 
 
Despite the non-invasive discriminatory features of multiphasic CT scans, renal mass biopsy 
provides the best opportunity for preoperative diagnosis. However, there are numerous 
potential shortcomings for this procedure, leading to the inevitability of surgical excision. 
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One of the main drawbacks of renal mass biopsy is the relative difficulty faced by 
pathologists to accurately and conclusively diagnose renal tumour subtype from the limited 
tissue biopsy samples, as usually an entire range of cytoarchitectural features is necessary for 
examination to arrive at a diagnosis (Barocas et al. 2006). However, as a general rule, if the 
lesion looks like chRCC on needle biopsy, it can be confidently reported as such. In 
comparison, a lesion that looks like an RO may be incompletely sampled, with other areas 
merging into the eosinophilic variant of chRCC. This may be a hybrid tumour or simply 
oncocytoma-like areas in a chRCC. Therefore most pathologists would not diagnose an RO 
outright on a needle biopsy, and make a comment as to the possibility of having chRCC 
elsewhere in the tumour. In addition to the difficulties in differentiating RO from chRCC 
clinically, the pathological features following surgical resection of these tumours often 
overlap and pose a diagnostic challenge to pathologists.  
 
ChRCC are well-circumscribed encapsulated tumours which have a light-brown to tan cut 
surface. These are typically solid but cystic areas can be found. Central scarring may be seen. 
Histologically there are two types. The classic type has large polygonal cells with finely 
granular cytoplasm. These have prominent plant-like thick cell membranes. The eosinophilic 
variant is composed of polygonal cells with abundant eosinophilic cytoplasm. Nuclei are 
irregular, crinkled and angulated, often with perinuclear clearing. Binucleation is common. A 
solid sheet-like pattern with poor cellular cohesion is commonly found. RO are also well-
circumscribed, but unencapsulated, tumours which are typically mahogany brown but 
sometimes tan-coloured. A central stellate scar is present in about one third of cases. Rarely, 
cystic change or haemorrhage can be found. Histologically there are large round polygonal 
cells with abundant eosinophilic cytoplasm and round nuclei. Nucleoli are inconspicuous. 
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Cells form nests, tubules, acini and microcysts. Focal degenerative nuclear atypia may be 
seen. Figure 1.2 demonstrates histopathology of chRCC and RO. 
 
 
Figure 1.2: Histopathology of chromophobe renal cell carcinoma and renal oncocytoma 
 A. H&E-stained section of an example of eosinophilic variant of chromophobe renal cell 
carcinoma, showing typical large, pale, polygonal cells with prominent cell membranes. 
Nuclei tend to be irregular and wrinkled, and cells are sometimes binucleated (asterisks). 
18 
 
Perinuclear clearing can be prominent; B. H&E stained section of an example of renal 
oncocytoma, showing large oncocytes with densely granular eosinophilic cytoplasm. Cells 
are round to polygonal and nuclei are round and monotonous. Nucleoli are small and 
inconspicuous. 
 
Table 1.4 describes the macroscopic and microscopic features of RO and chRCC. Despite 
having some subtle distinguishing macroscopic, microscopic and ultrastructural differences, 
there is often need to use ancillary histochemical and IHC stains to differentiate these two 
entities. Recently, a new oncocytic variant of chRCC was described, that morphologically 
resembles RO but has the biological characteristics of chRCC (Kuroda et al. 2013). In the 5 
cases reported by Kuroda et al (2013), histologically the tumour cells had characteristics of 
RO; however positive cytokeratin 7 and mitochondrial antigen IHC staining and a subsequent  
fluorescence in situ hybridization study favoured chRCC. This “oncocytic variant” of chRCC 
adds to the difficulties for pathologists to discern RO from chRCC. 
 
Table 1.4: Comparison of macroscopic, microscopic and ultrastructural features for 
oncocytoma and chromophobe renal cell carcinoma 
 
Features Oncocytoma 
 
Chromophobe RCC 
Macroscopic Well-circumscribed, tan or mahogany 
brown, sometimes with a central 
stellate scar (Trpkov et al. 2010) 
  
Usually circumscribed, 
homogenous, light brown, beige, 
yellow or tan colour (Latham et al. 
1999). 
Microscopic 
 
 
Cytoplasm 
 
 
Nuclei 
Cells arranged in a nested or organoid 
pattern, but tubular, trabecular or 
solid structure can also be seen 
(Gudbjartsson et al. 2005).  
Granular eosinophilic cytoplasm  
 
 
Round, uniform nuclei (Tickoo and 
Amin 1998) 
 
Variants: classic, eosinophilic and 
mixed. 
Cells arranged in sheets, with 
distinct or accentuated cell borders 
(Abrahams et al. 2004).  
Granular eosinophilic (eosinophilic 
variant) or pale, reticular and almost 
transparent appearance (classic) 
(Crotty et al. 1995) 
Presence of peri-nuclear halos, 
wrinkled nuclei (Crotty et al. 1995).  
Ultrastructural Abundant mitochondria with lamellar 
or focally-stacked cristae. Absent or 
sparse vesicles (Tickoo et al. 1998).  
Scant mitochondria with tubule-
vesicular cristae. Abundant 
microvesicles between 
mitochondria. (Latham et al. 1999). 
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To date, none of the histochemical, IHC or cytogenetic features has been proven to be 
reliable and specific (Mazal et al. 2005). However IHC biomarkers may be a cost-effective 
and valuable form of information for monitoring disease for both prognosis and planning 
treatment regimens. Tables 1.5-1.8 list some of the histochemical and IHC biomarkers that 
have been published. Hale’s colloidal iron staining is still used. Currently, the most useful 
IHC markers for the differentiation of renal tumours are vimentin, cytokeratin (CK)7, CD10, 
and marker for RCC (RCCma). According to the literature, vimentin has been shown to be 
positive in ccRCC and negative in chRCC and RO, and CK7 is positive in chRCC and 
negative in RO and ccRCC. RCCma and CD10 are positive in ccRCC and negative in both 
chRCC and RO. Hale's colloidal iron staining with diffuse reticular pattern and peri-nuclear 
halo is present in chRCC but non-existent in RO and ccRCC (Geramizadeh et al. 2008). 
Colloidal iron and widespread CK7 positivity have been suggested to be useful in 
distinguishing chRCC from RO. In RO, colloidal iron staining is usually negative and CK7 
shows only focal positivity. However, there is overlap in the staining patterns, preventing 
these stains to be of much practical value. Negative staining for vimentin and widespread 
staining for CK7 versus negative staining for CK7 and positive staining for vimentin can be 
useful in distinguishing chRCC from ccRCC.  
 
However, as seen in Table 1.5 these IHC biomarkers still have their pitfalls in distinguishing 
between chRCC and RO. For example, the problems with Hale’s colloidal iron in certain 
instances is its failure to stain adequately, or the staining pattern (diffuse cytoplasmic versus 
luminal) could not be adequately assessed (Latham et al. 1999). However, vimentin may be 
useful in discriminating chRCC from other RCC, and a panel of vimentin with glutathione S-
transferase alpha (GST-α) and epithelial cell adhesion molecule (EpCAM) may achieve 
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100% sensitivity and specificity for the differential diagnosis of chRCC, RO and ccRCC (Liu 
et al. 2007). 
 
RO and chRCC share not only histologic and cytologic features, but also share IHC markers 
for S100A1 and CD117 (KIT) (Bing et al. 2013). Several other studies with IHC markers, 
including kidney-specific cadherin, CK7, EMA, CD10, RCC, c-KIT, and RON proto-
oncogene have been used to distinguish chRCC from RO, but the results of these studies are 
inconsistent and unsatisfactory (Lee et al. 2011).  
 
Table 1.5: Histochemical and immunohistochemical biomarkers to differentiate chRCC 
and RO. 
Method No. of patients Success as biomarker 
Hale’s 
colloidal iron 
stain  
 
Modified 
Mowry's 
colloidal iron 
stain better 
characterised 
chRCC  
28 cases (11 
chRCC, 12 RO, 6 
ccRCC) 
Colloidal iron was diffusely and strongly positive in 
9/11 of chRCC, focally and weakly positive in 5/12 of 
RO, and negative in all granular cell variants of ccRCC 
(0/6). (Wang and Mills 2005) 
62 cases (14 
chRCC, 19 RO, 
11 ccRCC, 7 
eosinophilic 
variants of pRCC) 
Positive colloidal iron stain was not limited to chRCC, 
however a diffuse and strong, reticular staining pattern 
was observed only in chRCC (100%). Staining patterns 
less consistent in all other renal neoplasms. Most RO 
(84%) had focal, weak, fine dust-like positivity. 100% 
ccRCC had focal, coarse, droplet-like positivity. 
(Tickoo et al. 1998) 
76 cases (30 
ccRCC, 16 
pRCC, 21 
chRCC, 8 RO, 1 
cdRCC) 
Fine reticular cytoplasmic pattern with peri-nuclear 
halo (87.5% chRCC; 16% ccRCC). 12.5% RO had 
focal, coarse, cytoplasmic staining without peri-nuclear 
halo. (Geramizadeh et al. 2008) 
CD10 
 
Outcome of 
CD10 to 
distinguish 
between 
chRCC and 
ROs is 
variable. 
76 cases (30 
ccRCC, 16 
pRCC, 21 
chRCC, 8 RO, 1 
cdRCC) 
CD10 positive, 79% ccRCC, 6.3% chRCC and 0% RO. 
CD10 reactivity favours ccRCC, and the absence of 
CD10 in RO shows CD10 could differentiate between 
chRCCs and RO in a panel of biomarkers. 
(Geramizadeh et al. 2008) 
83 cases (22 
chRCC, 17 RO,  
and 45 ccRCC) 
CD10 positive, ccRCC (91%), chRCC (45%) and RO 
(29%). (Liu et al. 2007) 
28 cases (11 CD10 positive, 100% ccRCC, 72% chRCC and 58% 
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chRCC, 12 RO, 6 
ccRCC) 
RO. Not useful as a biomarker. (Wang and Mills 2005) 
RCC marker 
(RCCma)  
RCCma is a 
relatively 
new IHC 
marker that 
has variable 
results. 
76 cases (30 
ccRCC, 16 
pRCC, 21 
chRCC,  8 RO, 1 
cdRCC) 
RCCma, positive in 62.5% ccRCC, 12.5% RO, but 
negative in chRCC. Holds potential as part of a panel 
to differentiate between chRCC and RO. (Geramizadeh 
et al. 2008) 
Renal cell 
neoplasm TMA 
(30 RO, 18 
chRCC, 64 
ccRCC, 50 
pRCCs, 31 RO) 
RCCma, positive in most RCC with 
granular/eosinophilic features. ccRCC (71%), pRCC 
(76%), negative in RO. (Huang et al. 2009) 
 
328 samples (256 
ccRCC, 27 
pRCC, 28 
chRCC, 5 
cdRCC, 5 
unclassified RCC, 
7 RO) 
RCCma was negative in chRCC but was positive in 3/7 
RO. (Kuroda et al. 2004)
 
 
 
 
29 cases (11 
chRCC, 12 RO, 6 
ccRCC) 
RCCma was observed in more than 80% of ccRCCs 
but was negative in all chRCCs and RO. (Wang and 
Mills 2005) 
Vimentin 76 cases (30 
ccRCC, 16 
pRCC, 21 
chRCC, 8 RO, 1 
cdRCC) 
Vimentin positive, 95% ccRCC, 6.3% chRCC, 12.5% 
RO. Negative staining for Vimentin, chRCC or RO. 
(Geramizadeh et al. 2008) 
83 cases (22 
chRCC, 17 RO, 
45 ccRCC) 
Vimentin positive exclusively in ccRCCs.  (Liu et al. 
2007) 
Renal cell 
neoplasm TMAs 
(30 RO, 18 
chRCC, 64 
ccRCC, 50 
pRCC, 31 RO) 
Positive in most RCC with granular/eosinophilic 
features (ccRCC 78%, pRCC 85%). Negative in RO 
and chRCC. (Huang et al. 2009) 
 
Cluster of differentiation (CD10), Collecting duct renal cell carcinoma (cdRCC), Renal cell 
carcinoma marker (RCCma), Papillary renal cell carcinoma (pRCC), Tissue microarray 
(TMA) 
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Table 1.6 describes emerging biomarkers used to differentiate chRCC from RO, directly or 
indirectly. BCA2, a RING H2 finger protein RING E3 ligase, holds potential as a tool to 
distinguish RO from its mimickers, like chRCC (Ehsani et al. 2013). In addition, RO has 
significantly higher expression of the cancer-testis antigens (CTAs), such as MAGE-A3/4 
and NY-ESO-1 (Demirovic et al. 2010). Further investigation is needed to evaluate the 
potential diagnostic implications for these markers. 
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Table 1.6:  Emerging biomarkers used to differentiate chRCC from RO                               
Method No. of patients Significance of success as biomarker 
BCA2 
  
 
158 patients (104 
ccRCC, 8 chRCC, 
2 pRCC, 38 RO, 
6 oncocytic 
neoplasms  
All RO and oncocytic neoplasms, which favour 
RO, were positive for BCA2 while all RCC were 
negative, including chRCC. (Ehsani et al. 2013) 
C-kit 
(encodes the 
membrane-
bound 
tyrosine 
kinase KIT) 
mRNA levels, 17 
chRCC, 20 RO 
from cDNA 
microarrays 
 
IHC analysis, 226 
renal tumors in 
TMAs (40 
chRCC, 41 RO, 
40 ccRCC, 29 
renal angio-
myolipoma, 21 
pRCC).  
Significant increment of c-kit mRNA and 
overexpression of KIT protein by IHC in chRCC 
and RO hence low potential for differentiating 
between the two types. However there was 
potential for differentiating chRCC/RO from the 
other renal cell tumors (ccRCC and pRCC). 
(Huo et al. 2005) 
EMA 
 
86 retrospective 
nephrectomy 
specimens (15 
ccRCCs, 15 
pRCCs, 15 
chRCCs, 10 ROs, 
6 cdc)   
EMA was positive in chRCC (75-100%), ccRCC 
(50-77%) and oncocytomas (51-86%), showing 
no major promise as a marker. (Comparison 
made with 3 tubulocystic carcinoma, 3 renal 
medullary carcinoma, 3 mucinous tubular and 
spindle cell carcinoma, 4 metanephric adenoma, 
12 invasive high-grade urothelial carcinoma) 
(Skinnider et al. 2005) 
76 cases (30 
ccRCC, 16 
pRCC, 21 
chRCC, 8 RO, 1 
cdc) 
EMA was positive in 100% of ChRCCs, 100% 
of ROs and 75% of ccRCC. So, we concluded 
that EMA is not a good marker for the 
differentiation of renal tumours. (Geramizadeh et 
al. 2008) 
Carbonic 
anhydrase IX 
(CA IX) 
TMAs, 20 cases 
of each ccRCC, 
chRCC, pRCC 
and RO  
CA IX was highly sensitive for ccRCCs (90% 
positivity) and was negative in all other renal 
epithelial tumours except for 1 chRCC. (Bing et 
al. 2013) 
Galectin-3 
 
TMAs, 20 cases 
of each ccRCC, 
chRCC, pRCC 
and RO 
Galectin-3 found mostly in renal tumours with 
oncocytic features, including RO (100%) and 
chRCCs (89%). May hold small promise to 
distinguish these from other RCC. (Bing et al. 
2013) 
Glutatione S-
transferase 
alpha (GST-
α) 
22 chRCC, 17 
RO, 45 ccRCC 
GST-α exclusively observed in ccRCCs. (Liu et 
al. 2007) 
KIT 
(CD117)  
256 ccRCC, 29 
chRCC, 25 
pRCC, 6cdc, 6 
83% chRCCs and 71% RO had membranous 
immunoreactivity for KIT, while none of the 
other RCC or the angiomyolipomas expressed. 
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unclassified RCC, 
7 RO, 20 UC, 7 
NB, 2 AM 
Cannot be used to differentiate chRCC and RO. 
(Pan et al. 2004a) 
11 chRCCs, 12 
RO, 6 ccRCC 
KIT was a very sensitive marker for both chRCC 
and RO, but not useful to differentiate between 
the two. KIT with RCCma may be useful when 
trying to differentiate ccRCCs from chRCCs or 
ROs. (Wang and Mills 2005) 
 22 chRCC, RO & 
ccRCC 
CD117, strongly expressed in chRCC (82%) and 
RO (100%), whereas none of the ccRCCs were 
immunoreactive. (Liu et al. 2007) 
CD15 10 ccRCC, 
pRCC, chRCC 
and RO 
CD15 was able to distinguish between chRCCs 
and RO. 7/10 RO (70%) stained positive for 
CD15 and none of the chRCC stained for CD15. 
(Ray et al. 2011)  
MAGE-A3/4 
cancer testis 
antigen/CTA 
35 patients (17 
RO, 18 chRCC) 
88% RO stained positively for MAGE-A3/4; 
39% chRCC stained positively. (Demirovic et al. 
2010) 
RON proto-
oncogene, 
encoding 
a receptor 
tyrosine 
kinase, 
TMAs (55 RO, 52 
chRCCs).15 & 5 
conventional 
sections of RO & 
chRCC were also 
analysed  
69 of 70 RO and 55 of 57 chRCC had strong, 
diffuse cytoplasmic stain. (Patton et al. 2004) 
11 chRCC, 12 
RO, 6 ccRCCs 
11/11 chRCCs, 12/12 RO, but only 3/6 of 
ccRCC. (Wang and Mills 2005)  
NY-ESO-1 
CTA 
35 patients (17 
RO, 18 chRCC) 
15/17 RO stained positive, and 6/18 chRCC 
were positive. (Demirovic et al. 2010) 
Interphase 
fluorescence 
in situ 
hybridization 
(FISH)  
11 chRCC, 12 
RO, compared 
with conventional 
metaphase 
cytogenetics by 
karyotyping. 
RO often show normal DNA content by 
interphase and metaphase analyses. The loss of 2 
or more of chromosomes 1, 2, 6, 10, and 17 
favours the diagnosis of chRCC over RO. FISH 
analysis is shown to be a useful tool that helps 
identify differences between these 2 tumour 
types. (Brunelli et al. 2010) 
 
Endogenous 
avidin-
binding 
activity 
(EABA) 
Renal TMAs (30 
RO, 18 chRCC, 
64 ccRCC, 50 
pRCC, 31 benign 
renal tissues) 
 
97% RO, 26% ccRCC, 35% pRCC with 
granular/eosinophilic (GE) features and 6% of 
chRCCs positive for EABA. RCC without GE 
features were negative. EABA is an excellent 
marker for RO, and so useful in differentiating 
RO from chRCC. (Huang et al. 2009) 
 
PAX8 and 
MUC-1 
TMAs of 36 
chRCC, 20 RO 
Expression of PAX8 more frequent in RO than 
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in chRCC (55% vs 25%). 
MUC1 expressed more diffusely and frequently 
in chRCC than RO (94% vs. 55%). (Bing et al. 
2013) 
Breast cancer-associated gene 2 (BCA2), epithelial membrane antigen (EMA), proto-
oncogene that encodes for a transmembrane tyrosine kinase receptor KIT (Ckit), carbonic 
anhydrase IX (CAIX), glutatione S-transferase alpha (GST), transmembrane tyrosine kinase 
receptor (KIT), cluster of differentiation (CD15), melanoma-associated antigen A3/4 
(MAGE-A3/4), Recepteur d'Origine Nantais (RON), NY-ESO-1 type of cancer-testis antigen 
(NY-ESO-1 CTA), Endogenous avidin-binding activity (EABA), paired box gene 8 (PAX 8), 
mucin-1 (MUC-1),Fluorescence in situ hybridization (FISH). 
 
The cadherins comprise of a family of transmembrane glycoproteins that function as calcium-
dependent homotypic adhesion molecules and are expressed by the majority of epithelium. 
Currently, over 20 different tissue-specific cadherins have been identified (Langner et al. 
2004). The promise of cadherin proteins in distinguishing chRCC from RO is shown in Table 
1.7. CKs are a family of intermediate filaments that are characteristic markers of epithelial 
differentiation. Currently, 20 distinct CKs have been identified. They can be useful in the 
differential diagnosis of neoplasms of epithelial origin, and consequently several CKs have 
been investigated in renal neoplasms (Skinnider et al. 2005). The CKs that have been trialed 
to discriminate chRCC from other RCC and also RO are listed in Table 1.8, but none holds 
major promise, including CK7. Caveolin-1 (Cav-1) is a scaffolding protein encoded by the 
Cav-1 gene. This has demonstrated better promise in differentiating chRCC from RO than 
CK7 (Liu et al. 2007). 
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Table 1.7: Biomarkers from the cadherin family (also known as calcium-dependent 
adhesion) 
Method No. of patients Significance of success as biomarker 
Kidney-
specific 
cadherin 
(Ksp-cad) 
 
102 ccRCC, 46 
pRCC, 30 
chRCC, 3 
cdRCC, 31 RO 
Ksp-cad was expressed almost exclusively in chRCCs 
(97.7% of cases). Ksp-cad offers a quick, dependable 
approach for differentiating between RO and chRCCs. 
(Mazal et al. 2005) 
42 ccRCC, 30 
pRCC, 13 
chRCC, 20 RO 
using whole 
sections 
In contrast to Mazal et al., 2004, here both chRCC 
(13/13) and RO (19/20) were positive for Ksp-cad. Ksp-
cad not a useful marker for differentiating. (Shen et al. 
2005) 
15 chRCC, 15 
RO for mRNA 
analysis  & 
IHC on TMAs 
containing 36 
chRCC, 41 RO 
Ksp-cad differentiate RO from chRCC. Ksp-cad was 
present in chRCCs and ROs at mRNA (89% chRCC and 
64% RO) and IHC (31/36 chRCCs and 31/41 RO). 
(Adley et al. 2006b) 
N-Cadherin 21 Japanese 
cases chRCC, 
ccRCC, RO.  
chRCC and RO were positive for E-cadherin but not 
for N-cadherin.  All ccRCCs were negative for E-
cadherin, and 58% were positive for N-cadherin. Useful 
to distinguish chRCC from ccRCC but not between 
chRCC and RO. (Taki et al. 1999) 
E-Cadherin 
Ep-CAM 
(epithelial 
cell adhesion 
molecule) 
22 chRCC, 17 
RO,45 ccRCC 
 
Expressed in all chRCC in more than 90% of cells. 
EpCAM-positive RO (5/17; 29%) had single cell or 
small cell cluster positivity. The homogeneous EpCAM 
expression assists to diagnosis chRCC from RO. (Liu et 
al. 2007) 
10 each of 
ccRCC, pRCC, 
chRCCs, RO 
EpCAM distinguished between RO and chRCC. RO 
were negative for EpCAM but positive in 8/10 (80%) of 
chRCC. (Ray et al. 2011) 
Kidney specific (Ksp), Neural-cadherin (N-cadherin), Epithelial-cadherin (E-cadherin), 
Epithelial cell adhesion molecule (EpCAM), Tissue microarray (TMA). 
 
 
 
 
 
 
 
 
27 
 
Table 1.8: Biomarkers from the cytokeratin family  
Method No. of patients Significance of success as biomarker 
CK7 (Basic or 
neutral 
cytokeratin) 
6 chRCC, 11 RO 
 
All chRCC, strong cytoplasmic staining with 
peripheral cell accentuation. 8/11 RO, negative, 3 
weakly staining. (Leroy et al. 2000) 
21 chRCC, 26 RO  chRCCs (100%) and  almost all RO (96%) were 
positive for CK7. (Garcia and Li 2006) 
11 chRCC, 21 RO 
from 4 hospitals 
73% chRCC, 25% RO positive for CK7; 33% RO 
focally positive for CK7. No consistency in 
differentiating the 2 neoplasms. (Wu et al. 2002) 
 Positive in 100% chRCC, 8% ccRCC and negative 
in RO. (Geramizadeh et al. 2008) 
22 chRCC, 17 RO, 
45 ccRCC 
Positive in 80% chRCC, 0% RO. (Liu et al. 2007) 
TMAs (20 each 
ccRCC, chRCC,  
pRCC, RO) 
Positive in pRCC (90%), chRCC (89%), and RO 
(90%). (Bing et al. 2013) 
TMAs (36 chRCC, 
20 RO) 
Expressed significantly more often in chRCC than 
RO, both diffusely (53% vs. 10%) and focally 
(42% vs. 15%). (Bing et al. 2013) 
TMAs (30 RO, 18 
chRCC, 64 ccRCC, 
50 pRCC) 
81% pRCC, 63% chRCC, essentially negative in 
ccRCC and RO. (Huang et al. 2009) 
10 each ccRCC, 
pRCC, chRCC, RO 
Distinguished RO and chRCC. RO were not 
stained 80% chRCCs were positive. (Ray et al. 
2011) 
 
CK8 (Basic or 
neutral 
cytokeratins) 
76 cases (30 ccRCC, 
16 pRCC, 21 
chRCC, 8 RO, 1 
cdRCC) 
Positive in 70% ccRCC, 93% chRCC and 87.5% 
RO. (Geramizadeh et al. 2008) 
 
 
CK18 (Acidic 
cytokeratin) 
76 cases (30 ccRCC, 
16 pRCC, 21 
chRCC, 8 RO, 1 
cdRCC) 
Positive in 87% ccRCC, 100% chRCC and 87.5% 
RO. (Geramizadeh et al. 2008) 
 
 
CK19 (Acidic 
cytokeratin) 
76 cases (30 ccRCC, 
16 pRCC, 21 
chRCC, 8 RO, 1 
cdc) 
Positive in 41% ccRCC, 37.5% chRCC and 62.5% 
RO. Not a useful marker for differentiation among 
these subtypes. (Geramizadeh et al. 2008) 
 
 
CK20 (Acidic 
cytokeratin) 
 
 
 
15 RO only from 
archives 
12/15 RO were positive for CK20. (Stopyra et al. 
2001) 
11 chRCC, 21 RO 
from 4 hospitals 
chRCC and RO were uniformly negative for 
CK20. (Wu et al. 2002) 
76 cases (30 ccRCC, 
16 pRCC, 21 
Positive in only 8% ccRCCs, 12.5% chRCCs, 
negative in RO. Not a useful marker for 
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chRCC, 8 RO, 1 
cdRCC) 
differentiation among these subtypes. 
(Geramizadeh et al. 2008) 
Cytokeratin (CK), Tissue microarray (TMA), Collecting duct carcinoma (cdc) 
 
Other recently investigated IHC biomarkers which could aid in the differentiation of these 
two entities include: amylase α1A (Jain et al. 2013), FXYD2 (Gaut et al. 2013) and 
transforming growth factor β1 (TGF-β1) (Demirovic et al. 2014). These IHC biomarkers will 
also be discussed in the meta-analysis section in Chapter 3. 
 
The ISUP recently convened a consensus conference on renal cancer, preceded by an online 
survey, to address issues relating to the diagnosis and reporting of renal neoplasia (Tan et al. 
2013). In their report, the role of biomarkers in the diagnosis and assessment of prognosis of 
renal tumors is addressed. In particular the study consensus group focused upon the use of 
IHC markers and the approach to specific differential diagnostic scenarios (Tan et al. 2013). 
Tan et al noted that although no individual antibody or panel of antibodies reached consensus 
for classifying renal tumors, or for confirming renal metastatic disease, it was noted from the 
online survey that 87% of respondents used IHC to subtype renal tumors sometimes or 
occasionally. The selection of these IHC antibodies depends on the familiarity of pathologists 
as well as ready availability of the antibodies. In their report, Tan et al listed the commonly 
used IHC differential staining patterns for differentiating chRCCs and ROs as: CK7, MOC31, 
EpCam, Cav-1, EABA, CD82, S100A1, parvalbumin, Ksp-cadherin and CD117 (Tan et al. 
2013). 
One of the interesting biomarkers in RCC is nuclear factor – kappa B (NF-κB). NF-κB is a 
collective term for transcription factors of the reticuloendotheliosis (Rel) family of DNA-
binding proteins that recognize a common sequence motif (5′GGG(A/G)NN(T/C)(T/C)CC-3′, 
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where N is any base), called the κB site (Makarov 2000). NF-κB was first described as a B-
cell factor that binds to a site in the enhancer region on the gene encoding the 
immunoglobulin κ light chain (Sen and Baltimore 1986). All five NF-κB members (p65, p50 
p52, RelB, c-Rel) contain a Rel homology domain (RHD) of 300 amino acids in the amino 
terminal, which is essential for dimerization, DNA-binding, and transcription. The RHD 
contains a nuclear localization sequence towards the carboxyl end. These proteins fall into 
two categories based on the mode of synthesis, proteolytic cleavage and transcription 
activities: those that do not, and those that do, require proteolytic cleavage. p65, RelB and c-
Rel proteins do not require proteolytic cleavage and are synthesized in their mature form. The 
second group consists of NF-κB1 and NF-κB2, which are synthesized in the immature form 
as p105 and p100 respectively and their activation requires proteolytic cleavage. These 
proteins have ankyrin repeats (AR) at their carboxyl terminals making them inactive. 
Ubiquitin-dependent proteolytic cleavage removes the carboxyl terminal domain, resulting in 
the production of the mature p50 from NFκB1 and p52 from NF-κB2 (Hayden and Ghosh 
2004; Karin and Ben-Neriah 2000). 
 
NF-κB transcription factors have been implicated in various cancers, including RCC. In 
tumours, NF-κB affects target genes involved in immunity, cellular proliferation, pro- or anti-
apoptotic functions and carcinogenesis. In addition, NF-κB is unique in RCC as it regulates 
all important aspects of RCC biology that pose a challenge to conventional therapy: 
resistance to apoptosis; angiogenesis; and multi-drug resistance (Morais et al. 2011). 
Therefore we investigated the expressions of NF-κB subunits in renal tumour subtypes and 
their normal counterparts, and will be further discussed in Chapter 4. 
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Similarly, IHC with established (CK7, caveolin-1, S100A1) and novel biomarkers (kidney 
injury molecule-1, leptin and leptin receptor) were also investigated to further elucidate the 
differences in expressions between RCC tumour subtypes (ccRCC, chRCC and RO). The 
reasons for these selection will be further discussed in Chapter 5.  
 
1.2.6 Conclusion 
The current clinical paradigm remains treatment of all localised renal lesions suspicious for 
renal cell carcinoma on the assumption they are malignant and the standard treatment for 
these lesions  remains surgical resection with either complete or partial nephrectomy when 
feasible. The increasing detection of small renal masses with a significant chance of benign 
aetiology provides a diagnostic and management challenge. RO and to a lesser extent small 
chRCC are two lesions that could be managed conservatively, in many situations, avoiding 
the morbidity inherent to resection of renal lesions. However, a very high level of diagnostic 
certainty is required if surgical intervention is to be avoided. Current imaging and biopsy 
techniques do not always provide this certainty as evidenced by the number of benign small 
renal lesions reported in contemporary surgical series. If confident diagnosis of renal lesions 
with low or no malignant potential can be achieved then active surveillance will usually be 
appropriate, with intervention reserved for tumours demonstrating excessive growth or 
symptoms. The ability to diagnose RO and chRCC with a high level of confidence may lead 
to improved utility of preoperative diagnostic techniques and reduced intervention rates for 
indolent renal lesions. Importantly, identification of reliable and reproducible IHC 
biomarkers which can aid in the differentiation between chRCC and RO, will pave the way 
for more accurate pathological diagnoses, which will determine the further management 
strategies for patients.  
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Therefore, there is need for further research into the identification of molecular profiles of 
renal tumours to address not only diagnostic issues mentioned above; but also further 
understanding of tried and novel biomarkers can be translated into diagnostic and therapeutic 
targets, thus making a difference in patients with renal tumours. 
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1.3 HYPOTHESIS 
 
This PhD research is centred upon the hypothesis that there are distinct differences in the 
molecular signatures between renal cancers that can be exploited. The differences in the 
unique molecular signatures of various renal tumours can be utilised to distinguish between 
malignant chRCC and benign RO phenotypes. 
 
1.4 AIMS 
 
The aims of this research include:  
1) Identification of panel of IHC biomarkers which can effectively differentiate chRCC from 
RO through a comprehensive literature search and meta-analysis approach;  
2) Assessment of the different molecular profiles of renal cancers via immunohistochemistry 
and morphometry techniques using selected biomarkers on renal tumour and normal tissue 
samples;  
3) Analyses of IHC biomarkers that are useful in differentiating chRCC from RO via IHC 
and Aperio ImageScope morphometry techniques; and 
 4) Creation of comprehensive Renal Tumour Biobank (clinical data, urine, sera, renal tumour 
and normal tissue) from patients with renal tumours undergoing nephrectomy. 
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CHAPTER 2 
MATERIALS AND METHODS 
 
In this chapter, general materials and methods are presented, including the use of prospective 
RCC patient samples, IHC of archived RCC tissue blocks, morphometry and statistical 
analyses. The materials and methods involved in original research chapters 4 and 5 generally 
follow the details mentioned in this chapter. However, specific materials and methods are 
described in the meta-analysis in chapter 3. Prospective RCC patients’ samples which 
included renal tumour, normal renal tissue, sera and urine were collected, processed and 
stored in the CKDR at the TRI, Brisbane Australia, leading to the creation of the Renal 
Tumour Biobank, which is located in the CKDR. This work comprised Aim 4 of the thesis 
and will be a legacy of this PhD research. Although the Biobank itself will not be described, 
its formation involved a significant amount of time and resources throughout the PhD 
research project. 
With ethics approvals and patient consent, archived human RCC tissue blocks were obtained 
from the University Malaya Medical Centre (UMMC) in Kuala Lumpur Malaysia and 
Aquesta Pathology, Toowong Australia. IHC of the biomarkers on the tissue slides was 
performed with assistance from Mr. Clay Winterford in Queensland Institute of Medical 
Research (QIMR), Dr. David Small (CKDR and Bonventre Lab, Boston USA)  and Ms 
Crystal Chang in Histology Core Facility, TRI.  
 
2.1 Prospective RCC patient samples – the Kidney Tumour Biobank 
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This component of research involved recruitment of patients, collection, processing and 
storage of samples. The success of this part of the research was achieved after months of 
planning, application with approval of ethics and invaluable team coordination and effort of 
various departments. Ethics approval for collection of patient samples was obtained from 
Metro South Human Research Ethics Committee (HREC/05/QPAH/95) for Princess 
Alexandra Hospital and from Greenslopes Research and Ethics Committee (protocol 13/23) 
for Greenslopes Private Hospital. Relevant ethics approval for investigational research work 
into these samples and other relevant work involved in this PhD was obtained from Metro 
South Human Research Ethics Committee (HREC/12/QPAH/125) and also from the 
University of Queensland Institutional Human Research Ethics Committee (approval number 
2013001265). These ethics approvals are included in Appendix 2. The collection of samples 
started around mid June 2013 and the process is still ongoing. We are proud to report that at 
time of writing this thesis, there have been approximately 200 samples obtained from RCC 
patients and stored in the Renal Tumour Biobank in CKDR, TRI with comprehensive clinical 
data of the patients stored in a secure database.  
 
2.1.1 Clinical data 
Prospective patients with renal tumours undergoing nephrectomy that presented to Princess 
Alexandra Hospital and Greenslopes Private Hospital were recruited following informed 
consent and discussion about the research project. As per ethics protocols, patients were 
given the Patient Information and Consent Form (PICF) to be signed. Along with these, 
clinical data (Queensland Renal Tumours Clinical Record) were recorded by the attending 
clinician. These forms (PICF and Queensland Renal Tumours Clinical Record) are included 
in Appendix 3. The comprehensive clinical data included patient characteristics, biochemical 
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parameters, tumour characteristics, pathology report and also follow up data on tumour 
progression. The clinical data are then stored in a de-identified coded form in soft and hard 
copies locked away in the office at CKDR. Corresponding H&E-stained histology slides of 
these patients are also scanned with Aperio ScanScope digital imaging and stored in de-
identified coded forms as soft copy in the CKDR computer files in the TRI.  
 
2.1.2 Collection, processing and storage of serum samples 
Pre-operatively, approximately 6-10 mls of venous or arterial blood were collected from the 
patient in EDTA blood collection tubes. This was transported back to the CKDR laboratory 
in ice. The samples were then centrifuged for 15 minutes at 2000 rpm at 25°C. Resultant 
plasma was then aliquoted into 3 Eppendorf tubes with each tube containing 1ml of plasma. 
The buffy coat was also stored in another Eppendorf tube. The plasma, buffy coat and 
remnant whole blood cells were then coded accordingly to the corresponding patient and 
stored in the -80°C Biobank freezer. 
 
2.1.3 Collection, processing and storage of urine samples 
Pre-operatively, approximately 15-20 ml of fresh urine were collected from the patient. This 
was transported in ice immediately to the laboratory and then centrifuged at 1200 rpm for 10 
min at 25°C. The resultant supernatant was then divided into 1ml aliquots and placed in 
Eppendorf tubes with the corresponding unique patient’s de-identified code. These were 
stored in the -80°C Biobank freezer in CKDR. 
 
2.1.4 Collection, processing and storage of kidney tissue samples 
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Following nephrectomy, the kidney was transported fresh in a cooler box filled with ice to the 
Pathology Department at the Princess Alexandra Hospital (if nephrectomy from Greenslopes 
Hospital, then transported to Aquesta Pathology in Toowong). The pathologist then located 
the tumour and 2 pieces of tumour tissue with 2 pieces of normal renal cortical tissue were 
retrieved for tumour biobanking (approximately 5x5 mm size). These were transported back 
in a cooler filled with ice to the CKDR laboratory. 
 
Back in the laboratory, fresh normal kidney tissue was divided into 4 pieces. One piece was 
fixed in 4% buffered formalin and stored in a 4°C fridge. Within 24 h, this piece of tissue was 
removed from formalin and placed into phosphate buffered saline (PBS) and stored in the 
4°C fridge. This was later paraffin-embedded into tissue blocks using routine histology 
procedures (Histology Core Facility, TRI) and kept in locked storage at the CKDR. The other 
normal fresh piece of kidney tissue was divided into 3 smaller tissue cubes and stored into 
individual Eppendorf tubes (with unique patient’s code) at -80°C freezer as part of the Renal 
Tumour Biobank.  
 
On occasions where there were metastatic and tumour thrombus tissues available, these 
samples were also retrieved in similar fashion to above from the pathologist and transported 
back in container filled with ice to the TRI. There, the samples were divided into smaller 
pieces and stored similarly (fresh at -80°C and fixed in formalin) as described above for the 
renal tissue. 
 
All tissue samples stored were recorded in soft copy and hard copy in CKDR. These Renal 
Tumour Biobank samples, together with the clinical database of the patients, provide a 
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comprehensive collection of RCC patients. The clinical database is continually updated and 
provides an ongoing database of progression in these patients. It is envisioned that this 
clinical database will be an invaluable resource for future studies. Likewise, the Renal 
Tumour Biobank will be a rich resource (sera, urine, tumour and normal tissue) for future 
research into renal tumours. I believe that this Renal Tumour Biobank is the first dedicated 
exclusive renal tumour tissue biobank in Australia. There are many other established tissue 
banks that store renal tumour tissue (for example, Wesley Research Institute Biobank, 
Victorian Cancer Biobank, Australasian Biospecimen Network), but they do not store renal 
tissue exclusively, unlike ours. 
 
Currently at time of writing we have approximately 200 patient samples stored in our 
Biobank and along with that, the corresponding clinical data of these patients. The snapshot 
summary of patient clinical characteristics is listed in Table 2.1. 
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Table 2.1: Clinical data from prospective patients 
Patients  N = 202 
Male : Female 127 : 75 
Mean age at presentation (years) 57.0 ± 13.5 
BMI 28.9 ± 6.0 
Hypertension (%) 126 (62.4) 
Mean preoperative eGFR (ml/min/1.73m
2
) 72.7 ± 26.4 
Median tumour size (cm) 4.5 (1.2 – 22) 
Clinical T stage (%) 
 
T1 = 158 (78.2) 
T2 = 16 (7.9) 
T3 = 17 (8.5) 
T4 = 6 (2.9) 
M1 = 5 (2.5) 
Pathology (%) Clear cell RCC = 131 (64.8) 
Papillary RCC = 22 (10.9) 
Chromophobe RCC = 20 (9.9) 
Clear cell tubulopapillary RCC = 4 (2) 
Multilocular cystic RCC = 5 (2.5) 
Oncocytoma = 9 (4.5) 
Others (benign and malignant) =11 (5.4) 
Body mass index (BMI); Tumour (T), Metastates (M), Estimated glomerular filtration rate 
(eGFR); Renal cell carcinoma (RCC)  
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2.2 Immunohistochemistry of archived human renal tumour samples 
Archived human renal tumour tissue paraffin blocks were obtained from University Malaya 
Medical Centre (UMMC), Kuala Lumpur Malaysia (for IHC of nuclear factor–kappa B/NF-
κB) and Aquesta Pathology Toowong Australia (for IHC of cytokeratin7, caveolin-1, leptin 
(Ob), leptin receptor (ObR), S100A1, kidney injury molecule-1/KIM-1). The archived tissue 
blocks were collected retrospectively from a period of 2003-2013 for UMMC and from 2009-
2014 for Aquesta Pathology. The ethics approvals for scientific use of archived pathology 
blocked samples were obtained from University Malaya Ethics Committee (Ref: 848.17) and 
Aquesta Pathology Ethics Committee (protocol 14/02). These are included in Appendix 4. 
The clinical data collected retrospectively from these two sets of archival pathology renal 
tumour tissue blocks are listed in Table 2.2 (clinical data of UMMC) and Table 2.3 (Aquesta 
Pathology). The clinical staging system used for UMMC and Aquesta Pathology was the 
2010 Tumour Node Metastasis (TNM) staging classification as previously described in 
chapter 1 (Edge and Compton 2010). Fuhrman grading of ccRCC was based on the nuclear 
features: Grade 1. Small nuclear diameter, round nuclear shape and absent nucleoli; Grade 2. 
Larger nuclear diameter, irregular nuclear outline and visible nucleoli at x400; Grade 3. Even 
larger nuclear diameter, obvious irregular nuclear outline and prominent nucleoli at x100; 
Grade 4. Bizarre large often multilobed nuclei with or without spindle cells (Fuhrman et al. 
1982). 
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Table 2.2 Clinical data for University of Malaya Medical Centre tissue blocks 
Period 2003 - 2013 
Patients 96 
M : F 67.7%    :    32.3% 
Median age 62 (39-83) 
Median size 6cm (1.5-17) 
Clear cell RCC (stage) 43 (T1) 22 (T2) 9 (T3) 2 (T4) 
Clear cell RCC (grade) 10 (G1) 37 (G2) 22 (G3) 7 (G4) 
Papillary RCC (stage) 5 (T1) 3 (T2) 2 (T3) 1 (T4) 
Papillary RCC (grade) 0 (G1)  7 (G2) 4 (G3) 0 (G4) 
Chromophobe RCC (stage) 3 (T1) 0 (T2) 2 (T3) 0 (T4) 
Multilocular cystic RCC (stage) 1 (T1) 0 (T2) 0 (T3) 0 (T4) 
Clear cell tubulopapillary RCC (stage) 1 (T1) 1 (T2) 1 (T3) 0 (T4) 
Stage    T1 53 (55.2%) 
              T2 26 (27.1%) 
              T3 14 (14.6%) 
              T4 3 (3.1%) 
Metastases (M1) 22 (22.9%) 
Tumour (T); Metastases (M) 
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Table 2.3 Clinical data for Aquesta Pathology tissue blocks 
Patients N = 75 
Period 2009 – 2014 
Gender 49 Male : 26 Female 
Median age (years) 64 (18-88) 
Median size (cm) 3.8 (1.2-18) 
Nephrectomy Partial = 25 (33.3%) 
Radical = 50 (66.7%) 
Subtype 30 ccRCC 30 chRCC 15 RO 
T stage                 
 
ccRCC chRCC 
 
RO 
 
T1 = 47 (62.7%) 20(66.7%) 15(50%) 12(80%) 
T2     7 (9.3%)              0 5(16.7%) 2(13.3%) 
T3 = 20 (26.7%) 9(30%) 10(33.3%) 1(6.7%) 
T4= 1 (1.3%) 1(3.3%) 0 0 
M1 stage            2 (2.67%) 
Fuhrman (ccRCC)      
                                 
                 
Grade1 Grade2 Grade 3 Grade 4   
0 63.3%  
20% 
 
16.7% 
Poor prognostic 
histological features 
21 (28%) 
                Tumour (T); Metastases (M) 
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2.2.1 Haematoxylin and eosin staining of renal tumour sections 
All histology sections were cut from the formalin-fixed paraffin-embedded renal tumour 
tissue blocks at 3-4µm thickness using the Leica microtome and placed onto Menzel-Glaser 
Superfrost® Plus slides (Thermo Scientific, USA). This work was performed in the Histology 
Core Facility, TRI, with aid from Ms Crystal Chang. Histology sections for each specimen 
were also stained with H&E for general morphology and pathological analysis. This work 
was carried out at the Histology Facility in QIMR by Mr. Clay Winterford. Sections were 
dewaxed in xylene and rehydrated in descending grades of alcohol. Sections were briefly 
washed in distilled water before staining in Mayer’s haematoxylin for 5-10 minutes. Sections 
were then washed in water for 2 minutes before the nuclear stain was blued in Scott’s 
solution (potassium bicarbonate 2g/ml, magnesium sulphate 20g/ml in distilled water) and 
washed in water for 2 minutes. Sections were then washed in 70% alcohol before alcoholic 
eosin was added as a counter stain for 1-3 minutes. Absolute alcohol was used to dehydrate 
the sections before being cleared in xylene and mounted using Depex (Sigma-Aldrich, USA) 
for the coverslips.  
 
2.2.2 IHC for Nuclear factor kappa B (NF-κB), leptin receptor (ObR), S100A1, kidney 
injury molecule -1 (KIM-1) 
The IHC for NF-κB, ObR, S100A1 was manually batch-stained at QIMR with help of Mr. 
Clay Winterford. IHC of KIM-1 was manually batch-stained by Dr. David Small in the 
Bonventre Lab, Harvard USA. Batch staining allows comparison of kidney tumour samples 
using semi-quantitative IHC. Antibody optimisation and positive control tissue samples 
(tissue microarray of human liver, kidney and gut) were used to verify the staining activity of 
the biomarker in human tissue. Negative controls without primary antibody were prepared for 
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each batch stain. An example of positive and negative controls for S100A1 IHC is shown in 
Figure 2.1. The principles of IHC are similar and generally follow the steps listed. The buffer 
solutions, dilutions of primary and secondary antibodies and detection kits will differ and 
these are listed in Table 2.4. Mentioned briefly here are the general steps for IHC for NF-κB, 
ObR and S100A1. 
 
Sections were dewaxed in xylene and rehydrated through descending graded alcohols to 
water using standard protocol. Then the sections were transferred to Tris buffered saline 
(TBS) pH 7.6. Endogenous peroxidase activity was blocked by incubating the sections in 
2.0% hydrogen peroxide (H2O2) in TBS for 10 minutes. Sections were then washed in three 
changes of water, and transferred into buffer and subjected to 15 minutes heat antigen 
retrieval at 105°C using a Biocare Medical decloaking chamber. On completion of the 
cooling cycle the slides were allowed to cool for a further 20 minutes on the bench before 
transferring back to TBS. Then they were washed in 3 changes of TBS. Nonspecific antibody 
or peroxidase binding was inhibited by incubating the sections in Biocare Medical 
Background Sniper for 15 minutes. In a humidified chamber excess Sniper was decanted 
from the sections and the primary antibody was applied for 60-90 minutes at room 
temperature. Sections were washed in three changes of TBS. Detection kit of specific 
secondary antibodies of MACH 1 Universal HRP-Polymer Detection (Biocare Medical, 
USA) was applied for 30 minutes. Sections were then washed in three changes of TBS. 
Signals were developed in Betazoid diaminobenzidine hydrochloride (DAB) (MACH1 kit) 
for 5 minutes, with DAB as the chromogen. Sections were then washed in water three times 
to remove excess chromogen, then lightly counterstained in haematoxylin, washed in water, 
dehydrated through ascending graded alcohols, cleared in xylene, and mounted using DePex. 
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For KIM-1 IHC, paraffin sections were deparaffinised and rehydrated by routine methods as 
described above. Endogenous peroxidase activity was ablated by incubation in 2% H2O2 in 
methanol for 20 minutes. Then sections were washed with water. Antigen retrieval was 
carried out in a pressure cooker, in buffer pH 8. Sections were allowed to cool for 30 minutes, 
then they were washed in PBS 10 minutes (PBS x3 changes). Blocking was carried out in a 
humidifier chamber in 3% bovine serum albumin (BSA) in PBS for 60 minutes at room 
temperature. Sections were incubated with primary antibody diluted in 3% BSA:PBS, 
overnight at 4
o
C in a humidifier chamber, then washed in PBS (x3 times) and incubated with 
Biotin anti-mouse secondary antibody diluted in PBS for 30 minutes at room temperature. 
Slides were then washed in PBS and incubated with Avidin-Biotin-Complex (Vectorstain 
Elite ABC kit) diluted in PBS for 60 minutes at room temperature. Slides were then washed 
in PBS (x3 changes), and then DAB substrate (in 2.5 mL dH2O, add 1 drop buffer, 2 drops 
substrate, 1 drop H2O2) was added to slides generously and incubated for 5 minutes. Slides 
were thoroughly washed with dH2O to remove all DAB, and then counter stained with 
hematoxylin, blued as described previously, dehydrated in alcohols and cleared in xylene 
before DePex to mount coverslips. 
 
2.2.3 IHC for CK7, leptin (Ob), caveolin-1 (Cav-1) 
The IHC for CK7 and Ob, Cav-1 was performed with an automatic Ventana Discovery 
ULTRA Stainer (Ventana Medical Systems Inc, Roche) using their set protocols. This was 
done with help of Mr David Small and Ventana representative, Ms Janet Thompson. The 
slides were placed into the Ventana automated stainer. Primary and secondary antibodies 
were added to the autostainer at specific stages. Following staining, the slides were then 
dehydrated and cleared in xylene before coverslips were mounted automatically. The 
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protocols of IHC by the Ventana automated stainer have been included in Appendix 5. The 
details of the primary and secondary antibodies are given in Table 2.4. 
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Figure 2.1: TMA S100A1 positive and negative controls   
A. TMA of S100A1 positive control of melanoma; B. TMA of S100A1 positive control of 
colon; C. TMA of S100A1 negative control of melanoma; D. TMA of S100A1 negative 
control of colon cancer. (x10 Aperio magnification) 
 
 
 
  
A B 
C D 
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Table 2.4: Primary and secondary antibodies for IHC 
IHC Retrieval buffer Primary antibody with 
dilution 
 
Secondary antibody  
NF-κB For p50, p52, RelB and 
c-Rel: 
EDTA/Tris buffer 
(1mM/0.01M, pH9.0) 15 
minutes at 105°C  
For p65: citrate buffer 
(0.1M, pH6) at 125°C for 
5 minutes 
rabbit anti-human 
antibodies from Santa 
Cruz : p50 (sc-7178, 
dilution 1:100), p52 (sc-
298, 1:100), p65 (sc-372, 
1:150), RelB(sc-226, 
1:100) and c-Rel (sc-71, 
1:400) 
MACH 1 Universal 
Rabbit HRP-
Polymer Detection 
ObR Dako pH 6 Epitope 
Rerieval buffer 30 mins 
at 95°C 
Santa Cruz purified goat 
anti- ObR (1:50 dilution) 
(sc-1834) 
Goat HRP secondary 
Ab 40 mins room 
temperature 
S100A1 Dako pH 6 Epitope 
Rerieval buffer 15 mins 
at 105°C 
Sigma purified rabbit 
anti-S100A1 (1:125 
dilution) (HPA006462) 
MACH 2 Rabbit 
HRP secondary Ab 
for 30 minutes 
(105°C) 
KIM-1 0.1M citrate buffer pH8  
R-UNIVERSAL Epitope 
Recovery Buffer 
anti-KIM-1 mouse 
monoclonal antibody 
AKG7 (neat) 
Vector biotinylated 
anti-mouse IgG 
Caveolin-1 0.01M citric acid buffer 
pH6  
Santa Cruz rabbit anti-
Cav-1 (1:250 dilution) 
(sc-894) 
MACH2 HRP anti-
rabbit polymer 
CK7 CC 1 buffer pH6 Santa Cruz mouse anti-
CK7 (1:75 dilution) 
 (sc-23876) 
Anti-mouse HQ 
16 mins 
Ob CC1 buffer pH6 Santa Cruz rabbit anti-Ob 
(1:60dilution) (sc-842) 
Anti-rabbit HQ 16 
mins 
 
 
2.3 MORPHOMETRY ANALYSIS 
 
Stained slides were scanned with an Aperio ScanScope XT slide scanning system (Aperio 
Technologies, USA) at 20x magnification. Digital images of the sections were captured using 
Aperio ImageScope software (Leica Biosystems, Germany) (Staniszewski 2009).  A 
quantitative scoring of expression intensity and localisation of the various IHC biomarkers 
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was analysed with respect to overall expression, nuclear expression and membrane 
expression, following advice from Aperio staff and as demonstrated in peer-reviewed 
publications from our laboratory (Rajandram et al. 2012; Rajandram et al. 2014; Gobe et al. 
2016). 
 
2.3.1 Overall positive pixel expression analysis 
Three random fields of the same size were selected for each RCC and paired normal kidney 
section, using DAB positivity as the positive chromogen. Analysis was carried out using the 
Positive Pixel Count v9 algorithm (for total staining intensity) from the Aperio ImageScope 
software. Staining (% positive pixels) was scored according to the intensity and percentage of 
cells stained. The intensity output for Positive Pixel Count v9 algorithm was given as number 
of negative, weak positive, positive or strong positive pixels. The output was analysed in 
Excel. Overall positive pixels (%) were calculated by adding the values for “positive %” and 
“strong positive %” pixels staining. 
 
The average of the 3 overall positive pixels % from the 3 respective scanned fields of renal 
tumour sections was obtained. Similarly the average overall % positive pixels for 3 random 
fields in the normal kidney sections, paired to a particular tumour, were obtained. 
Subsequently, the intensities of tumour and normal kidney values were normalised against 
respective normal kidney regions and the data were expressed as the percentage of overall 
normal values. 
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These results of normal kidney overall % change and tumour overall % change were then 
tabulated and analysed with Graphpad Prism 6 (GraphPad Software, Inc). Graphs were 
generated to show the % expression change for tumour versus normal kidney. 
 
2.3.2 Nuclear expression analysis 
Similarly, three random fields of the same size were selected for each RCC and paired normal 
kidney section. Analysis was carried out using the algorithm IHC Nuclear v1.0 from the 
Aperio ImageScope software. The output for IHC Nuclear v1 algorithm was given as a 
percentage of pixels with 0, 1+, 2+ or 3+ staining intensity. These results were analysed using 
Excel. Nuclear positive pixels (%) were calculated by adding the values for 2+ % and 3+ % 
staining.  The average of the 3 nuclear positive pixels from 3 normal sections and average of 
3 nuclear positive pixels from 3 tumour regions was then calculated. These were then made 
into average nuclear percentage. The nuclear intensities of tumour and normal kidney were 
normalised against respective normal regions and the data were expressed as the percentage 
of overall normal values. 
 
The results of normal nuclear % change and tumour nuclear % change were then tabulated 
and analysed with Graphpad Prism 6 (GraphPad Software, Inc) programme. Graphs were 
generated to show the nuclear expression % change for tumour versus normal kidney. 
 
2.3.3 Membrane expression analysis 
Three random fields of the same size were selected for each RCC and paired normal kidney 
section. Analysis was carried out using algorithm IHC Membrane v1.0 from the Aperio 
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ImageScope software. The output for IHC Membrane v1 algorithm was given as percentage 
of pixels with 0, 1+, 2+ or 3+ staining intensity. These results were analysed in Excel. 
Membrane positive pixels (%) were calculated by adding the values for 2+ % and 3+ % 
staining. The average of the 3 membrane positive pixels from 3 normal sections and average 
of 3 membrane positive pixels from 3 tumour regions was then calculated. These were then 
made into average membrane percentage. The membrane intensities were normalised against 
respective normal regions and the data were expressed as the percentage of overall normal 
values. 
 
These results of normal kidney membrane % change and tumour membrane % were then 
tabulated and analysed with Graphpad Prism 6 (GraphPad Software, Inc). Graphs were 
generated to show the membrane expression % change for tumour versus normal kidney. 
 
2.3.4 Survival analysis for NF-κB subunits 
For survival analysis, the median positive pixel score was used to determine cut-off scores for 
‘high’ or ‘low’ staining for each biomarker subunit. These results were correlated against the  
patient cancer specific survival in months from treatment. Cancer specific survival is defined 
as net survival (in months) from death caused by the cancer rather than any other causes. It 
measures mortality directly due to cancer (Dickman and Adami 2006). 
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2.4 STATISTICAL ANALYSIS 
 
Statistical analysis was performed using Graphpad Prism 6 (GraphPad Software, Inc).  Data 
analysis comparing intensities of expression between 2 groups was carried out using 
Student’s t-test. A one way analysis of variance (ANOVA) was used for comparison among 
more than two groups, to determine the difference in positive pixels (%) or staining intensity 
between several groups. Statistical significance was determined at p<0.05. For survival 
analysis for NF-κB subunits, the survival curves were obtained using Kaplan-Meier. Survival 
differences between groups were evaluated using the log rank test. The Cox proportional 
hazards regression was used to analyse subunits of biomarkers that showed significance in 
the log rank test. For multivariate analysis, confounding variables included tumour subtype, 
grade and clinical TNM stage because all these factors affect survival. 
 
2.5 META-ANALYSIS 
 
The methodology for the meta-analysis employed in Chapter 3 will be discussed in detail in 
that chapter. Dr. Anne Bernard, biostatistician from the Queensland Facility for Advanced 
Bioinformatics (QFAB), TRI, Brisbane Australia advised on the methods involved in R 
studio statistical analysis required for this part of the research. 
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CHAPTER 3 
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CHAPTER 3 
META-ANALYSIS OF IMMUNOHISTOCHEMICAL BIOMARKERS THAT 
DIFFERENTIATE CHROMOPHOBE RENAL CELL CARCINOMA  
FROM RENAL ONCOCYTOMA 
 
Following the discussion in Chapter 1 in which numerous novel and existing IHC biomarkers 
had been reported as useful to differentiate chRCC from RO, the literature was examined for 
a detailed assessment of IHC biomarkers that are reliable and effective. Therefore, a meta-
analysis was conducted to answer this question. This meta-analysis has been published (Ng et 
al. 2016) (Appendix 6). 
 
3.1 INTRODUCTION 
 
As discussed in Chapter 1, both RO and chRCC arise from intercalated cells of the collecting 
ducts. Due to considerable morphological and histological overlap between the two entities, 
they are often considered to be extremes of the same morphological spectrum (Delongchamps 
et al. 2009). Accurate differentiation between benign RO and malignant chRCC will 
obviously lead to better patient management and follow-up strategies in the clinical setting. 
Following excision of RO, patients will not require any further surveillance imaging and are 
managed expectantly. On the other hand, despite having a more favourable prognosis 
compared with other counterparts of RCC, patients with chRCC will still require future 
surveillance imaging protocols to assess local recurrence or metastases. Proper differentiation 
largely relies on H&E histochemistry of sections, and an experienced histopathologist to 
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discern the characteristic histomorphological features between the two entities. However, 
pathologists generally have difﬁculties discriminating RO, especially from the eosinophilic 
variant of chRCC. Despite having some subtle distinguishing macroscopic, microscopic and 
ultrastructural differences, there is often a need to use ancillary histochemical and IHC stains 
to differentiate these two entities. To date, however, none of the histochemical, IHC or 
cytogenetic features has been proven to be reliable and speciﬁc (Mazal et al. 2005). Other 
techniques, for example, electron microscopy, ﬂuorescence in situ hybridisation, proteomics 
and cytogenetics have been used to delineate the two entities, but they are costly, not easily 
available and require more technical expertise. Therefore, IHC has been the mainstay of 
laboratory techniques due to its accessibility, ease of use and cheaper costs. Numerous 
biomarkers have been employed for IHC to differentiate RO from chRCC. However, 
consistent accurate diagnosis differentiating RO from chRCC is likely to remain elusive until 
modern molecular biomarkers are identiﬁed and applied routinely to ensure reproducibility 
(Ng et al. 2014).  
 
Therefore, the aim of this study was to analyse and summarise selected results from 
published literature regarding the discriminatory role of IHC biomarkers in differentiation of 
chRCC from RO. Following this, we identify and propose IHC biomarkers that are useful in 
this respect so as to assist in the important distinction between chRCC and RO. This 
distinction will affect management pathways of the two clinically distinct entities and also 
perhaps be useful in future implications for preoperative diagnostic modalities. 
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3.2 METHODS 
3.2.1 Literature search 
For the assessment of research that involved IHC biomarkers that differentiated chRCC from 
RO, a literature search via the PubMed medical literature database was performed up to 19 
January 2015, with the help from an expert librarian from Princess Alexandra Hospital, 
Queensland. The main criteria for the literature search centred on the differential ability of 
biomarkers in discriminating chRCC and RO. The search strategy was based on the 
combination of terms used: ‘chromophobe renal cell carcinoma and renal oncocytoma’; and 
‘differentiation or diagnoses’; and ‘biomarkers or proteins or antibodies’. Following the 
search and with help from the librarian, the full texts were obtained of selected articles, with 
both soft and hard copies available for further analysis. These publications were initially 
scrutinised through inspection of their contents for their relevance to the aim of this review, 
which was the differential ability of IHC biomarker(s) to identify chRCC and RO. 
Publications that did not conform to the main aim of this review were discarded. 
 
3.2.2 Quality appraisal of publications  
There were strict inclusion and exclusion criteria set out to assess the validity of the 
publications obtained from the literature search. For inclusion eligibility, publications were 
English articles from 1991 which had to contain: clear objectives in prospective or 
retrospective cohort design in the assessment of IHC biomarkers in differentiating renal 
cancers; description of IHC for biomarkers/proteins/antibodies used; human renal tumour 
tissue of histology slides/tissue microarray/tissue core biopsies; techniques and analyses of 
the IHC on subtypes of renal cancers but must include chRCC and RO; clear documentation 
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of IHC results of biomarkers with negative results (no difference between chRCC and RO) 
also recorded and statistical analyses of results, which included p values or sensitivity and 
speciﬁcity data. Publications that were excluded : 3 non-English articles (2 Chinese, 1 
German); 6 non-IHC methods; 14 single case reports or limited case series (<10 cases); 3 
analyses of other subtypes of RCC without inclusion of chRCC and RO; 5 reply or letter to 
editor; 11 studies involving familial RCC syndromes; and abstracts or conference 
proceedings. Quality assessment of these publications was made and some were discarded 
from further analyses, if found lacking in the criteria mentioned above. Publication bias was 
actively avoided, with all publications pertaining to the use of IHC biomarkers in renal 
tumours included, and studies with negative or inconclusive results also analysed. 
  
3.2.3 Extraction of data  
All the eligible publications were then fully reviewed. Data from the included publications 
were then extracted into an Excel spreadsheet. Study characteristics that were gathered 
included: title; ﬁrst author’s name; journal site; publication year; biomarker(s) studied; IHC 
design; sample size (total and individual chRCC and RO); measurement of IHC analyses 
(staining intensity or differential staining expression); results of IHC biomarker for chRCC 
and RO and methods and signiﬁcance of statistical analyses (p value, sensitivity and 
speciﬁcity). Data were then further analysed and publications were ranked 1–4, according to 
the quality of the IHC results, which had the best differential ability in discriminating chRCC 
from RO based on their objective of the study, IHC results and statistical strength of their 
results.  
Rank 1: publications in which the objective was to assess the role of IHC biomarker in 
differentiating exclusively chRCC and RO, with good signiﬁcant discriminatory ﬁnal results.  
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Rank 2: publications in which the objective was to assess IHC biomarker(s) in differentiating 
subtypes of renal cancers, which included chRCC and RO with ﬁnal signiﬁcant 
discriminatory results. 
Rank 3: publications in which the objective was to assess IHC biomarker in only chRCC and 
RO, but ﬁnal results were unclear or did not show any discriminatory value.  
Rank 4: publications in which the objective was to assess IHC biomarker in subtypes of renal 
cancers which included chRCC and RO, but ﬁnal results were inconclusive. 
 
Once these publications were ranked, only the rank 1 and 2 publications were further 
analysed. The results (both qualitative and descriptive expression) of the biomarkers from 
these publications were further evaluated for odds ratios (ORs) and 95% confidence intervals 
(CIs). Some biomarkers (termed repeated biomarkers) had been investigated in numerous 
publications and were further analysed in a subset analysis with pooled ORs. Finally, a panel 
of biomarkers was selected based on the strength of their statistical results and reproducibility 
of such results in various studies. 
  
3.2.4 Statistical analyses 
 Statistical analyses were performed with the help of Dr Anne Bernard, biostatistician from 
QFAB Bioinformatics, Institute for Molecular Bioscience, University of Queensland. 
Following the ranking and selection of the most relevant biomarkers, statistical analyses of 
ORs for chRCC compared with RO and 95% CIs were calculated using R statistical software 
(http://www.r-project.org). When the biomarkers were investigated in at least two 
publications, the pooled ORs with 95% CI and I
2
 test for heterogeneity were computed using 
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the R function ‘metabin’ available in the ‘meta’ R package. The statistical test of 
heterogeneity among studies was performed using the Q test and result represented by I
2
 
percentage (derived from the Q test). The I
2
 is a measure of the degree of inconsistency in the 
study results and represents the percentage of total variation across studies that is due to 
heterogeneity rather than chance (Higgins et al. 2003). A value of 0% indicates no observed 
inconsistency, and larger values show increasing heterogeneity. We considered heterogeneity 
to be present if p value was <0.1. Forest plots of repeated biomarkers were also prepared. For 
studies with a zero cell count, a treatment arm continuity correction is used instead (Diamond 
et al. 2007; Sweeting et al. 2004). Studies with zero or inﬁnite OR are not presented on the 
plot, as their variance cannot be calculated sensibly. Nevertheless, their signiﬁcant results 
based on different staining patterns are discussed to provide the readers with the 
understanding behind the value of the biological results, despite the calculated zero or infinite 
OR. Throughout the work in this review, published guidelines outlined by PRISMA 
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses) (Juni and Egger 
2009), were adhered to. 
 
3.3 RESULTS 
 
3.3.1 Relevant studies and ﬂow chart 
Following the literature search, 109 manuscripts were available for review. From this, 42 
manuscripts were excluded based on inclusion and exclusion criteria mentioned above. Sixty-
seven relevant publications from 1991 to 2014 were then analysed. The full texts of all 67 
manuscripts that were deemed most appropriate and relevant in achieving the aim of this 
meta-analysis were then reviewed. After data extraction of the 67 publications, further 
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assessment and ranking of these publications were made as described above. Consequently, 
40 publications which presented signiﬁcantly discriminatory IHC results of biomarkers were 
ranked accordingly. Only rank 1 and 2 publications were further analysed as these studies 
revealed biomarkers that could differentiate chRCC and RO appropriately as shown in Tables 
3.1 and 3.2. There were 20 publications ranked 1, 20 ranked 2, 4 ranked 3 and 23 ranked 4. 
The 40 rank 1 and 2 publications yielded 49 biomarkers: 31 biomarkers that were studied 
once and 18 biomarkers that had been investigated in at least 2 or more studies. OR and 95% 
CI of these 49 biomarkers were calculated. Biomarkers that did not have statistically 
signiﬁcant differentiating results were noted and ﬁltered, leaving behind 25 biomarkers 
studied once (single biomarkers) and 12 repeated biomarkers. Finally, the 6 most-effective 
single biomarkers were chosen from the 25, and 4 most-effective repeated biomarkers were 
chosen from the 12 repeated biomarkers. This is depicted in the ﬂow chart in Figure 3.1 
below. This ﬁnal selection was based on strength of the study where the biomarkers exhibited 
the best differentiating ability for chRCC and RO in regards to larger sample size (n>34; as 
the median sample size from the studies was calculated to be 34), signiﬁcant p value <0.05, 
high OR and pooled OR with 95% CI, high sensitivity and speciﬁcity and distinctive staining 
patterns. 
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Table 3.1: Rank 1 publications 
 
Author Journal  Year/Vol/Pages Biomarkers 
(Cochand-
Priollet et al. 
1997) 
Arch Pathol 
Lab Med 
1997,121,1081-
1086 
Peanut agglutinin antigen, UEA-1, 
cytokeratin KL1, epithelial 
membrane antigen, vimentin, S100 
protein, lysozyme 
(Leroy et al. 
2000) 
European 
Urology 
2000,37,484-
487 
CK7  
(Kuroda et al. 
2004) 
Histology and 
Histopathology 
2004,19,23-28 CK 7,8, 10, 10/13, 14, 18 19,20 
AE1/AE3 
(Mazal et al. 
2005) 
Human 
Pathology 
2005,36,22-28 Ksp cadherin, CK7, EMA 
(Mete et al. 
2005) 
Virchows Arch 2005,447,38-
946 
anti-mitochondrial, caveolin 1, 
CD63, CK14 
 (Garcia and Li 
2006) 
Am J Clin 
Pathol 
2006,125,392-
398 
caveolin 1, CK7 
(Adley et al. 
2006a) 
Anal Quant 
Cytol Histol 
2006,28,228-
236 
CK7, parvalbumin 
(G. Li et al. 
2007) 
Histopathology 2007,50,642-
647 
S100A1 
(Sukov et al. 
2009) 
Human 
Pathology 
2009,40,1296-
1303 
cyclin D1 
(Osunkoya et al. 
2009) 
Human 
Pathology 
2009,40,206-
210 
Claudin 7, claudin 8 
(Kim et al. 
2009) 
Histopathology 2009,54,633-
635 
cytokeratin 7, S100A1 and claudin 
8 
(Demirovic et 
al. 2010) 
Pathology- 
Research and 
Practice 
2010,26,695-
699 
MAGE-A3/4, NY-ESO-1 
(Kuroda et al. 
2011) 
Med Mol 
Morphol 
2011,44,111-
115 
S100A1 
(Carvalho et al. 
2011) 
Histopathology 2011,58,169-
179 
 CK7, vimentin,S100A1 and C-kit  
(Ohe et al. 2012) Med Mol 
Morphol  
2012,45,98-104  KAI1, epithelial specific antigen, 
and epithelial related antigen, 
claudin 7, claudin 8 
(Zheng et al. 
2013) 
Exp and Mol 
Path 
2013 , 94, 29-32 LMP2 
(Gaut et al. 
2013) 
Modern 
Pathology 
2013, 26, 716-
724 
FXYD2, Ksp-cadherin 
(Ehsani et al. 
2013) 
Tumor 
Biology 
2013, 34,787-
791 
BCA2 
(Jain et al. 2013) AM J Surg 
pathol 
2013,37,1824-
1830 
amlyase alpha1A 
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(Demirovic et 
al. 2014) 
Eur J 
Histochemistry 
2014 58:2265 TGF β1  
Ulex europaeus agglutinin-1 (UEA-1), cytokeratin (CK), anti-cytokeratin AE1/AE3 clone 
antibodies (AE1/3), kidney specific (Ksp), epithelial membrane antigen (EMA), cluster of 
differentiation (CD), S100 calcium binding protein A1 (S100A1), melanoma-associated 
antigen A3/4 (MAGE-A3/4), NY-ESO-1 type cancer-testis antigen (NY-ESO-1), proto-
oncogene that encodes for a transmembrane tyrosine kinase receptor KIT (C-kit), 
immunoproteasome LMP2 (LMP2), distal tubule regulator of the trimeric Na+/K+ -
transporting ATPase (FXYD2), breast cancer-associated gene 2 (BCA2), transforming 
growth factor beta1 (TGF β1). 
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Table 3.2: Rank 2 publications 
Author Journal Year/Vol/pages Biomarkers 
(Bonsib et al. 
1991) 
Modern Pathology 1991,4,16-23 CK7, CK18 
(Tickoo et al. 
1997) 
Am J Surg Pathol 1997,21,922-
930 
antimitochondrial antibody (113-
1) 
(Liu and 
Fanning 2001) 
Cancer (Cancer 
Cytopathology) 
2001,93,390-
397 
cytokeratin cocktail (AE1/3, 
CAM5.2,MNF116), vimentin, 
Hale colloidal iron 
(Rampino et 
al. 2003) 
 Am J Surg Pathol 2003,27,779-
785 
Ron, Ki-67, p53,Bcl-2 
(Pan et al. 
2004b) 
Histopathology 2004,45,452-
459 
Pan-CK, HMCK,LMCK, CK7, 
EMA, MOC31, BerEP4, RCCma, 
CD10, E cadherin, CD15, 
vimentin  
(Skinnider et 
al. 2005) 
Am J Surg Pathol 2005,29,747-
754 
CK (1,5,5/6, 
7,8,10,13,14,17,18,19,20), 
vimentin 
(Liu et al. 
2007) 
Arch Pathol Lab 
Med 
2007,131,1290-
1297 
vimentin, glutathione S-transferase 
α, CD10, CD117, CK7, epithelial 
cell adhesion molecule 
(Shomori et al. 
2007) 
Modern Pathology 2007,20,199-
207 
ARPP (ankyrin-repeated protein 
with a proline rich region), EMA, 
CD10 
(Choi et al. 
2007) 
J Korean Med Sci 2007,22,305-
310 
Claudin 7, parvalbumin 
(Geramizadeh 
et al. 2008) 
Indian J Pathol 
Microbiol 
2008,51,167-
171 
Hale colloidal iron, CK7, CK8, 
CK18, CK19, CK20, vimentin, 
EMA, CD10,RCC marker 
(Rao et al. 
2010) 
Tumori 2010,96,304-
309 
Wnt-5a 
(Sari et al. 
2012) 
APMIS 2011,120,187-
194 
nucleophosmin/B23 (NPM) 
(Al-Ahmadie 
et al. 2011) 
Am J Surg Pathol 2011,35,949-
961 
CAIX, CD117,AMACR, CK7, 
CD10 
(von 
Brandenstein 
et al. 2012) 
Am J of 
Pathology 
2012,180,1787-
1797 
protein kinase C α 
(Yasir et al. 
2012) 
Appl 
Immunohistochem 
Mol Morphol 
2012,20,454-
461 
CD10, CK7, c-KIT, E-cadherin, N 
cadherin, Ksp-cadherin, Recepteur 
d'origine nantais (RON) 
(Cui et al. 
2012) 
European J of 
Histochemistry 
2012,56,245-
249 
parafibromin 
(Hu et al. 
2012) 
J Clin Pathol 2012,65,254-
256 
PAX8 
(Han et al. 
2013) 
Annals of 
Diagnostic 
2013, 172-175 HP-1α/β 
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Pathology 
(Bing et al. 
2013) 
Annals of 
Diagnostic 
pathology 
2013, 58-62 carbonic anhydrase IX, α-
methylacyl coenzyme  a racemase, 
cytokeratin 7, and galectin-3  
(Patricio et al. 
2013) 
J of Cellular and 
Molecular 
Medicine 
2013,8,1048-
1058 
PAX2 
Cytokeratin (CK), anti-cytokeratin AE1/AE3 clone antibodies (AE1/3), Recepteur d'origine 
nantais (RON), high molecular weight cytokeratin (HMCK), low molecular weight 
cytokeratin (LMCK), epithelial membrane antigen (EMA), monoclonal antibody that 
recognises epithelial glycoprotein 2 (MOC31), renal cell carcinoma marker 
(RCCma),epithelial cadherin  (E-cadherin), cluster of differentiation (CD), Ankyrin-repeated 
protein with a proline-rich region (ARPP), nucleophosmin (NPM), carbonic anhydrase IX 
(CAIX), alpha-methylacyl-Coenzyme A racemase (AMACR),neural cadherin (N-cadherin), 
paired box gene (PAX), heterochromatin-associated protein - 1 alpha/beta (HP-1α/β). 
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Figure 3.1 Flow chart 
Flow chart reveals the algorithm by which publications were selected, excluded and analysed. 
Final results showed there were 6 specific and 4 repeated biomarkers. 
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3.3.2 Quality of the studies  
The characteristics of the studies extracted from rank 1 and 2 publications are summarised in 
Table 3.3. Not surprisingly, there was an increase in the number of studies published in the 
last two decades in regards to biomarkers differentiating renal tumour subtypes. Twenty-nine 
of the 40 publications (72.5%) were reported in the last decade. Forty per cent of the 
publications involved studies investigating 1 IHC biomarker, with 11 studies conducted on 5 
or more biomarkers (range of 1–12 biomarkers investigated per study). Eleven out of 40 
studies (27.5%) investigated only chRCC and RO tissue samples, whereas most studies 
assessed biomarkers in a variety of subtypes of renal tumours including chRCC and RO. 
Across the 40 studies analysed, there were adequately large sample sizes (range 10–321) used 
in assessing the IHC biomarkers, with 40% of studies having more than 90 samples.  
 
All studies described the IHC staining protocols for the tissue slides or tissue microarrays. 
The majority of the studies (28/40, 70%) detailed the speciﬁc measurements for staining 
intensities, while 12 studies described only number of positively stained slides from the total 
number of samples. The number and percentage of positively-stained slides in chRCC and 
RO were compared in all 40 studies. Twenty-one studies included the statistical p value for 
the difference in staining between the two entities. Four studies also included sensitivity and 
speciﬁcity of the IHC biomarker and eight studies described differences in staining patterns 
between chRCC and RO. There were 31 biomarkers (single biomarkers) that were studied 
only once. Some biomarkers have been repeatedly investigated by various researchers 
(repeated biomarkers), with CK7 being investigated in 11 previous studies. 
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Table 3.3: Characteristics of 40 studies ranked 1 and 2 
Year No. of pubs Biomarkers  No. of pubs 
Renal 
tumours No. of pubs 
1991- 
1995 1 (2.5%) 1 16 (40%) 
only chRCC and 
RO 11(27.5%) 
1996- 
2000 3 (7.5%) 2 7 (17.5%) 
other RCC 
subtypes 29(72.5%) 
2001- 
2005 7 (17.5%) 3 2 (5%) 
  2006- 
2010 12 (30%) 4 4 (10%) 
  2011- 
2014 17 (42.5%) >/= 5 11 (27.5%) 
          
  
Sample 
size no. of pubs Results no. of pubs 
no. of  rpt 
studies biomarkers 
 1-10 1 (2.5%) 
% positive 
slide 40 
repeated 11 CK7 
 11-30 6 (15%) p value 21 
repeated 7 vimentin 
31-50 5 (12.5%) sens/spec 4 
repeated 6 CD10 
51-70 4 (10%) stain pattern 8 
repeated 5 EMA 
71-90  8 (20%) 
 
  
repeated 4 S100A1, c-KIT 
>90 16 (40%) 
 
  
repeated 3 
claudin 7, claudin 
8, Ksp-cadherin 
    
 
  
repeated 2 
RCC marker, 
caveolin-1, 
parvalbumin, 
antimitochondrial 
antibody, 
AMACR, E 
cadherin, Ron, 
CAIX 
    
single study 31  
 
Alpha-methylacyl-CoA racemase (AMACR), carbonic anhydrase IX (CAIX), cytokeratin 7 
(CK7), cluster of differentiation 10 (CD 10), epithelial membrane antigen (EMA), Kidney 
specific (Ksp), Renal cell carcinoma (RCC), Recepteur d'Origine Nantais (Ron), sensitivity 
(sens), specificity (spec), pubs = publications. 
  
68 
 
3.3.3 Meta-analysis  
The individual and pooled statistical results (p value and OR) of 25 single biomarkers and 12 
repeated biomarkers are shown in Tables 3.4 and 3.5. The OR is calculated as the odds of 
chRCC staining with the particular biomarker as compared with RO. OR <1 means that RO 
will stain more than chRCC counterparts. Some OR will be equal to zero or inﬁnity because 
the mathematical calculation and their variance cannot be calculated to reach a finite ratio 
number. However, the relevant studies with OR=0 will be discussed in depth and their 
signiﬁcant results described. 
 
As seen in Table 3.4, the results of the 25 single biomarkers are significant. The 
differentiation ability of these biomarkers is reflected by their statistical results of p value 
<0.05 obtained from the studies and the calculated significant OR with 95% CI. The single 
IHC biomarkers are Amylase α1A, Wnt 5a, FXYD2, Ankyrin-repeated protein with a 
proline-rich region (ARPP) which displayed significant calculated OR and CI; while cluster 
of differentiation 63 (CD63), and TGFβ1 were chosen for their differential staining patterns 
rather than calculated ORs which were zero (bold in Table 3.4). 
 
3.3.4 Amylase α1A 
In the study by Jain et al (Jain et al. 2013), amylase α1A, a salivary type amylase enzyme, 
was investigated. A large sample size (chRCC = 54, RO = 75) was obtained from whole 
slides and tissue microarray (TMA) cores. While 87% of chRCC cases were negative for the 
immunostain, all RO were positive for amylase α1A (p<0.001). The sensitivity and 
specificity for distinguishing RO from chRCC was 100% and 90.74%, respectively. The 
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computed OR (for chRCC compared to RO) was 0.001 (95% CI 0.0001-0.019). Conversely, 
the odds ratio of RO being stained with amylase α1A when compared to chRCC was 1000. 
 
3.3.5 Wnt-5a 
Wnt-5a, a member of the Wnt family of proteins, acts as a tumour suppressor or a tumour 
stimulator depending on tumour types in various non-renal tumours (Kremenevskaja et al. 
2005; Kurayoshi et al. 2006). Wnt-5a was investigated in a study of 18 chRCC and 20 RO 
(Rao et al. 2010). Wnt-5a was expressed only in 16% of chRCC compared to expression in 
all oncocytomas (p<0.01). The calculated OR for chRCC compared to RO for Wnt-5a 
staining was 0.0076 (95% CI 0.0004 - 0.15). Therefore, the OR for Wnt-5a immunostaining 
for RO compared to chRCC was 131.  
 
3.3.6 FXYD2 
FXYD2, a distal tubule regulator of the trimeric Na
+
/K
+ 
-transporting ATPase (Gaut et al. 
2013), was expressed in 96% (26/27) of chRCC whereas this biomarker expression was 
absent in 83% (25/30) of ROs. In this series, the sensitivity for differentiating chRCC from 
RO was 97% and specificity was 83%. The OR calculated was 130 (95% CI 14.2 – 1192.3).  
 
3.3.7 Ankyrin-repeated protein with a proline-rich region (ARPP) 
ARPP, highly expressed in skeletal and cardiac muscles, was originally discovered in 
oesophageal carcinoma cells (Moriyama et al. 2001) and was investigated by Shomori et al as 
a biomarker to distinguish RO and chRCC (Shomori et al. 2007). From the analysis, all 
chRCC failed to express ARPP while 12/14 (85.7%), while RO had high expression of 
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ARPP. The computed OR for chRCC compared to RO in ARPP IHC reactivity was 0.0054 
(95% CI 0.002 – 0.12). In other words, RO will express ARPP more than chRCC by an OR 
of 200. 
 
3.3.8 Cluster of differentiation 63 (CD63) 
CD63 is a lysosomal membrane glycoprotein translocated to the plasma membrane after 
platelet activation (Rous et al. 2002). Mete et al investigated the IHC expression of CD63 in 
renal tumours of epithelial origin with eosinophilic cytoplasm, especially RO from 
eosinophilic chRCC (Mete et al. 2005). In that study, 94% of RO had apical and/or polar 
CD63 immunostaining compared to 96% of chRCC with diffuse staining (p< 0.0005). The 
differential staining patterns of CD63 in RO versus chRCC had 95% sensitivity and 100% 
specificity recorded by the authors. OR calculated in this case was zero because the chRCC 
and RO had similar numbers of slides with positive immunostaining. Nevertheless, the 
distinction here is the biological nature of staining pattern difference rather than intensity or 
positivity of staining. 
 
3.3.9 Transforming growth factor beta 1 (TGFβ1) 
TGFβ1 is a multi-potent cytokine involved in regulating a number of cellular processes. 
Demirovic et al studied the expression of TGFβ1 in 18 RO and 16 chRCC (Demirovic et al. 
2014). In that study, the intensity of TGFβ1 expression in chRCC was weaker compared to 
RO (p<0.05), with chRCC predominantly staining in a membranous pattern while RO had 
predominantly cytoplasmic staining (p<0.05). There was no conclusive OR as it equalled 
zero as the chRCC and RO slides had similar number of positive stained slides. Again the 
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discriminatory ability of TGFβ1 is the differential staining pattern between the two tumour 
subtypes, displaying its biological distinctive staining nature. 
Table 3.4: Results of 25 single IHC biomarkers 
Biomarker 
n(chRCC)/n(RO) 
p value/ sens/spec% 
(obtained from 
studies) 
Calculated OR 
(chRCC >RO) 
Calculated 
95%CI 
amylase alpha1A 
54 / 75 
p<0.001; 
sens 100% spec 
90.74% 
0.001 
(RO>chRCC 1000) 0.0001-0.019 
Wnt-5a 
18 / 20 p<0.01  
0.0076 
(RO>chRCC 131) 0.0004-0.15 
FXYD2 
27 / 30  sens 97%; spec 83%,  130 14.2 - 1192.3 
ARPP  
21 / 14 0 
0.0054 
(RO>chRCC 200) 0.0002-0.12 
TGF β1  
16 / 18 
p<0.05 
0 
Different stain 
pattern - 
CD63 
27 / 35 
P=0.0005 
0 
Different stain 
pattern - 
Bcl2 
5 / 18 - 
0.0007 
 0-0.39 
MAGE-A3/4 
18 / 17 p 0.0013  0.0848485 0.01-0.49 
Parafibromin 
22 / 19 p=0.00198 0.03 0.0016-057 
Ki 
18 / 18 p<0.005 0 - 
PAX2 
30 / 30 
p<0.01; sens 67% spec 
90% 0.0555556 0.01-0.23 
KAI1 
20 / 10 P<0.001 81 6.45-1017.14 
p53 
18 / 18 p<0.05 0 - 
protein kinase C α 
18 / 5 p<0.05 0.0025 0-0.14 
NY-ESO-1 
18 / 17 p0.0008  0.0666667 0.01-0.39 
ESA 
20 / 10 p<0.001 11 9.57-3055.52 
BCA2 
8 / 38 - 0.0008 0-0.41 
HP-1α/β 
20 / 20 - 0.1428571 0.04-0.57 
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ERA 
20 / 10 p<0.001 11 9.57-3055.52 
Lysozyme 
21 / 103 
 - 3.72 1.18-11.74 
EpCAM 
22 / 17 - 102.27 5.21-2006.44 
nucleophosminB23 
18 / 9 p<0.001 0 - 
MOC 31 
28 / 7 - 64.09 3.16-1299.57 
CD15 
28 / 7 - 0.09 0.01-0.61 
PAX8 
66 / 16 - 0.2717949 0.03-2.25 
Ankyrin-repeated protein with a proline-rich region (ARPP), Transforming growth factor 
beta 1 (TGF β1), cluster of differentiation (CD), melanoma-associated antigen A3/4 (MAGE 
A3/4), paired box gene (PAX), tumour metastasis suppressor gene (KAI1), epithelial specific 
antigen (ESA), breast cancer-associated gene 2 (BCA2), heterochromatin-associated protein - 
1 alpha/beta (HP-1α/β), epithelial-related antigen (ERA), epithelial cell adhesion molecule 
(EpCAM), monoclonal antibody that recognises epithelial glycoprotein2 (MOC 31); number 
(n). 
 
 
3.3.10 Cytokeratin 7 (CK7) 
CK7 is a low molecular weight keratin expressed in various epithelia and related neoplasms. 
Eleven relevant studies that investigated CK7 were analysed with the individual and pooled 
OR results shown graphically in the Forest plot in Figure 3.2 (Adley et al. 2006a; Al-
Ahmadie et al. 2011; Carvalho et al. 2011; Geramizadeh et al. 2008; Kim et al. 2009; Kuroda 
et al. 2004; Leroy et al. 2000; Liu et al. 2007; Mazal et al. 2005; Skinnider et al. 2005; Yasir 
et al. 2012). In combining those studies, there were 448 samples (chRCC 242, RO 206) with 
a calculated pooled OR (chRCC compared to RO) of 44.22 (95% CI 22.52 – 86.64).The 
derived I
2
 percentage from Q test of heterogeneity I
2
=15%, suggested that there was no 
significant level of heterogeneity amongst the studies.  
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3.3.11 S100A1 
There were 4 studies that evaluated the IHC of S100A1 in renal tumours. S100 proteins are 
involved in different biological activities such as transduction of intracellular calcium 
signalling, cytoskeleton-mediated interactions, cell cycle progression and cell differentiation 
(Li et al. 2007). Individual and pooled OR results are shown in a Forest plot in Figure 3.3. 
(Carvalho et al. 2011; Kim et al. 2009; Kuroda et al. 2011; Li et al. 2007) The pooled OR 
(chRCC compared to RO) was 0.01 (95% CI 0-0.03), with I
2
 = 0%. Therefore, the OR of RO 
compared to chRCC for S100A1 staining is 100 and I
2 
study heterogeneity revealed similar 
consistency between the effects of the 4 studies. 
 
3.3.12 Caveolin-1 (Cav-1) 
Cav-1 is a membrane protein present in most cells. Two previous studies of Cav-1 are 
included in this analysis. In the study by Garcia et al, all 21 (100%) of chRCC were stained 
positively for Cav-1 compared to 88% (23/26) of RO which were negative (Garcia and Li 
2006). The OR from that study was 265.66 (95% CI 7.79-9061.79). Another study produced 
positive immunostains in all 27 chRCC and 34 out of 35 of RO. The OR calculated therefore 
was 2.85 but the 95% CI (0.1-85.04) which included 1. However in that study, the authors 
showed that there was significantly-different staining patterns in chRCC (diffuse peripheral) 
and RO (diffuse) (p0.0005) (Mete et al. 2005). The pooled OR calculated was 32.95 (95% CI 
3.67-296.1) with I
2 
= 70%, suggesting heterogeneity between the two study results. 
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3.3.13 Claudin-7 
Claudin-7 together with claudin-8 code for tight junction proteins that are expressed in distal 
nephrons. (Li et al. 2004) There were 3 studies that investigated claudin-7 in renal tumours. 
The individual and pooled OR results are shown in Figure 3.4 (Choi et al. 2007; Ohe et al. 
2012; Osunkoya et al. 2009). The pooled OR was 24.7 (95% CI 6.28-97.1) with I
2
 = 0%, 
displaying no significant heterogeneity between the 3 study results. 
 
Similarly, repeated biomarkers that were investigated in various studies have their results 
documented with calculated pooled OR with 95% CI and Q test of heterogeneity with I
2
 % 
described.   The summary of repeated IHC biomarkers are cytokeratin 7 (CK7), S100A1, 
caveolin-1 and claudin-7 are shown in bold in Table 3.5. 
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Table 3.5: Twelve repeated IHC biomarkers 
Repeated biomarkers 
no. of 
pubs 
pooled OR 
(chRCC>RO
) 95% CI I
2
 (%) 
cytokeratin 7 11 44.22 22.52 - 86.64 15 
S100A1 4 
0.01 
(RO>ch 100) 0 - 0.03 0 
caveolin-1 2 32.95 3.67-296.10 70 
Claudin7 3 24.7 6.28-97.1 0 
Ksp-cadherin 3 4.43 2 -9.79 90.7 
claudin8 4 0.63 0.36-1.09 91.7 
anti-mitochondrial 2 0.11 0.01-2.23 NA  
EMA  5 1.87 0.89-3.96 81.7 
Ron   2 0.04 0.01-0.14 81.4 
Carbonic anhydrase IX  2 4.25 0.32-55.82 0 
CD10  3 10.46 1.24-88.04 0 
Hale colloidal iron 3 3.87 1.87-8 93.7 
 
Cluster of differentiation 10 (CD10), epithelial membrane antigen (EMA), kidney specific 
(Ksp), epithelial membrane antigen (EMA), Recepteur d'Origine Nantais (Ron). 
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Figure 3.2: Forest plot for CK7 
Forest plot of CK7 showing the respective OR and CI together with the pooled OR and 
pooled CI. Noted that all studies shown here revealed higher CK7 expression in chRCC. 
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Figure 3.3: Forest plot for S100A1 
Forest plot of S100A1 showing the respective OR and CI together with the pooled OR and 
pooled CI. Noted that all studies shown here revealed higher S100A1 expression in RO. 
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Figure 3.4: Forest plot for Claudin-7 
Forest plot of claudin-7 showing the respective OR and CI together with the pooled OR and 
pooled CI. Noted that all studies shown here revealed higher claudin-7 expression in chRCC. 
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3.4 DISCUSSION 
It is worthwhile mentioning from the outset that the gold standard for differentiating chRCC 
from RO remains careful discernment of histopathological features on H&E staining. In fact, 
all studies in this meta-analysis which investigated IHC biomarkers were performed on slides 
or microarrays of known tumour tissue subtype based on H&E. Nevertheless, IHC is still 
beneficial and relevant in cases where differentiation of chRCC from RO is too difficult on 
routine H&E. 
 
From this analysis, there are already numerous IHC biomarkers that have been used routinely 
across laboratories, which can aid in the differentiation between chRCC and RO. Often some 
of the results of trialled and novel IHC biomarkers are not consistent or reproducible across 
laboratories. The meta-analysis indicates that it is unlikely that a single molecule can 
consistently differentiate the two entities. It is more likely a panel of biomarkers with 
differential expression would be required to assist in the differentiation. Consequently, we 
identified 10 biomarkers that are differentially expressed in these two entities: 6 specific 
biomarkers (amylase α1A, Wnt-5a, FXYD2, ARPP, CD63, TGFβ1); and 4 repeated 
biomarkers (CK7, S100A1, Cav-1, claudin-7), as outlined in Table 3.6. 
 
Seventeen of the 40 studies (42.5%) were conducted in the last 5 years (Table 3.3). This may 
be because clinicians are increasingly faced with the diagnostic dilemma of differentiating the 
two entities and therefore more research has been generated to resolve this difficult 
distinction. There were also various biomarkers (CK7, vimentin, CD10, EMA, S100A1, c-
KIT, claudin 7 and 8, Ksp-cadherin, RCC marker, Cav-1, parvalbumin, antimitochondrial 
antibody, AMACR, E-cadherin, Ron and carbonic anhydrase IX) that have been repeatedly 
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investigated in different studies. This is not surprising as some of these biomarkers have been 
implicated or involved in important cellular mechanisms pertaining to cell growth, apoptotic 
pathways and tumorigenesis. However, from our results of studies involving repeated 
biomarkers, only CK7, S100A1, Cav-1, claudin-7 have been shown to be consistently useful 
in this differentiation. These repeated biomarkers are crucial in this analysis as they provide 
us the ability to compare results between studies of the same biomarker and assess their 
consistency, reproducibility and heterogeneity.  
 
CK7 was involved in 11 previous studies in this analysis, with all studies in the Forest plot 
showing similar trend of OR for CK7 staining when chRCC was compared to RO (Figure 
3.2). This suggests that CK7 is a reliable biomarker that numerous researchers have relied 
upon to differentiate the two tumour entities. Cytokeratins are a large family of structural 
polypeptides that are the fundamental markers of epithelial differentiation. They consist of at 
least 20 distinct molecules, the expression of which depends on cell type and differentiation 
status, making them useful in differential diagnosis of many epithelial tumours (Chu and 
Weiss 2002). The CKs found in simple epithelia (CK7, CK8, CK18, and CK19) were widely 
expressed in normal kidney and renal neoplasms (Skinnider et al. 2005). 
 
 In this meta-analysis, the calculated pooled ratio was 44.22 (95% CI 22.52-86.64) which 
showed that chRCC are 44 times more likely to express CK7 when compared to RO. All 
studies revealed that chRCC were more likely to express CK7 than RO with individual ORs 
ranging from 5 to 900. The large combined sample size of 448 chRCC and RO only 
strengthened this analysis and proved the usefulness of CK7. In fact, the low level of 
heterogeneity of I
2
 = 15%, suggests that all 11 studies consistently provided similar reliable 
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reproducible results in chRCC and RO. From Figure 3.2, all studies recorded an OR of >1 in 
95% CI. Only one study had 95% CI that included 1 (0.46-54.04) in which the OR was 5 (Al-
Ahmadie et al. 2011). However in that study, the small sample size of 5 RO, where 4 out of 5 
RO showed negative expression of CK7, would have influenced the result. Therefore, despite 
that study, all the other 10 studies showed that chRCC had significantly higher expression of 
CK7 when compared to RO.  
 
Another biomarker that was investigated in 4 different studies was S100A1. S100A1 is a 
member of the S100 family of calcium binding molecules, most of which are clustered on 
chromosome 1q21, and expressed in RCC (Teratani et al. 2002). Importantly, these proteins 
are involved in cell cycle progression and cell differentiation (Li et al. 2007) and therefore 
implicated in tumorigenesis, a basis for investigation of S100A1 in renal tumour subtypes. 
The calculated pooled OR (chRCC vs RO) was 0.01, with I 
2 
=
 
0% (Figure 3.8). In other 
words, RO will express S100A1 biomarker a hundred fold more than chRCC. As per the 
Forest plot in Figure 3.3, RO showed higher expression of S100A1 compared to chRCC. 
Even with a fairly large sample of 124 (chRCC 59, RO 65) from the combined 4 studies, 
there is hardly any heterogeneity detected amongst all studies. In one study, the OR 0.03 with 
95% CI 0 – 1.73 which included 1 therefore rendering the OR insignificant (Kuroda et al. 
2011). However that study analysed only 4 RO and 10 chRCC and therefore, the weightage 
of that study only contributed 7.7% for the pooled OR analysis. When all data were 
combined, 61/65 (93.8%) of RO expressed S100A1 immunoreactivity compared to only 4/59 
(6.8%) of chRCC. Therefore, S100A1 is another reproducible IHC biomarker that can 
differentiate RO from chRCC. 
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Another repeated biomarker that was selected was claudin-7. Claudin-7 belongs to a family 
of tight junction proteins and is expressed in the cell membrane of distal tubules and 
collecting ducts. The tight junction structure is important for restricting lateral effusion of 
lipids and membrane proteins, thereby physically defining the border between the apical and 
basolateral components of the cell (Choi et al. 2007). The tissue specificity of claudins 
strongly suggests that they may have other functions, in addition to being structural 
components of tight junctions (Zheng et al. 2003). The results of the 3 studies that were 
analysed for claudin-7 are shown in Figure 3.9 (Choi et al. 2007; Ohe et al. 2012; Osunkoya 
et al. 2009). The pooled OR was 24.7 (chRCC compared to RO) with 95% CI (6.28-97.1) and 
I
2 
= 0% reflecting no significant heterogeneity between the results of all 3 studies. The 
combined sample size was 89 (51 chRCC, 38 RO). The Forest plot (Figure 3.4) revealed all 
studies showing that chRCC have higher expression of claudin-7 compared to RO. Therefore 
chRCC is 24 times more likely to express claudin-7 than RO and thus can aid in the IHC 
differentiation of chRCC from RO. 
 
Cav-1, a 24-kd membrane protein, is a major component of membrane caveolae. 
Functionally, Cav-1 serves important roles in macromolecular transcytosis, endocytosis of 
pathogens, lipid metabolism, and cellular signal transduction (Cohen et al. 2004). In two 
studies that investigated Cav-1, all the chRCC stained positively for Cav-1 (Garcia and Li 
2006; Mete et al. 2005). The calculated pooled OR was 32.95 (95% CI 3.67-296.1). In 
contrast to the 100% immunostaining of chRCC, 88% of RO failed to express Cav-1 (Garcia 
and Li 2006). In the other study by Mete et al, 34/35 RO also expressed Cav-1 (compared to 
27/27 of chRCC), but chRCC had diffuse and peripheral Cav-1 staining while 88% of RO 
had diffuse cytoplasmic staining (p=0.0005) (Mete et al. 2005). However, as a reflection of 
differing results between the two studies, I
2 
was moderate at 70%. Therefore the pooled OR 
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ratio should be interpreted cautiously as there is significant heterogeneity. Nevertheless, both 
studies portrayed different strengths of results in quantitative and qualitative aspects (which 
accounted for the high I
2
), and so Cav-1 is considered to be a useful marker for differentiating 
chRCC from RO. 
 
Of the 6 specific biomarkers selected (amylase α1A, Wnt-5a, FXYD2, ARPP, CD63, TGF-
β1), amylase α1A, FXYD2, Wnt-5a and TGFβ1 were investigated in the last 5 years. Perhaps 
one reason for this discovery of novel biomarkers stems from better understanding of the 
molecular basis of renal tumour profiling, coupled with newer technologies that are available. 
As can be seen in Table 3.4, RO significantly express amylase α1A, wnt-5a and ARPP more, 
when compared to chRCC, with ORs (RO compared to chRCC) of 1000, 131 and 200, 
respectively. In contrast, chRCC had higher expression of FXYD2 when compared to RO 
(OR of 130). The 95% CIs of these 4 studies were significant and valid as none included the 
value of 1.These significant results prove that these biomarkers are useful in distinguishing 
between chRCC and RO in quantitative IHC. In both CD63 and TGFβ1, there were 
significantly-different staining patterns between chRCC and RO. The sample sizes of chRCC 
and RO involved in these 6 studies of specific single biomarkers are relatively large with a 
range from 32 – 129. Obviously these large sizes add power to the studies and provide further 
strength to their results.  
 
The significance and functions of these 6 single biomarkers would have led the investigators 
to study their expressions in renal tumour subtypes. In the case of amylase α1A, chRCC have 
deletions in the 1p21.1 region including the amylase α1A gene, with no such deletions in 
oncocytomas. The AMY1A gene encodes the salivary gland–type amylase isoenzyme that 
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hydrolyzes the 1,4-a-glucoside bonds in oligosaccharides and polysaccharides to produce 
maltose, which is cleaved to 2 molecules of glucose by the enzyme maltase (Jain et al. 2013). 
For the biomarker Wnt-5a, it belongs to a large family of cysteine-rich secreted molecules 
that play diverse biological roles in the regulation of several normal and pathological 
processes including cell growth, differentiation and tumorigenesis (Kurayoshi et al. 2006).  
 
In regards to FXYD2, the protein is a single pass type III membrane protein and the gamma 
subunit of trimeric Na
+
/K
+
-transporting ATPase whose regulatory function is to modulate the 
kinetic properties and stabilize the renal tubular Na+/K+-transporting ATPase. Previous 
studies have shown that the FXYD2 protein is highly enriched in kidney tissue (Floyd et al. 
2010; Geering 2006). Whereas in the investigation of ARPP, it is characterized by the 
presence of four ankyrin-like repeat motifs in its middle portion and proline (P), aspartic and 
glutamic acids (E), serine (S) and threonine (T) (PEST-like) sequences in the amino-terminal 
regions. ARPP is implicated in the regulation of protein turnover (Shomori et al. 2007). 
Lastly, TGF-β1 is a potent, pleiotropic cytokine involved in regulating a number of cellular 
processes including proliferation, differentiation, apoptosis, development, tissue repair, cell 
motility, extracellular matrix formation, inflammation, immunosuppression, and 
tumorigenesis (Demirovic et al. 2014). 
 
Consequently from this study, 10 biomarkers were identified with their results of IHC 
staining summarised in Table 3.10. Typically chRCC shows positive expression for CK7, 
FXYD2, Cav-1, claudin-7 and diffuse CD63 and membranous TGFβ1 staining patterns. In 
contrast, RO will usually express positivity for amylase α1A, Wnt-5a, ARPP, S100A1 and 
apical/polar CD63 and cytoplasmic TGF-β1 staining patterns. Obviously, this positivity and 
85 
 
negativity staining expression holds true in most instances and there will be inevitably small 
samples that do not conform to these results. However, the specificity and accuracy of 
differentiation will be enhanced if two or more of these biomarkers were utilised in difficult 
situations of equivocal staining results. It is recommended that laboratories utilise a few of 
these biomarkers in future to distinguish difficult cases of chRCC from RO. 
 
There are notable strengths and limitations in this meta-analysis. To our knowledge, our 
study is the first to report a meta-analysis and systematic review in this highly specialised yet 
clinically challenging field of the IHC differentiation between chRCC and RO. From the 
diverse unbiased survey of the current available literature on differentiation of chRCC and 
RO, with standardised approach in meta-analysis methods, we were able to summarise the 
robust data extracted, and select out the panel of most relevant IHC biomarkers. This will in 
turn provide clinicians with the most sensitive IHC biomarkers that can distinguish the two 
entities and guide further management.  
 
There are several limitations in our study. The small number of studies, which investigated 
specific biomarkers, except for the 11 studies of CK7, may not produce robust available data 
for analysis. However, this is because of the paucity of successful usage of available IHC 
biomarkers in the differentiation. With evaluation of studies pertaining to only IHC method 
of biomarkers in the differentiation, some studies which report significant results from 
combination of IHC with another different technique (such as in situ RNA hybridisation) 
might not have been analysed appropriately. In the present analysis, an aspect of publication 
bias was unavoidable as we only included published studies and did not search unpublished 
studies or abstracts due to our methodology strategy. Another potential source of bias is that 
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there was no uniformity in the measurement of the IHC expression in the samples and inter-
observer variability in interpretation of positivity across all studies.  
 
In summary, our findings show that these 10 biomarkers have demonstrated their ability to 
differentiate chRCC and RO. It is hoped that larger scale studies will be performed on these 
10 biomarkers in the future to further consolidate or affirm the reproducibility of similar 
results in differentiation of RO from chRCC. Hopefully, there will also be further novel 
biomarkers investigated in this respect. 
 
3.5 CONCLUSION 
The clinical diagnostic dilemma and difficult histopathological differentiation of RO from 
chRCC still persist. This systematic review and meta–analysis have revealed numerous IHC 
biomarkers that have been investigated and regularly used across laboratories to aid 
differentiating chRCC and RO. Despite this, there are no consistently-reproducible robust 
IHC biomarker(s) that can accurately differentiate the two tumour entities. However, this 
analysis has provided us with a panel of the most relevant IHC biomarkers that may help to 
discriminate the two entities. Following this meta-analysis, we set out to replicate and 
validate the differential ability of certain IHC biomarkers (CK7, Cav-1 and S100A1) on our 
Australian cohort of patients in our laboratory (discussed in chapter 5). Further large 
international collaborative studies are needed to further validate the clinical usefulness of 
these biomarkers. Currently, when faced with difficult histopathological distinction of chRCC 
and ROs, we suggest the application of IHC of some biomarkers from the panel presented in 
Table 3.6. 
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Table 3.6:- Final panel of discriminatory IHC biomarkers 
 
Biomarker ChRCC RO 
amylase α1A - + 
Wnt-5a - + 
FXYD2 + - 
ARPP - + 
CD63 Diffuse Apical/polar 
TGFβ1 Membranous Cytoplasmic 
CK7 + - 
S100A1 - + 
Caveolin-1 + (diffuse peripheral) - (diffuse if +) 
Claudin-7 + - 
 + = majority positive;    - = majority negative  
Ankyrin-repeated protein with a proline-rich region (ARPP), cluster of differentiation 63 
(CD 63), transforming growth factor beta1 (TGFβ1). 
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CHAPTER 4 
IMMUNOHISTOCHEMICAL ANALYSIS OF NUCLEAR FACTOR –KAPPA B  
IN RENAL TUMOURS 
 
As mentioned in the first chapter, better understanding of the molecular profiling of renal 
tumours will ultimately translate into better diagnostic, therapeutic and prognostic  
management pathways. Discovery of newer and novel biomarkers will add to further 
delineation of molecular signatures of renal tumours.  The objective of this chapter was to 
achieve the 2nd aim of the research: assessment of the different molecular profiles of renal 
cancers via IHC and morphometry techniques using selected biomarkers on renal tumour and 
normal tissue samples. Therefore in this chapter, nuclear factor kappa B (NF-κB) was 
investigated in RCC disease.  Furthermore, the expressions of the five NF-κB subunits have 
not been investigated in such an extensive set of patients with RCC and this study provided 
the opportunity to carefully compare expressions and localisations in different subtypes of 
RCC (including chRCC). From our close collaboration with Surgery Department of 
University Malaya, we had the opportunity to assess the expression of NF-κB in human RCC 
tissue via IHC analyses. The IHC research work was performed here in CKDR, TRI with the 
help of Mr. Clay Winterford from QIMR. This is the first and largest study to report on the 
IHC expressions of NF-κB subunits (p65, p50, p52, cRel) in human RCC tissue. 
 
4.1 INTRODUCTION 
Among the biomarkers of interest implicated in RCC are the NF-κB subunits. The NF-κB 
family of proteins comprises p65 (RelA), NF-κB1 (p105/p50), NF-κB2 (p100/p52), RelB and 
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c-Rel. The NF-κB subunits may form homo or heterodimers in the cell. They act as 
transcription factors regulating inflammation, angiogenesis, immunity, cell proliferation and 
apoptosis (Morais et al. 2011). NF-κB is present in the cytoplasm in an inactive form, bound 
to one of the IκB inhibitor molecules, such as IκB-α, IκB-β, IκB-γ, IκB-ε, p100, p102 or Bcl-
3 (Morais et al. 2011). NF-κB is then released into the nucleus in its active form to activate its 
transcriptional target when IκB is degraded by IκB kinase (IKK).   
 
The p65 subunit is the most studied NF-κB subunit in cancers, including RCC. Studies 
showed that p65 expression is upregulated and constitutively activated in RCC tissue 
(Djordjevic et al. 2008; Peri et al. 2013). NF-κB p65 and p50 have both been correlated with 
apoptotic and proliferation markers in RCC tissue (Kankaya et al. 2015). Activation of NF-
κB induces anti-apoptotic factors such as inhibitors of apoptosis (IAPs) or anti-apoptotic 
members of the Bcl-2 family (Chen et al. 2000; Dolcet et al. 2005). NF-κB activity is 
enhanced in the absence of functional pVHL and furthermore, expression of NF-κB p65 is 
associated with vascular endothelial growth factor (VEGF) in ccRCC, the most common type 
of the RCC (Djordjevic et al. 2008; Meteoglu et al. 2008; Qi and Ohh 2003). Hence, the NF-
κB family likely plays an important role in the carcinogenesis and progression of RCC. 
However, the prognostic implications of NF-κB in RCC are contradictory, based on previous 
research where NF-κB was  associated with poorer prognosis  (Oya et al. 2003; Peri et al. 
2013; Djordjevic et al. 2008) while others did not correlate NF-κB with survival or prognosis 
(Kankaya et al. 2015; Meteoglu et al. 2008;; Sourbier et al. 2007). Currently to our 
knowledge, there is no published literature on NF-κB2 (p100/p52), RelB and c-Rel 
expression in human RCC and their prognostic value. Additionally, most studies did not 
assess the survival outcome of RCC patients in relation to NF-κB expression. 
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The aim of the current study was to report the expression of p65 (RelA), NF-κB1 (p105/p50), 
NF-κB2 (p100/p52), RelB and c-Rel in RCC tissue in comparison with the corresponding 
normal kidney. The association of the NF-κB subunits with the tumour characteristics and 
survival outcome was also evaluated. 
 
4.2 MATERIALS AND METHODS 
Ethics approval for retrospective and prospective tissue collection was obtained from the 
University Malaya Ethics Committee (Ref: 848.17) (Appendix 4). The present study 
examined 96 cases of formalin fixed and blocked RCC tissue with paired normal kidney from 
patients who have undergone nephrectomy in University of Malaya Medical Centre (UMMC) 
from 2003-2013. The clinicopathological data and demographics of patients were collected 
from UMMC online database or patients’ medical record folders.  Survival information was 
acquired from patients’ medical records or the National Registration Department, Malaysia. 
The discussion of the IHC methodology and description of the morphometry analyses with 
statistical analysis have been detailed in chapter 2. 
 
4.3 RESULTS 
Table 4.1 shows the clinical and pathological data from 96 renal tumour archived specimens. 
Two thirds of patients were males who underwent nephrectomy in the UMMC between 2003 
till 2013 (male:female = 2:1). Median age was 62 (range 39-83 years) with median renal 
tumour size of 6 cm (1.5 – 17 cm). Approximately half the patients presented with clinical 
stage T1, with 22 patients (22.9%) having metastases at presentation. As expected, the 
majority of the tumour pathological subtype was ccRCC (n=76), followed by papillary RCC 
(n=11), chRCC (n=5), clear cell tubulopapillary RCC (n=3) and one multilocular cystic RCC. 
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Median follow up for this cohort of RCC patients was 54.5 months (0.2 – 135 months), with 
28 deaths noted at time of analysis.  
 
Table 4.1: Clinical and pathological data 
Patients 96 
M : F 67.7%    :    32.3% 
Median age 62 (39-83) 
Median size 6cm (1.5-17) 
Clear cell RCC (stage) 43 (T1) 22 (T2) 9 (T3) 2 (T4) 
Clear cell RCC (grade) 10 (G1) 37 (G2) 22 (G3) 7 (G4) 
Papillary RCC (stage) 5 (T1) 3 (T2) 2 (T3) 1 (T4) 
Papillary RCC (grade) 0 (G1)  7 (G2) 4 (G3) 0 (G4) 
Chromophobe RCC (stage) 3 (T1) 0 (T2) 2 (T3) 0 (T4) 
Multilocular cystic RCC (stage) 1 (T1) 0 (T2) 0 (T3) 0 (T4) 
Clear cell tubulopapillary RCC (stage) 1 (T1) 1 (T2) 1 (T3) 0 (T4) 
Stage    T1 53 (55.2%) 
              T2 26 (27.1%) 
              T3 14 (14.6%) 
              T4 3 (3.1%) 
Metastases (M1) 22 (22.9%) 
Renal cell carcinoma (RCC); Tumour (T); Metastases (M) 
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The IHC staining characteristics and morphometric results of 4 NF-κB subunits (p50, p52, 
p65 and c-Rel) are shown in Figures 4.1 - 4.16.  Based on the immunostaining patterns of the 
tumour and normal cells, overall, nuclear and membrane morphometric expression analyses 
were performed with Aperio ImageScope. Despite the positive control slides (human tonsil) 
showing staining for the fifth NF-κB subunit: RelB; normal kidney and RCC tissue had 
minimal RelB immunostaining. Therefore these could not be analysed for positive pixels 
using morphometry, and consequently results for RelB are not reported. Cancer survival 
analyses were performed for high and low overall and nuclear NF-κB subunits expressions 
and results portrayed as Kaplan Meier curves; except for membrane expressions as there were 
no significant differences between tumour expression results. 
 
4.3.1 NF-κB p65 subunit analysis 
IHC staining characteristics of p65 subunit in normal and renal tumour tissues are shown in 
Figure 4.1. The immunostaining pattern was mainly cytoplasmic and nuclear. Overall 
positive pixel, nuclear and membrane expression of p65 were significantly higher in RCC 
compared to normal renal tissue (p < 0.0001, p = 0.0015 and p < 0.0001 respectively) (Figure 
4.2A, 4.3A and 4.4A).  
 
For  overall, nuclear and membrane immunostaining p65 expression of renal tumour 
subtypes, chRCC recorded the least intensity (p=0.004, p=0.02, p=0.004 respectively) 
(Figures 4.2D, 4.3D and 4.4D).  There was no significant correlation of overall or nuclear or 
membrane expression of tumours in regards to clinical T staging, tumour grading or 
metastases. 
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With regards to cancer-specific survival analysis, high p65 nuclear expression (higher than 
median cut-off value) was significantly associated with worse survival outcome (p = 0.03) 
(Figure 4.3F). Using Cox regression analysis, nuclear p65 was a significant prognostic factor 
in univariate analysis (HR 2.39, 95% CI 1.08-5.29, p = 0.03). For multivariate analysis 
adjusted for subtype, stage and grade (Hazards ratio 2.77, 95% CI 1.12-6.86, p = 0.02); 
higher nuclear p65 was noted to be an independent prognostic factor. No significant 
association of overall and membrane expression of p65 was seen with cancer-specific 
survival.  
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Figure 4.1: p65 immunostaining for renal tumours and normal kidney  
A. Immunostaining of p65 in normal kidney; B. Immunostaining of p65 in ccRCC; C. 
Immunostaining of p65 in pRCC; D. Immunostaining of p65 in chRCC. Scale bar 200µm. 
(x20 Aperio magnification)    
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Figure 4.2: Overall positive pixel expression of p65 with survival analysis 
A. p65 overall expression in tumour vs normal (****p<0.0001); B. p65 overall expression in 
various tumour stages; C. p65 overall expression in various tumour grades; D. p65 overall 
expression in tumour subtypes; E. p65 overall expression in M1 vs M0 stages; F. Kaplan 
Meier cancer specific survival analysis for p65 overall expression. (--- low, --- high) 
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Figure 4.3: Nuclear expression of p65 with survival analysis 
A. p65 nuclear expression in tumour vs normal (**p0.0015); B. p65 nuclear expression in 
various tumour stages; C. p65 nuclear expression in various tumour grades; D. p65 nuclear 
expression in tumour subtypes; E. p65 nuclear expression in M1 vs M0 stages; F. Kaplan 
Meier cancer specific survival analysis for p65 nuclear expression (p=0.03). (--- low, --- 
high) 
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Figure 4.4: Membrane expression of p65  
A. p65 membrane expression in tumour vs normal (***p<0.0001); B. p65 membrane 
expression in various tumour stages; C. p65 membrane expression in various tumour grades; 
D. p65 membrane expression in tumour subtypes; E. p65 membrane expression in M1 vs M0 
stages. 
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4.3.2 NF-κB p50 subunit analysis 
 
The staining characteristics of p50 was mainly cytoplasmic and nuclear as shown in Figure 
4.5 (A-D). The overall, nuclear and membrane expression of p50 IHC were lower in all RCC 
subtypes compared to normal renal tissue (p < 0.0001, p < 0.0001 and p = 0.0001 
respectively) as shown in Figure 4.6A, 4.7A and 4.8A. Among the tumour subtypes, clear cell 
tubulopapillary RCC (ccpRCC) had highest overall and nuclear expression of p50 compared 
to the rest of the subtypes; with multilocular cystic RCC (mcRCC) recording the lowest 
expression as shown in Figure 4.6D, 4.7D and 4.8D. There were no significant differences in 
expression between tumour subtypes for overall expression, nuclear or membrane analyses. 
There were no significant differences in p50 expression noted in clinical T stage, tumour 
grading and metastatic nature. 
 
Higher p50 overall expression was significantly associated with worse survival outcome (p = 
0.005) (Figure 4.6F). Using Cox regression analysis, overall p50 was a significant prognostic 
factor in univariate analysis (Hazards ratio 3.23, 95% CI 1.42-7.34, p = 0.005). For 
multivariate analysis adjusted for subtype, stage and grade (Hazards ratio 3.42, 95% CI 1.34-
9.02, p = 0.01); overall p50 was noted to be independent prognostic factor. No significant 
association for nuclear or membrane expressions of p50 was seen with cancer-specific 
survival. 
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Figure 4.5:  p50 immunostaining for renal tumours and normal kidney  
A. Immunostaining of p50 in normal kidney; B. Immunostaining of p50 in ccRCC; C. 
Immunostaining of p50 in pRCC; D. Immunostaining of p50 in chRCC. Scale bar 200µm. 
(x20 Aperio magnification) 
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Figure 4.6: Overall positive pixel expression of p50 with survival analysis 
A. p50 overall expression in tumour vs normal (****p<0.0001); B. p50 overall expression in 
various tumour stages; C. p50 overall expression in various tumour grades; D. p50 overall 
expression in tumour subtypes; E. p50 overall expression in M1 vs M0 stages; F. Kaplan 
Meier cancer specific survival analysis for p50 overall expression (p 0.005) (--- low, --- high) 
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Figure 4.7: Nuclear expression of p50 with survival analysis 
A. p50 nuclear expression in tumour vs normal (****p<0.0001); B. p50 nuclear expression in 
various tumour stages; C. p50 nuclear expression in various tumour grades; D. p50 nuclear 
expression in tumour subtypes; E. p50 nuclear expression in M1 vs M0 stages; F. Kaplan 
Meier cancer specific survival analysis for p50 nuclear expression (--- low, --- high) 
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Figure 4.8: Membrane expression of p50  
A. p50 membrane expression in tumour vs normal (***p = 0.0001); B. p50 membrane 
expression in various tumour stages; C. p50 membrane expression in various tumour grades; 
D. p50 membrane expression in tumour subtypes; E. p50 membrane expression in M1 vs M0 
stages. 
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4.3.3 NF-κB p52 subunit analysis 
 
The p52 subunit expression was mainly cytoplasmic and occasionally nuclear in both normal 
and tumour tissues as shown in Figure 4.9 (A-D). Similar to p50 expression, RCC tumour 
tissues had lower expression in overall, nuclear and membrane p52 intensity when compared 
to normal renal tissue (p < 0.0001, p = 0.003, p < 0.0001 respectively) (Figures 4.10A, 4.11A 
and 4.12A). No differences in p52 expression were noted in RCC subtypes, clinical T stages 
and evidence of metastasis. 
 
 Patients with high p52 overall expression (higher than median cut off value) were 
significantly associated with worse survival prognosis (p = 0.02) (Figure 4.10F). Using Cox 
regression analysis, overall p52 expression was a significant prognostic factor in univariate 
analysis (Hazards ratio 2.74, 95% CI 1.17-6.4, p = 0.02). In addition, high nuclear p52 
expression (higher than median cut off value) was significantly associated with worse 
survival prognosis (p = 0.03) (Figure 4.11F). However on multivariate analysis adjusted for 
subtype, stage and grade; both overall and nuclear p52 expression were not independent 
prognostic factors. 
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Figure 4.9:  p52 immunostaining for renal tumours and normal kidney  
A. Immunostaining of p52 in normal kidney; B. Immunostaining of p52 in ccRCC; C. 
Immunostaining of p52 in pRCC; D. Immunostaining of p52 in chRCC. Scale bar 200µm. 
(x20 Aperio magnification) 
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Figure 4.10: Overall positive pixel expression of p52 with survival analysis 
A. p52 overall expression in tumour vs normal (****p<0.0001); B. p52 overall expression in 
various tumour stages; C. p52 overall expression in various tumour grades; D. p52 overall 
expression in tumour subtypes; E. p52 overall expression in M1 vs M0 stages; F. Kaplan 
Meier cancer specific survival analysis for p52 overall expression (p0.02) (--- low, --- high) 
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Figure 4.11: Nuclear expression of p52 with survival analysis 
A. p52 nuclear expression in tumour vs normal (**p=0.003); B. p52 nuclear expression in 
various tumour stages; C. p52 nuclear expression in various tumour grades; D. p52 nuclear 
expression in tumour subtypes; E. p52 nuclear expression in M1 vs M0 stages; F. Kaplan 
Meier cancer specific survival analysis for p52 nuclear expression (p0.03) (--- low, --- high) 
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Figure 4.12: Membrane expression of p52  
A. p52 membrane expression in tumour vs normal (****p<0.0001); B. p52 membrane 
expression in various tumour stages; C. p52 membrane expression in various tumour grades; 
D. p52 membrane expression in tumour subtypes; E. p52 membrane expression in M1 vs M0 
stages. 
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4.3.4 NF-κB cRel subunit analysis 
 
The cRel immunostaining was noted mainly as cytoplasmic with occasionally nuclear pattern 
as shown in Figure 4.13(A-D). RCC subtypes showed significantly lower overall, nuclear and 
membrane cRel expressions when compared to normal renal tissue (all p < 0.0001). (Figure 
4.14A, 4.15A and 4.16A). There were no significant differences in cRel expression noted in 
clinical T stages, tumour subtypes grading and metastatic status. All tumour subtypes were 
noted to have minimal cRel immunostaining compared to normal renal tissue as shown in 
Figures 4.14D, 4.15D and 4.16D. There was also no significant correlation of cRel expression 
with cancer-specific survival. 
 
Figure 4.13:  cRel immunostaining for renal tumours and normal kidney  
A. Immunostaining of cRel in normal kidney; B. Immunostaining of cRel in ccRCC; C. 
Immunostaining of cRel in pRCC; D. Immunostaining of cRel in chRCC. Scale bar 200µm. 
(x20 Aperio magnification) 
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Figure 4.14: Overall positive pixel expression of cRel with survival analysis 
A. cRel overall expression in tumour vs normal (****p<0.0001); B. cRel overall expression 
in various tumour stages; C. cRel overall expression in various tumour grades; D. cRel 
overall expression in tumour subtypes; E. cRel overall expression in M1 vs M0 stages; F. 
Kaplan Meier cancer specific survival analysis for cRel overall expression (--- low, --- high) 
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Figure 4.15: Nuclear expression of cRel with survival analysis 
A. cRel nuclear expression in tumour vs normal (****p<0.0001); B. cRel nuclear expression 
in various tumour stages; C. cRel nuclear expression in various tumour grades; D. cRel 
nuclear expression in tumour subtypes; E. cRel nuclear expression in M1 vs M0 stages; F. 
Kaplan Meier cancer specific survival analysis for cRel nuclear expression. (--- low, --- high) 
 
 
 
 
 
P
e
rc
en
t 
(%
) 
C
h
an
ge
P
e
rc
en
t 
(%
) 
C
h
an
ge
P
e
rc
e
n
t 
(%
) 
C
h
an
ge
P
e
rc
en
t 
(%
) 
C
h
an
ge
P
e
rc
e
n
t 
(%
) 
C
h
an
ge
112 
 
 
Figure 4.16: Membrane expression of cRel  
A. cRel membrane expression in tumour vs normal (****p<0.0001); B. cRel membrane 
expression in various tumour stages; C. cRel membrane expression in various tumour grades; 
D. cRel membrane expression in tumour subtypes; E. cRel membrane expression in M1 vs 
M0 stages. 
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In summary, higher expression of p65 in RCC tumour tissue compared with normal kidney 
was seen in comparison with lower expressions of p50, p52 and cRel in RCC tumour tissue 
when compared to normal kidney tissue. Higher nuclear expression of p65, overall and 
nuclear expression of p52 and higher overall p50 were also correlated with worse cancer-
specific survival in this cohort of RCC patients. (Table 4.2) 
 
Table 4.2: Summary of IHC expression of NF-κB subunits in RCC tumours and normal 
kidney with correlation to cancer-specific survival. 
 p65 p50 p52 cRel 
RCC vs normal 
(overall and nuclear 
expresion) 
    
Worse cancer-specific 
survival  
nuclear 
expression 
independent 
prognostic 
factor 
overall 
expression 
independent 
prognostic 
factor 
overall & nuclear 
expression 
_ 
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4.4 DISCUSSION 
 
The role of NF-κB subunits in RCC development and progression has not been well defined 
before. Here we have shown the expressions of four NF-κB subunits in human RCC tissue 
and described the association of p65, p50and p52 with cancer-specific survival.  
NF-κB is found in its sequestered inactive form in the cytoplasm, where it is bound to the 43-
kDa inhibitor protein IκB that covers the nuclear localization signal (NLS) region of the 
predominant p65/p50 dimer (Brasier 2006). In unstimulated cells, the NF-κB dimers are 
sequestered in the cytoplasm by a family of inhibitors, called IκBs (inhibitor of κB), which 
are proteins that contain multiple copies of the ARs. By virtue of their AR domains, the IκB 
proteins mask the NLS of NF-κB proteins, thereby keeping them sequestered in an inactive 
state (Karin and Ben-Neriah 2000). Activation of the NF-κB pathway is initiated by the 
signal-induced degradation of the evolutionarily conserved IκB proteins. This occurs 
primarily via the activation of IκB kinase (IKK) which is composed of a heterodimer of the 
catalytic IKKα and IKKβ subunits and a regulatory protein termed NEMO (NF-κB essential 
modulator), or IKKγ.  
When activated, the IKK phosphorylates two serine residues located in an IκB regulatory 
domain. When phosphorylated on these serines (e.g., serines 32 and 36 in human IκBα), the 
IκB inhibitor molecules are modified by ubiquitination, which then leads them to be 
enzymatically degraded by a proteasome (Brasier 2006; Fusco et al. 2009; Gilmore 2006). 
With the degradation of IκB, the NF-κB complex is then freed to enter the nucleus where it 
can ‘turn on’ the expression of specific genes that have DNA-binding sites for NF-κB nearby. 
The activation of these genes by NF-κB then leads to the given physiological response, for 
example, an inflammatory or immune response, a cell survival response, or cellular 
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proliferation (Doyle and O'Neill 2006; Hayden et al. 2006). Aberrant regulation of NF-κB has 
been linked to certain conditions such as inflammatory and autoimmune diseases, septic 
shock, viral infections, improper immune responses and cancers (Haddad and Abdel-Karim 
2011). 
 
In anti-apoptotic pathways, NF-κB induces the expression of many anti-apoptotic genes of 
the Bcl-2 family including Bcl-XL, and Bcl-2 (Kurland et al. 2001; Lee et al. 1999; Viatour 
et al. 2003; Wang et al. 1999b). Matusan-Ilijas et al showed that p65 NF-κB signaling 
pathway may be involved in osteopontin-mediated ccRCC progression, partly by protecting 
tumour cells from apoptosis (Matusan-Ilijas et al. 2011).  
 
Evidence of NF-κB-induced pro-angiogenic pathways includes VEGF, epidermal growth 
factor (EGF), interleukin-6 and interleukin-8 (Huang et al. 2001; Morais et al. 2009; Mukaida 
et al. 1994). Djordjevic et al showed there was significant association between cytoplasmic 
NK-κB/p65 staining and VEGF staining of diffuse pattern and that higher expression of 
VEGF in tumour cells, especially in clear cell RCC, is associated with NF-κB/65 activity 
(Djordjevic et al. 2008). Epidermal growth factor receptor (EGFR) gene has been shown to 
be upregulated in clear cell RCC and associated with osteopontin expression and NF-kB 
activation and signalling (Matusan-Ilijas et al. 2013). Recently, Du et al reported that 
downregulation of phospholipase Cε (PLCε) expression repressed growth and induced 
apoptosis in RCC cells by suppressing the nuclear factor kappa (NF-κB) signaling pathway 
which led to decreased VEGF expression (Du et al. 2014). 
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In addition, tumours with constitutive activation of NF-κB are generally resistant to chemo 
and radiotherapy and an inverse correlation between NF-κB activity and sensitivity of cancer 
cells to chemotherapy, due to up-regulation of multidrug resistance (MDR) genes, has been 
reported (Wang et al. 1999a). Recently, Zhu et al showed that oncogenic activation of p21-
activated kinase 1 defines an important mechanism for maintaining stem-like phenotype and 
sunitinib resistance through NF-κB/IL-6 activation in RCC (Zhu et al. 2015).  
 
Numerous NF-κB dependent mechanisms have been shown in the activation and promotion 
of RCC carcinogenesis. One of the well-studied mechanisms is the aberrant von Hippel 
Lindau (VHL) pathway which is the most commonidentified factor for the development of 
sporadic clear cell RCC. Loss of VHL tumour suppressor gene will lead to decreased VHL 
protein activity leading to accumulation of hypoxia inducible factor 1a which in turn 
increases angiogenic factors that promote unregulated neoangiogenesis, favouring tumour 
growth. The VHL gene is mutated in 34–56% and hyper-methylated in 19% of the sporadic 
ccRCC (George and Kaelin 2003; Lopez-Beltran et al. 2006). Moreover, the VHL syndrome 
(dominantly inherited cancer syndrome characterised by tumours of brain, eye, kidney, 
pancreas and adrenal) is also a predominant pre-disposing factor for the development of 
familial RCC. As VHL negatively regulates NF-κB; therefore in the absence of functional 
protein encoded by VHL gene (pVHL), NF-κB activation will be increased. 
 An et al have shown that VHL loss drives NF-κB activation by resulting in HIFα 
accumulation, which induces expression of transforming growth factor alpha, with 
consequent activation of an EGFR/phosphatidylinositol-3-OH kinase/protein kinase B 
(AKT)/IκB-kinase alpha/NF-κB signaling cascade. Thus, VHL expression reduces 
constitutive NF-κB activity (An and Rettig 2005; An et al. 2005). Qi et al also showed that 
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pVHL facilitates TNF-alpha-induced cytotoxicity in RCC cells, at least in part, through the 
down-regulation of NF-κB dependent anti-apoptotic pathway (Qi and Ohh 2003). 
 
Therefore, increased activity of NF-κB in RCC will promote invasiveness and metastatic 
potential. Numerous studies have shown a positive association of increased NF-κB, in 
particular the p65 subunit, with higher tumour grade, increased tumour stage, larger tumour 
size, increased invasiveness and metastases (Kankaya et al. 2015; Oya et al. 2003; Ozbek et 
al. 2012). Interestingly, Meteoglu et al showed that there was no significant correlation 
between NF-κB p50 subunit with tumour grade, stage, age and sex (Meteoglu et al. 2008). 
With respect to RCC cancer overall survival, a recent meta-analysis on clear cell RCC gene 
expression identified a key NF-κB regulator (IKBKB) and established mediators of the NF-
κB cell-survival and pro-inflammatory responses (MMP9, PSMB9, and SOD2), correlated 
with higher relative risk, poorer prognosis, and reduced overall patient survival (Peri et al. 
2013). In comparison, some have reported that NF-κB was not a prognostic factor in RCC 
survival (Kankaya et al. 2015; Sourbier et al. 2007). 
 
VHL loss also results in epithelial to mesenchymal transition (EMT). Tumour cells have 
reverted to EMT to enhance their invasive and metastatic potentials. Activation of NF-κB has 
been causally linked to an invasive phenotype and can directly or indirectly induce 
expression of transcription factors Snail, Slug, Twist, Zeb1, and Zeb2 which induce EMT 
program (Min et al. 2008). Pantuck et al provided evidence that in RCC, VHL loss induces 
an EMT that is largely dependent on HIFα-induced NF-κB pathway (Pantuck et al. 2010).  
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Due to the numerous target genes affected by NF-κB in promoting RCC carcinogenesis, 
research has tended to concentrate on targeting its pathway for therapeutic means. In the 
review by Morais et al, these therapeutic modalities include genetic or chemotherapeutic 
approaches. Most of the genetic approaches can be classified under three categories: over-
expression of mutant IκB-α, RNA silencing (siRNA) or specific peptides; while 
chemotherapy approaches involved chemoinhibition of the NF-κB pathway (Morais et al. 
2011). Other promising newer compounds targeting NF-κB in RCC include physalin F, 
chrysin and bortezomib (Rehman et al. 2013; Thapa et al. 2013; Wu et al. 2012). 
 
Therefore, with the reliable evidence of the role of NF-κB in RCC tumourigenesis and its 
potential target for treatment; it is no doubt why there are still ongoing research into NF-κB  
family. Despite these extensive knowledge so far, little is known about the intimate 
interactions of the 5 subunits of NF-κB and their role in RCC. Therefore, this study explored 
the expression of all 5 subunits of NF-κB (p65, p50, p52, RelB and c-Rel) in human RCC 
tissue via IHC and studied the association of each subunit with clinico-pathological aspects of 
the RCC patients. As mentioned previously, RelB IHC staining was inadequate for 
interpretation and therefore only 4 subunits were described. To our knowledge, this is the first 
study that report the findings of various subunits NF-κB (p65, p50, p52 and c-Rel) in human 
RCC and also involving the largest series of human RCC tissue (n=96) with 76 ccRCC 
samples. The hypothesis is that these subunits interact and influence each other, leading to 
RCC tumourigenesis. Therefore, firstly we need to assess the expressions of these subunits in 
RCC. 
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The clinico-pathological data presented as above from the 96 patients are consistent with 
other published RCC data. RCC tend to occur more frequently in males. In this case the male 
to female ratio is 2.1:1. The most prevalent RCC subtype was ccRCC, as is well-published. 
The higher proportion of metastatic RCC patients at presentation and slightly larger median 
tumour size in this cohort of Malaysian patients is reflective of the delay by patients in 
seeking medical attention partly due to decreased health awareness, access to imaging 
facilities and reliance on traditional/local complimentary medicine. The median follow up 
assessment was approximately 4.5 years, during which 29% of patients succumbed to the 
disease. This highlights the lethal nature of metastatic RCC disease despite newer targeted 
molecular therapies which can prolong survival but fall short of providing cure. 
 
In NF-κB p65 subunit analysis, overall, nuclear and membranous expression were higher in 
tumour when compared to normal, which concurs with other published results. The overall 
positive pixel expression of papillary RCC (pRCC) was noted to be highest among all 
subtypes. However, Sourbier et al presented that ccRCC had higher expression of NF-κB 
compared other subtypes (Sourbier et al. 2007). There was a slight trend for increasing 
overall expression of p65 with increasing tumour stages (T4 > T3 > T1/2) and metastatic 
cases (M1 > M0) but this showed no significant differences Importantly we were able to 
show that patients had worse cancer specific survival outcomes with increasing p65 nuclear 
expression (Figure 4.3F). On closer analysis, p65 nuclear expression was found to be an 
independent prognostic factor following multivariate analysis. However, p65 overall 
expression was found not to be an independent prognostic factor, which suggests that there 
must be other mechanisms or pathways that are involved at the nuclear microenvironment. A 
possible explanation for the link between nuclear p65 and poor survival outcome could be 
that activated NF-κB exerts its numerous downstream carcinogenesis effects only once 
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translocated into the nucleus where it binds with NF-κB target genes. One possible outcome 
is that cancer cells display better survival. Therefore NF-κB expression in nuclear 
compartments will be more influential in tumorigenesis and progression compared with the 
overall p65 expression. 
Whilst p65 is the most studied subunit in the past, p50 is another subunit of NF-κB that has 
been studied singly or together with p65 in human RCC tissue (Meteoglu et al. 2008; Oya et 
al. 2003). In the current chapter, overall, nuclear and membrane expression of p50 were 
significantly lower in tumour when compared to normal kidney. This result is in contrast to 
results shown by Meteoglu et al; where their IHC p50 expression were higher in ccRCC than 
normal (n=40) (Meteoglu et al. 2008). Oya et al showed in their immunoblotting analysis that 
there was higher augmented p50 immunoblotting in tumour when compared to normal (n=45) 
and both increased p65 with p50 electrophoretic mobility shift assay correlated to higher 
stage and metastases (Oya et al. 2003). 
 These 2 studies were performed on only ccRCC tumour (all 40/40 cases in Meteoglu et al 
and 42/45 cases in Oya et al). Moreover, in Meteoglu et al (2008) there was weak or no p50 
staining in 11/40 patients and 22/40 patients had cytoplasmic staining in the non-tumoral 
tubular cells. A possible explanation for differences seen between our results and other 
published data is that we investigated 5 different renal tumour subtypes and paired normal 
kidney tissue, an important comparison often omitted in many reports. However, our results 
also indicate that expression of p50 was not associated with tumour stage, grade or 
metastasis. Interestingly, increased overall expression of p50 led to worse cancer specific 
survival (p=0.005) (Figure 4.6F) and on multivariate analysis, was noted to be an 
independent prognostic indicator. 
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This is the first description of results for p52 and cRel NF-κB subunits IHC analysis in 
human RCC tissue. Similar to p50, overall expression, nuclear and membrane expressions of 
p52 and cRel were significantly lower in tumour when compared to normal renal tissue. 
There were no significant association between expression of these two subunits with tumour 
stage, grade and metastases. However, interestingly higher overall expression and nuclear 
expression of p52 were associated with worse survival prognosis (Figure 4.10F and 4.11F) 
and were independent prognostic factors in uni- and multi variate analyses. Based on these 
findings, it is worthwhile that these patients with increased expressions of p65 or p52 in their 
RCC tissue, will need closer radiological surveillance for early detection and opportunity for 
usage of targeted treatment if there was RCC progression. 
 
These results of lower expressions of p50, p52 and cRel IHC analyses in RCC tumour 
compared to normal are difficult to explain. Unlike p65, RelB, and c-Rel, the p50 and p52 
NF-κB subunits do not contain transactivation domains in their C terminal halves. Due to the 
presence of ARs in their C-terminal halves, p105/p50 and p100/p52 also function as IκB 
proteins. Nevertheless, the p50 and p52 NF-κB members play critical roles in modulating the 
specificity of NF-κB function. Although homodimers of p50 and p52 are, in general, 
repressors of the κB site of transcription, both p50 and p52 participate in target gene 
transactivation by forming heterodimers with p65, RelB, or c-Rel. In addition, p50 and p52 
homodimers also bind to the nuclear protein Bcl-3, and such complexes can function as 
transcriptional activators (Brasier 2006; Fusco et al. 2009). Interestingly, NF-κB turns on the 
expression of its own repressor, IκBα. The newly synthesized IκBα then re-inhibits NF-κB 
and, thus, forms an auto feedback loop, which results in oscillating levels of NF-κB activity 
(Haddad et al. 2000; Li and Verma 2002). Therefore, we suggest that there are complex 
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interactions at the molecular and cellular level between these 5 subunits of NF-κB which will 
account for these results. 
 
There were some limitations noted with this study: limited number of samples from the non 
ccRCC renal tumour subtypes; and the investigation was performed on an Asian population 
and may not reflect an Australasian cohort of patients’ samples. With further time and 
funding, a multi-institutional, multi-national collaborative study on expression of NF-κB will 
be useful. 
 
4.5 CONCLUSION 
 
This chapter addressed Aim 2 of research theme which was to analyse the different molecular 
profiles of renal cancers via immunohistochemistry and morphometry techniques using 
selected biomarkers; and this case, NF-κB on renal tumour and normal tissue samples. From 
our knowledge, this is the first and largest series of IHC analysis on 4 subunits of NF-κB 
family in RCC human tissue. There is higher IHC expression of p65 (overall, nuclear and 
membrane) and lower IHC expression of p52, p50 and cRel (overall, nuclear and membrane) 
in RCC tumour compared to normal counterparts. Both higher nuclear expression of p65, 
overall and nuclear expressions of p52 and higher overall expression of p50 were associated 
with worse cancer specific survival; with higher nuclear p65 and overall p50 expression as 
independent prognostic factors in RCC.  
 
From this chapter, the IHC expressions of NF-κB family, especially on the less studied 
subunits of p52, p50 and cRel, will aid in the further understanding of the molecular biology 
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and relationship between these subunits of NF-κB. This better understanding of the molecular 
profiles of NF-κB family in RCCs will encourage further research and pave the way for 
future targeted NF-κB subunit specific therapeutic pathways. 
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CHAPTER 5 
 
IMMUNOHISTOCHEMICAL ANALYSES OF VARIOUS BIOMARKERS IN 
RENAL TUMOURS (ccRCC, chRCC and RO) AND IDENTIFICATION OF 
BIOMARKERS TO DIFFERENTIATE chRCC FROM RO 
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CHAPTER 5 
 
IMMUNOHISTOCHEMICAL ANALYSES OF VARIOUS BIOMARKERS IN 
RENAL TUMOURS (ccRCC, chRCC and RO) AND IDENTIFICATION OF 
BIOMARKERS TO DIFFERENTIATE chRCC FROM RO 
 
Following the informative IHC results obtained for NFκB on the series of RCC specimens 
from Malaysia (Chapter 4), attention was now addressed to IHC of various biomarkers (CK7, 
Cav-1, S100A1 as established biomarkers; and Ob, its receptor ObR, and KIM-1 as novel 
biomarkers) on RCC specimens from an Australian cohort of patients using similar IHC 
methodology. In this chapter, IHC results obtained from these biomarkers were analysed 
from a perspective of achieving our research aim which was to identify biomarkers that 
would aid in the differentiation of chRCC from RO. Following the results gained from the 
meta-analysis (chapter 3), we investigated the differential IHC ability of three biomarkers, 
CK7, Cav-1 and S100A1 on our cohort of patients. In addition, we also investigated novel 
biomarkers, Ob and ObR to assess their differential expressions if any between chRCC and 
RO; and the biomarker KIM-1 that have not been specifically assessed to compare chRCC 
and RO in the past. 
 
5.1 INTRODUCTION 
 
Currently there is no “gold standard” for IHC biomarkers that can aid in the differentiation of 
chRCC and RO, with pathologists relying on the histological features on routine H&E. 
Therefore, since there exists considerable overlap in the histological features, especially 
eosinophilic variants of chRCC from RO, general pathologists who are relying on histology 
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and may be inexperienced uropathologists will face difficulties in discerning the two entities 
(Tan et al. 2013). As discussed in the meta-analysis of chapter 3, numerous IHC biomarkers 
have been employed to aid in distinguishing cases of chRCC from RO where overlapping 
morphological features present a diagnostic dilemma. Three biomarkers analysed in this 
chapter were chosen from extensive literature review. Following the meta-analysis, CK7, 
Cav-1 and S100A1 were chosen because of their apparent usefulness in differentiating the 
two renal tumour entities. As novel biomarkers, Ob, ObR and KIM-1 were  selected based on 
literature that indicates KIM-1 expression is increased in ccRCC but not chRCC and RO 
(Han et al. 2005; Zhang et al. 2014); and the significant association of obesity as a relative 
risk factor for development of RCC (Ljungberg et al. 2011). Since leptin is an adipokine that 
is produced by abundant adipocytes in obese patients, it was important to study the 
relationship of Ob and ObR in differentiation of chRCC and RO, and in malignancies such as 
ccRCC. Following the IHC results of these biomarkers, it is hoped that in future these results 
can be replicated in pre-operative diagnostic pathways via plasma, urine or biopsy tissue. 
 
5.2 MATERIALS AND METHODS 
 
The materials and methods employed in this Chapter have been described in Chapter 2. 
Archived human renal tumour slides with paired normal kidney were obtained from Aquesta 
Pathology. The renal tumour slides were obtained from a dedicated uropathology centre, 
Aquesta Pathology with experienced uropathologists who specialise in genitourinary 
malignancy. IHC analyses for various biomarkers were performed with help from Mr. Clay 
Winterford at QIMR-Berghofer Histology Facility and Dr. David Small at CKDR in TRI. 
Positive and negative controls were routinely stained with each batch of IHC. The relevant 
ethics approvals have also been discussed in Chapter 2 and are included in Appendix 4. 
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5.3 CLINICAL CHARACTERISTICS OF RCC NEPHRECTOMY SPECIMENS 
 
Seventy-five formalin-fixed, paraffin-embedded human renal tumour specimens were 
obtained from Aquesta Pathology. These were from 75 patients who underwent RCC tumour 
nephrectomy at various centres in Brisbane from 2009 to 2014. Each of the sections from 
these blocks had some non-cancerous kidney as well as the tumour. Ratio of males:females 
was 1.9:1, with median age of 64 years (range 18-88), in concordance with more RCC in 
males than females, and most patients being in the 50s to 60s age group. The median renal 
tumour size from this series was 3.8cm (range 1.2 – 18). From this case series, there were 30 
ccRCC, 30 chRCC and 15 RO. Although the ultimate aim was identifying IHC biomarkers 
that differentiated chRCC and RO, ccRCC was included for completeness as this subtype of 
RCC is the most common, constituting about 70-80% of all RCC. The low number (15 cases) 
of RO analysed in this study was because RO account for approximately only 5% of all adult 
renal tumours (Kawaguchi et al. 2011). Among the ccRCC cases, 63.3% were Fuhrman grade 
2, 20% grade 3 and 16.7% grade 4. The histopathological diagnoses were made by 
experienced uropathologists in Aquesta Pathology. Although it is recognised that the system 
for grading RCC has been modified in the past 2 years (Delahunt et al. 2014), these samples 
were graded using the older Fuhrman grading system, and these grades will be utilised for 
these specimens. 
 
One third of the patients underwent partial nephrectomy (25 out of 75 patients). The majority 
of the patients were in stage T1 (62.7%), and the rest were in T2 (9.3%), T3 (26.7%) and T4 
(1.3%). The trend of patients presenting with smaller confined tumours in T1 stage is due to 
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increasing detection rates for incidental renal tumours from widespread availability of 
radiological imaging; similar with other published series (Duchene et al. 2003). There were 
only 2 patients who presented with metastatic disease and underwent cytoreductive 
nephrectomy subsequently. These results are summarised in Table 5.1 
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Table 5.1:- Clinicopathological characteristics of the cohort of RCC patients  
Patients 75 
Period 2009 – 2014 
Gender 49 Male : 26 Female 
Median age (years) 64 (18-88) 
Median size (cm) 3.8 (1.2-18) 
Nephrectomy Partial = 25 (33.3%) 
Radical = 50 (66.7%) 
Subtype 30 ccRCC 30 chRCC 15 RO 
T stage                 
 
ccRCC chRCC 
 
RO 
 
T1 = 47 (62.7%) 20(66.7%) 15(50%) 12(80%) 
T2     7 (9.3%)              0 5(16.7%) 2(13.3%) 
T3 = 20 (26.7%) 9(30%) 10(33.3%) 1(6.7%) 
T4= 1 (1.3%) 1(3.3%) 0 0 
M1 stage            2 (2.67%) 
Fuhrman (ccRCC)      
                Grade 2  
                Grade 3 
                Grade 4   
 
63.3% 
20% 
16.7% 
        Tumour (T), Metastases (M),  
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5.4 RESULTS OF IMMUNOHISTOCHEMISTRY AND MORPHOMETRY 
 
5.4.1 Cytokeratin 7 (CK7) 
CK7 is a low molecular weight keratin, belonging to a large family of structural polypeptides 
that are the fundamental markers of epithelial differentiation. The CKs found in simple 
epithelia (CK7, CK8, CK18 and CK19) are widely expressed in normal kidney and renal 
neoplasms (Skinnider et al. 2005). In the present study, normal renal cortical tissue adjacent 
to the tumours showed positivity for CK7 in the cytoplasm of distal tubular cells (identified 
by structure). There was strong membranous and cytoplasmic expression of CK7 in chRCC, 
with minimal or no staining in ccRCC and RO, as seen in Figure 5.1. In chRCC, there was 
intense cytoplasmic immunostaining with characteristic strong peripheral membrane staining. 
Based on the IHC characteristics, overall positive pixel expression was analysed using Aperio 
ImageScope. 
 
5.4.1.1 Morphometry of CK7 (positive pixels) and overall expression 
The overall positive pixel expression in tumour (ccRCC, chRCC and RO included) was lower 
compared to normal renal tissue (Figure 5.2A). When compared separately, ccRCC and RO 
had significantly lower overall positive pixel expression compared to normal tissue 
(p<0.0001 and p=0.002 respectively) (Figure 5.2B, 5.2D). However, there was no significant 
difference between the overall expression of CK7 in chRCC compared to normal renal tissue 
(Figure 5.2C). Therefore, the expression of CK7 immunostaining was higher in chRCC when 
compared to RO and ccRCC (Figure 5.2E). Importantly, there was significantly higher 
expression of CK7 in chRCC in compared with RO (p=0.03) as shown in Figure 5.2F. This 
significantly different expression pattern of CK7 in both chRCC and RO provide a useful and 
efficient IHC biomarker that can aid in differentiating the two entities.  
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Figure 5.1: CK7 immunohistochemistry 
A. Immunostaining in normal renal cortical tissue shows CK7 positivity in the vessels and 
some tubular epithelium; B. In clear cell RCC, minimal CK7 IHC is visible; C. CK7 IHC is 
strong in chRCC; D. RO was clear of CK7 staining. Scale bar 200µm. (x20 Aperio 
magnification) 
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Figure 5.2: Expression of CK7 in renal tumours and matched normal renal tissue  
A. Expression of CK7 in normal vs tumour; B. Decreased expression of CK7 in ccRCC vs 
normal kidney (****p<0.0001); C. Increased expression of chRCC vs normal kidney; D. 
Decreased expression of CK7 in RO vs normal kidney (**p=0.002); E. Expression of CK7 in 
tumour subtypes; F. Significantly increased expression of CK7 in chRCC vs RO (*p=0.03). 
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5.4.2 Caveolin-1  
Cav-1 is a membrane protein present in most cells. Cav-1, a 24kDa membrane protein, is a 
major component of membrane caveolae. Functionally, Cav-1 serves important roles in 
macromolecular transcytosis, endocytosis of pathogens, lipid metabolism and cellular signal 
transduction (Cohen et al. 2004). In non-neoplastic renal tissue, there was minimal 
basolateral membrane and cytoplasmic staining in distal convoluted tubules, along with 
staining of vascular endothelial cells. The immunostaining patterns of Cav-1 were mainly 
membranous in ccRCC, diffuse cytoplasmic in chRCC and patchy cytoplasmic in RO, as 
shown in Figure 5.3A-D. On closer inspection, there was a distinguishing staining pattern 
observed in chRCC where there was diffuse cytoplasmic with peripheral membranous 
enhancement and a perinuclear halo; compared to patchy granular cytoplasmic staining in RO 
(Figure 5.3C, D). This distinctly different Cav-1 immunostaining pattern between chRCC and 
RO may prove to be useful in separating the two tumour subtypes. Based on the IHC staining 
patterns, overall and membrane expressions were analysed on Aperio ImagScope. 
 
5.4.2.1 Morphometry of Cav-1 (positive pixels) and overall expression 
All ccRCC, chRCC and RO had significantly higher overall expression of Cav-1 compared to 
normal renal cortical tissue (Figure 5.4A). Individually, ccRCC Cav-1 expression was 
significantly higher compared to normal kidney (p=0.01, Figure 5.4B); chRCC recorded 
similarly higher expression (p<0.0001, Figure 5.4C), with RO also having higher 
immunostaining compared to paired normal kidney (p=0.003, Figure 5.4D). As demonstrated 
in Figure 5.4E, ccRCC had higher expression compared to chRCC, which had higher 
expression than RO. There was very little difference in overall Cav-1 expression in chRCC 
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versus RO. However as shown in Figure 5.3, the useful discriminatory feature lies in the 
different staining patterns between chRCC and RO. 
 
 
Figure 5.3: Caveolin-1 immunohistochemistry 
A. Immunostaining of Cav-1 in normal renal cortical tissue localised to cytoplasm of distal 
convoluted cells and vascular endothelial cells. Proximal tubular epithelial cells were clear of 
Cav-1; B. In clear cell RCC, Cav-1 staining was mainly membranous; C. Strong diffuse Cav-
1 cytoplasmic staining with peripheral enhancement and a perinuclear halo was noted in 
chRCC; D. Patchy granular cytoplasmic staining was seen in RO. Scale bar 200µm. (x20 
Aperio magnification) 
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Figure 5.4: Expression of Cav-1 in renal tumours and matched normal renal tissue  
A. Increased expression of Cav-1 in tumour vs normal tissue (****p<0.0001); B. Increased 
overall Cav-1 expression in ccRCC vs normal kidney (*p=0.01); C. Increased overall Cav-1 
expression of chRCC vs normal kidney (****p<0.0001); D. Increased overall Cav-1 
expression in RO vs normal kidney (**p=0.003); E. Expression of Cav-1 in tumour subtypes; 
F. Overall expression of Cav-1 in chRCC vs RO. 
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5.4.2.2 Caveolin 1 membrane expression 
 
Since there was notable membranous enhancement in ccRCC and chRCC, the membranous 
immunostaining of Cav-1 was analysed quantitatively using Aperio ImageScope, asking the 
question “are there any differences in the membranous expression of Cav-1 in ccRCC, 
chRCC and RO?” Membranous expression of all tumours (ccRCC, chRCC and RO) was 
significantly higher when compared to normal renal cortical tissue (p<0.0001, p<0.0001 and 
p=0.003 respectively) as shown in Figures 5.5 A-D. Membranous expression was highest in 
ccRCC followed by chRCC then RO (Figure 5.5E). However, despite a higher membranous 
Cav-1 expression in chRCC compared to RO, it was not statistically significant (p=0.1) as 
shown in Figure 5.5F. 
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Figure 5.5: Expression of Cav-1 (membranous) in tumours and matched normal renal 
tissue 
A. Increased membranous expression of Cav-1 in tumour vs normal kidney(****p<0.0001); 
B. Increased membranous Cav-1 expression in ccRCC vs normal kidney(****p<0.0001); C. 
Increased membranous Cav-1 expression of chRCC vs normal kidney(****p<0.0001); D. 
Increased membranous Cav-1 expression in RO vs normal kidney(**p=0.003); E. Expression 
of Cav-1(membranous) in tumour subtypes; F. Expression of Cav-1 (membranous)  in 
chRCC vs RO. 
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5.4.3 Leptin (Ob) 
Leptin is a hormone made by adipose cells that helps to regulate energy balance by inhibiting 
hunger. Obesity is a known risk factor for RCC and leptin is increased in obesity. Studies 
have strongly suggested that leptin plays a role in carcinogenesis through cell proliferation, 
angiogenesis, apoptotic inhibition and proinflammatory effects (Housa et al. 2006; Renehan 
et al. 2008; Tilg and Moschen 2006). Ob was used as the alias for leptin as the Ob(Lep) gene 
codes for the human leptin protein. From the associated risk of obesity with the development 
of RCC and previous studies that correlated serum leptin and its receptor to RCC progression 
(Horiguchi et al. 2006), we investigated the expression of Ob and ObR in RCC. CcRCC 
tumour cells have “clear” cytoplasm due to its abundant lipids and glycogen. Therefore, we 
postulated that there might be differences in expression of these biomarkers in RCC subtypes, 
since other subtypes (ie chRCC and RO) do not share the same abundant lipids in their 
cytoplasm. Therefore we studied the IHC of both leptin (Ob antibody) and its receptor (ObR 
antibody) in our human renal tumour tissues. Based on the IHC Ob staining characteristics, 
overall, nuclear and membrane expression were analysed on Aperio ImageScope. 
 
5.4.3.1 IHC showing Ob positive pixel and overall expression 
IHC of Ob revealed mainly nuclear staining with some cytoplasmic expression in adjacent 
normal renal parenchyma and in ccRCC. In chRCC, the staining was mainly cytoplasmic 
with minimal or none in nuclear regions, in contrast to RO where the staining was more 
diffuse in the cytoplasm and prominent nuclear staining patterns were seen (Figure 5.6 A-D). 
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Figure 5.6: Immunostaining of leptin (Ob) 
A. Immunostaining of Ob is demonstrated in normal renal cortical tissue and shows nuclear 
and some cytoplasmic staining; B. In clear cell RCC, nuclear Ob staining was prominent; C. 
Ob IHC was localised to cytoplasm in chRCC, with minimal staining; D. Diffuse cytoplasmic 
and nuclear staining of Ob was seen in RO. Scale bar 200µm. (x20 Aperio magnification) 
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5.4.3.2 Morphometry of IHC showing overall Ob expression 
The expression of Ob in renal tumour tissue was higher than normal tissue (Figure 5.7A). In 
ccRCC, chRCC and RO, there was significantly increased overall expression of Ob compared 
to normal kidney (p=0.01, p=0.01, p=0.03 respectively) as shown in Figures 5.7B-D. When 
compared to each tumour subtype, there was a trend of highest to lowest expression of Ob 
noted in RO followed by chRCC then ccRCC (Figure 5.7E). There was no significant 
difference in the overall expression of Ob inRO compared to chRCC (p=0.16) (Figure 5.7F). 
 
5.4.3.3 IHC showing Ob nuclear expression 
When nuclear expression of Ob was analysed, there was no marked difference between 
tumour and normal tissue. For ccRCC, there was higher expression in the tumours compared 
to normal tissue, but the difference did not reach significance. In RO, the Ob nuclear 
expression was similar in tumour and normal kidney. However in chRCC, there was 
significantly higher Ob nuclear expression in normal compared to chRCC tumour cells 
(Figure 5.8A-D). Importantly, there was significantly higher expression of Ob in nuclear 
regions of RO in contrast to chRCC, where there was minimal/absent nuclear staining 
(p=0.02) (Figure 5.8E, F). This useful differential nuclear expression between chRCC and 
RO can aid in the diagnosis of one subtype from the other. 
 
5.4.3.4 Morphometry of IHC showing membrane expression of Ob 
Membrane expression of Ob was increased in ccRCC and RO, but lesser in chRCC compared 
to normal (Figure 5.9A-D). When compared across the board, membrane expression of Ob 
was highest in RO, followed by ccRCC and chRCC. Although there was an increase in Ob 
membrane expression in RO compared to chRCC, it was not statistically significant (p=0.13) 
as shown in Figure 5.9E and 5.9F. 
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Figure 5.7: Ob overall expression in renal tumours and matched normal renal tissue 
A. There was increased overall expression of Ob in tumour vs normal kidney 
(****p<0.0001); B. Increased overall Ob expression in ccRCC vs normal kidney (*p=0.01); 
C. Increased overall Ob expression of chRCC vs normal kidney (*p=0.01); D. Increased 
overall Ob expression in RO vs normal kidney (*p=0.03); E. Expression of Ob in is shown in 
tumour subtypes; F. Expression of Ob was higher in RO vs chRCC (not significant). 
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Figure 5.8: Ob nuclear expression in renal tumours and matched normal renal tissue 
A. Nuclear expression of Ob in tumour vs normal kidney; B. Increased Ob nuclear expression 
in ccRCC vs normal kidney; C. Minimal Ob nuclear expression of chRCC vs normal kidney 
(*p=0.03); D. Ob nuclear expression in RO vs normal kidney; E. Expression of Ob nuclear in 
tumour subtypes; F. Increased expression of nuclear Ob in RO vs chRCC (*p=0.02). 
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Figure 5.9: Ob membrane expression in renal tumours and matched normal renal tissue 
A. Membrane expression of Ob in tumour vs normal; B. Increased Ob membrane expression 
in ccRCC vs normal; C. Minimal Ob membrane expression of chRCC vs normal; D. Ob 
membrane expression in RO vs normal; E. Expression of Ob membrane in tumour subtypes; 
F. Increased expression of Ob membrane in RO vs chRCC (not significant). 
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5.4.4 Leptin receptor (ObR) 
Ob acts through its receptor ObR, a single-transmembrane-domain receptor of the cytokine 
receptor family. Previous study have shown that increased leptin/ObR signalling may 
promote renal cancer cell invasion and metastasis (Horiguchi et al. 2006a). For IHC, there 
was cytoplasmic staining of ObR in the proximal convoluted tubular cells of non-neoplastic 
renal cortical tissue. In ccRCC, both cytoplasmic and nuclear staining were evident. The cells 
in chRCC had variable mild cytoplasmic stains with no nuclear staining at all. In comparison, 
in RO, there was more intense diffuse cytoplasmic and nuclear staining. The examples of 
these sections are shown in Figures 5.10A-D. Overall, nuclear and membrane expression 
were analysed on Aperio ImageScope based on the IHC staining patterns of ObR. 
 
5.4.4.1 IHC and overall expression patterns of ObR 
Generally all tumours had stronger ObR expression than normal renal tissue (p<0.0001) as 
depicted in Figure 5.11A. The overall expression patterns of ObR in ccRCC, chRCC and RO 
were all significantly elevated compared with to normal kidney tissue (p=0.005, p=0.02, 
p=0.05, respectively) as shown in Figures 5.11B-D. RO had the strongest expression 
followed by similar but lowerlevels of intensity in ccRCC and chRCC. RO recorded a higher 
ObR overall expression compared to chRCC, but the difference was not significant, p=0.23 
(Figures 5.11E, F). 
 
5.4.4.2 Nuclear expression patterns of ObR 
All tumours recorded stronger ObR nuclear immunostaining compared to normal kidney 
tissue (Figure 5.12A-D), however, the differences were not significant. ccRCC had the 
highest nuclear staining followed by RO then chRCC. There was no difference in ObR 
nuclear expression between RO and chRCC (p=0.72) as shown in Figures 5.12E, F. 
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Figure 5.10: ObR immunostaining in renal tumour and matched normal renal cortical 
tissue  
A. Immunostaining of ObR in normal renal cortical tissue showing cytoplasmic staining; B. 
In clear cell RCC, nuclear and cytoplasmic ObR staining was visible; C. ObR staining was 
minimal in cytoplasm with no nuclear staining in chRCC; D. Diffuse cytoplasmic and nuclear 
staining of ObR in RO. Scale bar 200µm. (x20 Aperio magnification) 
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Figure 5.11: ObR expression patterns in renal tumours and matched normal renal 
tissue 
A. Increased expression of ObR overall in tumour vs normal kidney (****p<0.0001); B. 
Increased ObR overall expression in ccRCC vs normal kidney (**p=0.005); C. Increased 
ObR overall expression of chRCC vs normal kidney (*p=0.02); D. ObR overall expression in 
RO vs normal kidney; E. Expression of ObR in tumour subtypes; F. Expression of overall 
ObR in RO vs chRCC. 
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Figure 5.12: ObR nuclear expression in renal tumours and matched normal renal tissue 
A. Expression of ObR nuclear in tumour vs normal kidney; B. ObR nuclear expression in 
ccRCC vs normal kidney; C. ObR nuclear expression of chRCC vs normal kidney; D. ObR 
nuclear expression in RO vs normal kidney; E. Expression of ObR nuclear in tumour 
subtypes; F. Expression of ObR nuclear in RO vs chRCC. 
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5.4.4.3 Membrane expression of ObR 
Morphometry of membrane IHC of ObR revealed tumours collectively had more intense 
membranous staining compared to normal kidney tissue; except for chRCC which had lower 
expression (Figures 5.13 A-D). Oncocytoma had strongest membranous staining compared to 
ccRCC and chRCC. The difference in ObR membranous expression between RO and chRCC 
was not significant p=0.08 (Figure 5.13E, F). 
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 Figure 5.13:  ObR membrane expression in renal tumours and matched normal renal 
tissue 
A. Expression of ObR membrane in tumour vs normal kidney; B. ObR membrane expression 
in ccRCC vs normal kidney; C. ObR membrane expression of chRCC vs normal kidney; D. 
ObR membrane expression in RO vs normal kidney; E. Expression of ObR membrane in 
tumour subtypes; F. Expression of ObR nuclear in RO vs chRCC. 
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5.4.5 Kidney injury molecule-1 
KIM-1 is a type 1 transmembrane protein, with an immunoglobulin and mucin domain, 
whose expression is markedly up-regulated in the proximal tubule following kidney injuries. : 
KIM-1 has been investigated widely and has been found to be a useful biomarker in acute and 
chronic kidney injuries and also in RCC (Bonventre 2014). The utility of KIM-1 has not 
gained widespread clinical usage despite its promising published research results in acute and 
chronic kidney injury studies (Liangos et al. 2007, van Timmeren et al. 2007). However, 
there was increased expression of KIM-1 noted in renal tumours compared with normal 
kidney, mainly in ccRCC (Lin et al. 2007; Zhang et al. 2014). We wanted to investigate 
further if there was any differential expression in various renal tumour subtypes apart from 
ccRCC and to assess if there was any usefulness in differentiating chRCC from RO. Overall 
positive pixel expression of KIM-1 was analysed on Aperio ImageScope. 
 
5.4.5.1 IHC of kidney injury molecule-1 
In adjacent non neoplastic renal parenchyma, mainly cytoplasmic and some nuclear 
immunostaining of KIM-1 was noted in the proximal tubular cells (Figure 5.14 A). In the 
majority of ccRCC, there was intense diffuse cytoplasmic and membranous immunostaining 
(Figure 5.14B). There was also moderate cytoplasmic and nuclear staining in 12 out of 15 
(80%) slides of RO (Figure 5.14D). The adjacent normal renal tissue near the RO tumours 
expressed cytoplasmic and nuclear immunostaining. There was minimal focal cytoplasmic 
and occasional nuclear expression of KIM-1 in 7 out of 30 (23.3%) chRCC slides (Figure 
5.14C). In some chRCC tumour cells which did not express any immunostaining, the adjacent 
normal renal tissue did reveal positive immunostaining in cytoplasm of the tubular cells. 
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Figure 5.14: KIM-1 immunostaining in normal renal tissue and tumour tissue  
A. Immunostaining of KIM-1 in adjacent normal renal cortical tissue showing mainly 
cytoplasmic and some nuclear staining; B. In clear cell RCC, there was intense membranous 
and cytoplasmic KIM-1 staining; C. There was focal cytoplasmic and occasional nuclear 
KIM-1 staining in chRCC; D. Moderate cytoplasmic and nuclear staining of KIM-1 in RO. 
Scale bar 200µm. (x20 Aperio magnification) 
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5.4.5.2 Morphometry of IHC for kidney injury molecule-1 
 
All tumour subtypes recorded higher KIM-1 overall expression compared to normal kidney 
tissue (p<0.0001) (Figure 5.15A). In ccRCC, KIM-1 expression was markedly elevated when 
compared to its normal counterpart (p<0.0001) as shown in Figure 5.15B. As in ccRCC, RO 
tissue also recorded significantly higher levels compared to normal tissue, with p=0.001 as 
shown in Figure 5.15D. There was only a minimal increase (with no significant difference) in 
KIM-1 expression in chRCC compared with normal tissue (Figure 5.15C). When the tumours 
were compared, both RO and ccRCC had almost similarly-elevated expression of KIM-1 
(Figure 5.15E), but there was a significantly higher expression of KIM-1 expressions in RO 
compared with chRCC (p=0.002). The difference between RO and chRCC could help in 
differentiating these two difficult-to-separate histological entities (Figure 5.15F).  
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Figure 5.15: KIM-1 expression in renal tumours and matched normal renal tissue 
A. Increased KIM-1 expression in tumour vs normal kidney (****p<0.0001); B. Increased 
KIM-1 expression in ccRCC vs normal kidney (****p<0.0001); C. KIM-1 expression of 
chRCC vs normal kidney; D. Increased KIM-1 expression in RO vs normal kidney 
(**p=0.001); E. Expression of KIM-1 in tumour subtypes; F. Increased expression of KIM-1 
in RO vs chRCC (**p=0.002). 
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5.4.6 S100 calcium-binding protein α1 (S100A1) 
S100A1 is a member of the S100 family of calcium binding molecules, most of which are 
clustered on chromosome 1q21, and expressed in RCC (Teratani et al. 2002). Importantly, 
these proteins are involved in cell cycle progression and cell differentiation (Li et al. 2007) 
and therefore implicated in tumorigenesis, a basis for its investigation in renal tumour 
subtypes. Based on the IHC staining characteristics of S100A1, overall and nuclear 
expression were analysed in Aperio ImageScope. 
 
5.4.6.1 IHC of S100A1 
From our IHC study, S100A1 stained the cytoplasm of proximal and distal tubular cells in 
nearby normal renal tissue. In ccRCC, there was both cytoplasmic and membranous 
immunostaining noted. There was patchy cytoplasmic staining noted in chRCC while in RO, 
there was intense and diffuse cytoplasmic and nuclear staining (Figures 5.16 A-D). Overall 
and nuclear expression were analysed on Aperio ImageScope based on the IHC staining 
patterns of S100A1. 
 
5.4.6.2 Overall expression patterns of S100A1 
In the analyses of overall expression, all tumours recorded a higher expression of S100A1 
compared to normal as shown in Figure 5.17A. Both ccRCC and chRCC had higher 
expression to normal (not significantly); but in RO, there was significantly higher expression 
of S100A1 compared to normal with p=0.02 (Figures 5.17 B-D). However, there was no 
significant difference in expression between RO and chRCC. (Figure 5.17E, F). 
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Figure 5.16: S100A1 immunostaining in normal renal cortical tissue and renal tumour 
tissue  
A. Immunostaining of S100A1 in adjacent normal renal cortical tissue showing mainly 
cytoplasmic staining; B. In clear cell RCC, there was membranous and cytoplasmic S100A1 
staining; C. There was patchy cytoplasmic S100A1 staining in chRCC; D. Intense and diffuse 
cytoplasmic and nuclear staining of S100A1 in RO. Scale bar 200µm. (x20Aperio 
magnification) 
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5.4.6.3 IHC showing S100A1 nuclear expression 
When nuclear expression of S100A1 was analysed, there was no marked difference between 
tumour and normal tissue. For ccRCC, there was higher expression in the tumours compared 
to normal tissue, but the difference did not reach significance. In RO, the S100A1 nuclear 
expression was slightly higher in tumour than normal kidney. However in chRCC, there was 
higher S100A1 nuclear expression in normal compared to chRCC tumour cells (Figure 
5.18A-D). There was no difference in the expression of S100A1 in nuclear regions of RO in 
contrast to chRCC (p=0.06) (Figure 5.18E, F).   
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Figure 5.17:  S100A1 expression in renal tumours and matched normal renal tissue 
A. S100A1 expression in tumour vs normal kidney; B. S100A1 expression in ccRCC vs 
normal kidney; C. S100A1 expression of chRCC vs normal kidney; D. Increased S100A1 
expression in RO vs normal kidney (*p=0.02); E. Expression of S100A1 in tumour subtypes; 
F. Expression of S100A1 in RO vs chRCC (not significant). 
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Figure 5.18:  S100A1 nuclear expression in renal tumours and matched normal renal 
tissue 
A. S100A1 expression in tumour vs normal kidney; B. S100A1 expression in ccRCC vs 
normal kidney; C. S100A1 expression of chRCC vs normal kidney; D. Increased S100A1 
expression in RO vs normal kidney; E. Expression of S100A1 in tumour subtypes; F. 
Expression of S100A1 in RO vs chRCC (p=0.06)   
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5.5 DISCUSSION 
 
Histopathological diagnosis of renal tumour subtypes poses a significant diagnostic dilemma 
when the morphological characteristics of tumour subtypes overlap; especially eosinophilic 
variants of chRCC from RO and eosinophilic variants of ccRCC (Liu et al. 2007). Obviously, 
the distinction for RO from chRCC will dictate different management pathways as RO is 
benign while chRCC is a malignant subtype which will require further surveillance. Another 
important distinction will be chRCC from ccRCC as chRCC have a more favourable 
prognosis than ccRCC (Gelb 1997). 
 
Traditionally, Hale colloidal iron staining has been used to distinguish chRCC from the other 
mimics. However, the reproducibility of Hale colloidal iron staining is technically-difficult, 
due to variations in pH. Results are hard to interpret (Leroy et al. 2000) and its reproducibility 
in various laboratories is not consistent. Ultrastructurally, chRCC has numerous cytoplasmic 
microvesicles and RO on the other hand has abundant giant mitochondria (Cochand-Priollet 
et al. 1997) but electron microscopy facilities are not readily available, and this technique is 
not clinically practical in an era when cost and time must always be considered. 
 
Therefore utility of IHC remains the most readily accessible and efficient method of 
distinguishing RO and chRCC. In Chapter 3, our systematic review and meta-analysis of IHC 
demonstrated that there are numerous biomarkers which have been investigated to aid in the 
histological differentiation between the two entities. From this meta-analysis, we selected to 
analyse and validate some of the most apparently-efficient IHC biomarkers (CK7, S100A1 
and Cav-1) on Australian cohort of patients. Leptin, leptin receptor and KIM-1 were the other 
IHC biomarkers that we selected to investigate. 
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5.5.1 Cytokeratin 7 
 
Cytokeratins are important markers of epithelial differentiation. They consist of at least 20 
distinct molecules, the expression of which depends on cell type and differentiation status, 
making them useful in differential diagnosis of many epithelial tumours (Teratani et al. 
2002). As a result CK7 has been widely investigated as a biomarker in renal neoplasms, 
including the distinction of chRCC from other mimicking renal tumours (eg RO, eosinophilic 
variant of ccRCC).  
 
In the current study, CK7 immunostaining was seen in cytoplasm of normal distal tubular 
cells. This is consistent with published reports where CK7 staining in normal kidney was 
expressed in distal tubules and collecting ducts (Mertz et al. 2008). There was minimal CK7 
staining in ccRCC and RO in our study; with diffuse cytoplasmic and peripheral membranous 
enhancement in chRCC. This is in concordance with other previous works, where in chRCC, 
there was diffuse cytoplasmic with peripheral enhancement expression while only weak 
patchy sporadic expression was reported in RO (Bing et al. 2013; Mathers et al. 2002). In 
addition, the CK7 expression was weak or absent in most of our ccRCC. These strong 
expression of chRCC as compared to weak or absent expression in RO and ccRCC are 
consistent with previous published results (Geramizadeh et al. 2008; Kuroda et al. 2004; 
Mazal et al. 2005; Yasir et al. 2012). The exact reason behind these expression differences in 
these 3 subtypes of renal tumours remains to be defined or understood. 
 
The strong and enhanced peripheral membranous immunostaining noted in our chRCC cases 
was consistent with other reports as mentioned above. This may reﬂect the peripheral 
distribution of intermediate ﬁlaments within the tumour cells. Abundant cytoplasmic 
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microvesicles in chRCC may push the intermediate ﬁlaments aside in the peripheral area of 
the cytoplasm, because chRCC has more abundant cytoplasmic microvesicles (Latham et al. 
1999). 
 
The overall expression of chRCC was highest amongst the 3 tumour subtypes and was 
significantly higher compared to RO. This differential IHC result between positively-stained 
chRCC versus poorly-stained RO on our Australian cohort of patients provides further 
validation to other published results (Adley et al. 2006a; Leroy et al. 2000; Liu et al. 2007; 
Mathers et al. 2002). However, there were also some authors who had different results where 
RO had also prominent CK7 expression when compared to chRCC (Taki et al. 1999; Wu et 
al. 2002). Reasons for these disparate results could be due to small numbers of chRCC and 
RO being used in some studies, difficult histological interpretation of IHC and inaccurate 
initial diagnoses of the cases.  
 
Nevertheless, the CK7 IHC study provided similar results as revealed by our meta-analysis 
where CK7 has been identified as the most studied IHC biomarker in the differentiation 
between chRCC and RO (Ng et al. 2016). From this meta-analysis, we also recommended 
CK7 as part of our panel of IHC biomarkers than can be useful in differentiating chRCC from 
RO. Other authors have also recommended CK7 as part of their panel of IHC biomarkers for 
this purpose and these include: CK7, s100A1, claudin 8 panel (Kim et al. 2009); CK7 and 
EpCAM panel (Liu et al. 2007) and CK7, KIT, PAX2 panel (Memeo et al. 2007). 
 
The association of CK7 with RCC tumourigenesis or progression needs further evaluation. 
One proposed mechanism includes metalloproteinase. It is possible that the clinical behaviour 
and better prognosis of chRCC in contrast to other RCCs could be related to the association 
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of CK7 with absence of membrane type 1 matrix metalloproteinase (MT1-MMP). MMPs are 
zinc-dependent endopeptidases, which are largely involved in tissue remodelling, degradation 
of the extracellular matrix and basal membranes leading to tumour invasion and progression 
(Nagase and Woessner 1999). One study showed the absence of MT1-MMP in CK7-positive 
ccRCCs, suggesting that any good prognosis of CK7-expressing ccRCC can be partially 
explained by absence of MT1-MMP expression (Mertz et al. 2008). 
 
5.5.2 Caveolin-1 
Caveolae are morphologically identifiable plasma membrane invaginations that were 
identified first in the 1950s by electron microscopic examination. They constitute a 
membrane system that is essential for normal cellular functions. Caveolae are specialized 
lipid raft microdomains forming 50 to 100 nm flask-shaped vesicular invaginations of the 
plasma membrane, which serve as a scaffold for signalling molecules related to cell adhesion, 
growth and survival (Anderson 1998). Caveolins are functionally and structurally highly 
conserved, and they initiate caveolae formation from raft derived components. Cav-1 is 
involved in the regulation of numerous signalling cascades, including receptor and non-
receptor tyrosine kinases such as epidermal growth factor, Neu and the Src family tyrosine 
kinases, protein kinase C, heterotrimeric G-protein α-subunits and endothelial nitric oxide 
synthase (Okamoto et al. 1998). 
 
Some studies have demonstrated that Cav-1 acts as a tumour suppressor protein, inhibiting 
the functional signalling activity of several proto-oncogenes and, consequently, disrupting the 
process of cellular transformation (Cohen et al. 2004). Expression of Cav-1 has been studied 
in various types of tumours; and previous authors have published results in RCC (Carrion et 
al. 2003; Garcia and Li 2006; Mete et al. 2005). 
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From our study, there was minimal staining of Cav-1 noted in distal tubules and more 
pronounced staining of endothelial cells in normal renal tissue. This is reflective of previous 
studies where Cav-1 was localised to distal tubular cells, collecting ducts, parietal cells of 
Bowman’s capsule, endothelial and smooth muscle cells (Breton et al. 1998). All 3 tumours 
(ccRCC, chRCC and RO) recorded significantly higher overall and membranous expression 
of Cav-1 compared to normal renal tissue.  
 
There was prominent membranous staining of ccRCC. In chRCC, intense diffuse cytoplasmic 
staining with peripheral membranous enhancement and a distinctive perinuclear halo was 
noted; while in ROs there was patchy cytoplasmic staining. Membranous expression of Cav-1 
was highest in ccRCC followed by chRCC and RO. These staining patterns of the 3 tumours 
were similar to reports published by Tamaskar et al, where ccRCC were noted to have 
predominantly membranous expression while chRCC and RO had cytoplasmic expression 
(Tamaskar et al. 2007). Similarly Mete et al also recorded a difference in staining patterns 
between chRCC (diffuse and peripheral cytoplasmic) and RO (diffuse cytoplasmic) (Mete et 
al. 2005). The observations by previous authors strengthen our findings of differences in 
staining patterns noted in our chRCC and RO. The differential IHC Cav-1 staining pattern 
between the two entities will aid in the important differentiation of the two tumours.  
 
Although increased overall and membranous expression of Cav-1 was noted in chRCC as 
compared to RO, these were not statistically significant. Other published results have also 
shown that Cav-1 expression was higher in the majority of chRCC versus focal positivity in 
the minority of RO (Garcia and Li 2006; Lee et al. 2011). However, one contrasting report 
had RO with increased cytoplasmic staining and lower expression in chRCC (Carrion et al. 
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2003). Nonetheless, the different staining patterns may be beneficial in differentiation 
between chRCC and RO.  
 
The significance of Cav-1 over-expression in RCC has been linked to higher tumour grades, 
venous invasion, lymph node metastases, tumour progression and poorer prognosis 
(Horiguchi et al. 2004). It is well known that ccRCC have a more aggressive malignant 
nature and therefore, as expected, the highest expression of Cav-1 was noted in ccRCC 
compared to chRCC (less aggressive but malignant) and benign RO. A meta-analysis also 
recently reported the association of Cav-1 levels with cancer-specific survival in renal 
cancers with a hazard ratio of 1.98 (Liu et al. 2015).   
 
The mechanisms by which Cav-1 exerts its tumourigenesis include enhancement of VEGF 
secretion, thereby stimulating angiogenesis (Li et al. 2009); and interaction with phospho-
ERK-1/2 to promote tumour survival and growth (Campbell et al. 2013). Also in RCC, Cav-1 
may serve as a ‘gatekeeper’ for activation of the hypoxia-inducible factor (HIF) pathway HIF 
is a downstream effector molecule of mTOR that accumulates in RCC in response to the loss 
of function of VHL and promotes angiogenesis, vascular invasion and chemoresistance (Patel 
et al. 2006). Cav-1 has also been identified as a molecular target of bortezomib in advanced 
RCC clinical trials (Kondagunta et al. 2004). From the previous studies above, it appeared 
that Cav-1 can be utilised as diagnostic tool, prognostic indicator and also a possible 
therapeutic target in RCC. In our study, there was no difference in the overall or membranous 
expression between RO and chRCC. However, there was distinctive difference in the staining 
characteristics, with chRCC displaying diffuse staining in the peripheral cytoplasmic regions 
and a perinuclear halo devoid of staining compared to the patchy granular staining in RO. 
This difference in staining patterns may be useful in in distinguishing chRCC from RO.  
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5.5.3 Leptin and leptin receptor 
Obesity is considered a risk factor in many cancers, including renal cancers. The World 
Cancer Research Fund has estimated that 24% of incident kidney cancer cases in the United 
States can be attributed to adiposity (Ljungberg et al. 2011). With increasing obesity, there 
are raised serum Ob levels. Ob may act as a mitogenic promoter in renal tumourigenesis. Ob 
is a 16-kDa adipokine that is produced mainly, but not exclusively, by white adipose tissue. 
Others sites of production include the placenta, intestine, stomach, ovaries, bone marrow, 
brain, pituitary, liver, mammary epithelial cells and skeletal muscle. Ob levels are positively 
correlated with white adipose tissue mass, and are therefore increased in obesity. Its synthesis 
is influenced by insulin, tumour necrosis factor alpha (TNF-α), glucocorticoids, sex 
hormones and prostaglandins (Paz-Filho et al. 2011). Its expression is also stimulated by 
hypoxia (commonly found in solid tumours), through HIF-1 (Garofalo and Surmacz 2006). 
 
The main role of Ob is to regulate energy homeostasis by controlling energy intake and 
energy expenditure, through its action on the arcuate nucleus of the hypothalamus. It has 
additional effects in the endocrine and immune systems, including reproduction, glucose 
homeostasis, bone formation, tissue remodelling, and inflammation (Boguszewski et al. 2010; 
Kelesidis et al. 2010). Ob exerts its action through binding to the extracellular domains of 
leptin receptor (2 major isoforms): Ob-Ra (short form found in most cells) and Ob-Rb (long 
form found in hypothalamus, adipocytes, lungs and kidney) (Fantuzzi and Faggioni 2000). 
 
Ob binds to its receptor and activates different signalling pathways, such as the JAK/STAT 
(Janus Kinase/Signal Transducer and Activator of Transcription), MAPK (mitogen-activated 
protein kinase), PI3K/Akt (phosphatidylinositol 3-kinase/protein-kinase B), AMPK (5' AMP-
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activated protein kinase) and IRS (insulin receptor substrate) pathways, which affect cell 
proliferation and survival (Fruhbeck 2006). Ob is a pleiotropic hormone, being mitogenic, 
anti-apoptotic, pro-angiogenic, and pro-inflammatory in various cellular systems (Paz-Filho 
et al. 2011).  
 
Studies associating Ob and renal cancer are scarce. However, there is contradiction between 
the epidemiological and the molecular findings regarding the role of Ob in the pathogenesis 
of kidney cancer. In a case-control study that included 70 patients with RCC, serum Ob was 
inversely associated with cancer risk (OR: 0.53, CI: 0.28-0.99, p=0.05), which the authors 
attributed to the pro-immunogenic effects of Ob (Spyridopoulos et al. 2009). Conversely, 
higher serum Ob was an independent predictor of progression-free survival, and along with 
increased expression of ObR in renal tumour tissue, were also associated with tumour 
specimen venous invasion (Horiguchi et al. 2006a). 
 
ObR is present in human RCC cell lines (Caki-1, ACHN, 769P, A498, SKRC44 and 
SKRC49)and in the murine renal cancer cell line Renca. (Horiguchi et al. 2006b). In the 
murine cell, Ob induces invasiveness. In another in vitro study, Ob increased the proliferation 
and mobility capabilities of Caki renal carcinoma cells by up-regulating the expression of the 
JAK/STAT3 and ERK1/2 signalling pathways (Li et al. 2008). Ob also induces collagen gel 
invasion of non-tumorigenic kidney MDCK epithelial cells through PI3K-, Rho-, and Rac-
dependent signalling pathways (Attoub et al. 2000). Ob's effects on lymphangiogenesis, 
mediated by Akt and ERK1/2, and on lipid and protein biosynthesis, mediated by acyl-
coenzyme A: cholesterol acyl transferase (ACAT), may explain the roles of Ob in the 
pathogenesis and in the phenotype of renal cancer (Drabkin and Gemmill 2010). Ob has also 
been linked to mTOR activation that links nutrient signalling to cell growth, proliferation and 
167 
 
cancer (Dann et al. 2007). Furthermore, Ob together with other cytokines (IL-6, TNF) 
potently activates STAT3 signalling processes which include cell survival and proliferation in 
renal neoplasia (Horiguchi et al. 2002). 
 
Despite all the above studies on Ob and ObR, there was surprising paucity in the research 
into IHC of Ob and ObR on human renal tumour tissue; as most studies have concentrated on 
serum leptin and adiponectin levels instead. There was only one study by Horiguchi et al. 
which only analysed ObR expression (and not Ob expression) in 57 human renal tumour 
specimens (39 ccRCC, 18 others) and their corresponding serum Ob levels (Horiguchi et al. 
2006a). Therefore, we believe our study which examined IHC of Ob and ObR in a cohort of 
75 human renal tumour specimens is the largest to date, and the first to characterise and 
compare the IHC staining of Ob and ObR in less-studied subtypes of renal tumours (chRCC 
and RO), together with the most common ccRCC.  
 
In the normal renal tissue of the present study, Ob and ObR expression was noted mainly in 
the cytoplasm, with minimal nuclear regions of proximal and distal tubular cells and vascular 
endothelial cells. In ccRCC, there was moderate cytoplasmic, membranous and nuclear Ob 
and ObR expression. In chRCC, there was moderate cytoplasmic and nuclear Ob and ObR 
expression. In contrast, RO had intense diffuse cytoplasmic and nuclear expression. 
Horiguchi et al showed that ObR expression was predominantly cytoplasmic and 
membranous in tumour tissues (39 ccRCC, 18 others); with 10/38 ccRCC and 12/18 others 
having higher staining intensity than the staining intensity of vascular endothelial cells 
(Horiguchi et al. 2006a).  
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As described above, Ob and ObR IHC was significantly higher in tumour than in normal 
kidney tissue. Overall expression of Ob and ObR was highest in RO compared to chRCC and 
ccRCC. On closer scrutiny of overall, nuclear and membrane intensities of Ob and ObR in 
comparing chRCC and RO, Ob nuclear expression in RO had significantly higher intensity 
compared to chRCC. This important finding may prove to be helpful in the distinction 
between chRCC and RO. Ob could be added to the existing panel of useful IHC biomarkers. 
The exact reason or mechanism behind the more intense nuclear staining in RO compared to 
chRCC is yet to be determined. This is the first study to investigate Ob and ObR expression 
in chRCC and RO. Further studies investigating the role and mechanistic pathway for leptin 
and its receptor in RCC tumourigenesis are required. One possible explanation for high RO 
expression lies in the abundance of mitochondria in RO compared to scanty presence in 
chRCC. In breast cancer cell lines, Ob has been shown to improve mitochondrial biogenesis 
and dynamics with an amelioration of oxidative stress and higher mitochondrial ATP 
production, leading to tumoral growth (Blanquer-Rosselló et al. 2015). Nevertheless, this 
initial IHC result on Ob and ObR in ccRCC, chRCC and RO should enhance further studies 
in this respect on larger human renal tumour samples and subtypes. 
 
5.5.4 Kidney injury molecule-1 
KIM-1 was identified as the most highly upregulated protein in the proximal tubule of the 
kidney after acute or chronic insults (Bonventre 2014). KIM-1 (also known as T cell 
immunoglobulin domain and mucin domain protein 1 and hepatitis A virus cellular receptor 
1) is a type-1 membrane glycoprotein which contains an extracellular immunoglobulin- and 
mucin-like domain, with N- and O-glycosylation sites. It has a transmembrane domain and 
short intracellular domain with intracellular tyrosine phosphorylation sites. The ectodomain is 
heavily glycosylated and stable and appears in the urine after injury (Bonventre 2014).  
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The main functions of KIM-1 include: 1) As a phosphatidylserine receptor, it recognises 
apoptotic cells and directs them to lysosomes (Ichimura et al. 2008); 2) As a receptor for 
oxidized lipoproteins; and 3) As a unique first molecule that, although not also present on 
myeloid cells, can transform kidney proximal epithelial cells into semi-professional 
phagocytes to enhance clearance of dead cells (Bonventre 2014). Therefore KIM-1 has an 
important role in mounting an immune response in acute kidney injury. KIM-1 is approved 
by the United States Food and Drug Administration and the European Medicines Agency for 
preclinical assessment of nephrotoxicity and, on a case-by-case basis, for clinical evaluation. 
 
In renal cancers, KIM-1 has been shown to be expressed in various RCC, especially ccRCC 
and papillary RCC, both of proximal tubular origin; and urinary KIM-1 is also a good 
biomarker for RCC detection (Han et al. 2005; Zhang et al 2014). The authors concluded that 
KIM-1 expression occurs with dedifferentiation of the proximal tubule epithelial cell, which 
is also a property of RCC cells that are derived from the proximal tubule (Bonventre 2014). 
One proposed mechanism in ccRCC tumourigenesis involved KIM-1 inducing IL-6 
expression which activates STAT-3/HIF-1A axis in ccRCC derived cell lines and thus 
promotes expression of growth and angiogenic factors on tumour, and likely in non-tumour-
associated cells that would help tumour growth and metastasis (Cuadros et al. 2014).  
 
In the present study, minimal cytoplasmic staining of KIM-1 was noted in proximal tubular 
cells in normal renal tissue adjacent to the tumours. This result is similar to other published 
reports where KIM-1 expression was noted in adjacent normal tubular cells, irrespective of 
whether or not RCC tumour cells were negative or positive (Cuadros et al. 2014; Han et al. 
2005). The authors argued that KIM-1 expression in normal adjacent tubular cells was due to 
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tubular injury from compression by adjacent tumour cells or adjacent cells undergoing early 
stage of cancer transformation (Han et al. 2005); and probably related to an endogenous 
condition of individuals at risk of developing these renal tumours (Cuadros et al. 2014).  
 
In the renal tumour tissue, diffuse intense cytoplasmic and membranous KIM-1 
immunostaining was noted in the majority of ccRCC. Previous reports have also showed 
strong expression of KIM-1 in ccRCC (Han et al. 2005; Lin et al. 2007; Zhang et al. 2014). 
There was also diffuse cytoplasmic and nuclear expression in RO, whereas there was minimal 
or none in chRCC. Interestingly, the overall expression of KIM-1 in RO was significantly 
increased compared to chRCC. This is a novel result and may prove to be an important 
distinguishing feature of KIM-1 in separating chRCC from RO.  
 
From the present study, the majority of RO show overexpression of KIM-1 whereas majority 
of chRCC were negative. The poor expression of KIM-1 in chRCC concurred with other 
previous IHC results where the majority of chRCC were negative for KIM-1. However, our 
findings of KIM-1 expression in 80% of RO was certainly different to previous reports where 
RO were all negative for KIM-1 immunostaining (Han et al. 2005; Zhang et al. 2014) or only 
(4/41) 9.75% of ROs expressed KIM-1 (Lin et al. 2007). The reason behind our unique 
increased expression of KIM-1 in RO with minimal/absent expression in chRCC from the 
Australian cohort of patients remains uncertain. There were notable differences between our 
study which analysed renal tumour sections of 30 chRCC and 15 RO as compared to IHC on 
tissue microarray sections (25 chRCC and 25 RO) in Zhang et al (2014). In Han et al (2005), 
there was positive staining on tumour slides of 1/6 chRCC and 0/8 other renal tumours 
(which included oncocytoma, angiomyolipoma and transitional cell carcinoma of renal 
pelvis). In Lin et al (2007), they noted KIM-1 expression in 9.75% of 15 RO and none in 16 
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chRCC tissue microarray samples. So our results of increased KIM-1 in RO compared to 
minimal in chRCC support the expression pattern seen in the report by Lin and colleagues. 
Nevertheless, the increased expression of KIM-1 in RO compared to chRCC in this initial 
study can be further validated with larger national and international studies. Studies involving 
larger cohorts of RCC subtypes, analysing KIM-1 immunostaining, and measuring urinary 
KIM-1 pre and post-nephrectomy may allow correlation with the urinary and tissue levels to 
assess and validate the utility of KIM-1 in RCC.  
 
Urinary KIM-1 levels have also been closely associated with renal cancers, especially ccRCC 
and papillary RCC. In the first study, Han et al showed that in all 5 RCC patients with 
detectable prenephrectomy urinary KIM-1, there was either complete disappearance or 
marked reduction after nephrectomy. They concluded that the cleaved ectodomain of KIM-1 
can be detected in the urine of patients with RCC and may serve as a new biomarker for early 
detection of RCC (Han et al. 2005). Following this, another study reported signiﬁcant 
reduction in urinary KIM-1/urinary creatinine after nephrectomy in the KIM-1 positive group 
(8 ccRCC and 4 papillary RCC), suggesting that urinary KIM-1 may serve as a surrogate 
biomarker for kidney cancer and a non-invasive pre-operative measure to evaluate the 
malignant potential of renal masses (Zhang et al. 2014). Therefore, urinary KIM-1 can be 
used as a non-invasive diagnostic screening tool for patients at risk of RCCs and also serve as 
a prognostic surveillance investigation following RCC nephrectomy. 
 
In summary, there might be differences in the urinary KIM-1 levels in all renal tumour 
subtypes; in particular inpatients with RO having increased urinary KIM-1 levels compared 
to patients with chRCC. A small study which compared urinary KIM-1 between renal tumour 
subtypes (24 ccRCC, 4 pRCC and 3 chRCC) and controls (which included 3 oncocytomas, 3 
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benign lesions and 9 non-functioning kidneys) failed to reveal any differences among the 
groups (Shalabi et al. 2013). However, as can be seen, there were relatively small numbers of 
chRCC and RO in that study. Therefore future studies investigating larger samples to 
compare urinary KIM-1 levels in renal tumour subtypes might be useful.  
 
5.5.5 S100 calcium-binding protein A1 
A member of calcium-binding proteins, S100A1, has been found in renal cell neoplasms. 
This protein is a member of the S100 family, the largest subgroup of the EF-hand proteins 
(Schafer and Heizmann 1996). S100A1 has been reported to be involved in different 
biological activities such as transduction of intracellular calcium signalling, cytoskeleton-
mediated interactions, as well as cell cycle progression and cell differentiation (Li et al. 
2005). Therefore it has been studied in a variety of tumours, including renal cancers.  
 
From the present study, S100A1 immunostaining was noted in nuclei and cytoplasmic 
regions of proximal tubular cells and collecting ducts in adjacent non neoplastic renal 
parenchyma. This is similar to previous published results (Rocca et al. 2007). In ccRCC, 
strong S100A1 immunostaining in cytoplasmic and membranous regions of tumour cells was 
noted, while there was only patchy minimal cytoplasmic expression in chRCC and strong 
diffuse cytoplasmic and nuclear staining in RO. In comparing the recent studies examining 
IHC expression of S100A1 in renal neoplasms, ccRCC was found to have expression in 66–
73% of cases and 67–94% of pRCC. The highest level of expression was identiﬁed in RO, 
with 92–93% of cases demonstrating reactivity with S100A1 compared to 0–6% of chRCC, 
which have been found to be negative (Kim et al. 2009; Li et al. 2007; Rocca et al. 2007). 
Recently, Kuroda et al reported that IHC cytoplasmic expression of S100A1 was 100% of 
ROs compared to only 30% of chRCC (Kuroda et al. 2011). 
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The IHC results of the present study were in concordance with the differential 
immunostaining of S100A1 in RO when compared to chRCC. There were apparent higher 
overall and nuclear expressions of S100A1 in RO over chRCC in our cohort, but this 
unfortunately did not reach statistical significance. This is perhaps related to the small RO 
sample size of 15 cases. Nevertheless, the majority of the RO in the study expressed diffusely 
intense cytoplasmic and nuclear staining of S100A1 compared with minimal patchy 
cytoplasmic expression in chRCC, similar to other published reports. Following our meta-
analysis as well, the pooled OR of RO compared to chRCC for S100A1 staining is 100. 
Therefore, S100A1 is another reproducible IHC biomarker from a panel of IHC 
biomarkers,that can differentiate RO from chRCC (Ng et al. 2016). Other authors have 
suggested a panel of CK7, S100A1 and claudin 8 (Kim et al. 2009) and the utility of cluster 
analysis of S100A1 and CK7 (Carvalho et al. 2011) which could discriminate the two 
entities. Recently, Conner et al reported the usefulness of S100A1 IHC in fine needle 
aspirates and core needle biopsies which showed positivity in 80% of ROs versus 8% in 
chRCC (Conner et al. 2015); which could provide valuable distinction between the two 
entities in selective groups of patients with indeterminate small renal masses. 
 
The main limitation in this research into IHC biomarkers was the sample size of RO. A larger 
number of RO, for example, n= 30, may have strengthened the power of statistical analysis. 
However, incidence of RO is low, only 3-5% of all renal tumours (both benign and 
malignant). We wanted renal tumour slides from approximately the same range of years 
(2012-2015), from one dedicated uropathology centre. Larger multi-institutional studies 
investigating larger case numbers of chRCC and RO may provide stronger statistical 
comparisons of the biomarkers. 
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5.5.6 Summary of IHC results 
Various IHC biomarkers that could differentiate chRCC from RO were investigated. Most of 
the IHC staining patterns of the various biomarkers matched other previous published reports. 
In the present study, not only qualitative analysis of the expression and their differences in 
staining patterns and locations, but also quantitative expressions analysis (overall, membrane 
and nuclear) via morphometry using Aperio Imagescope, was presented.  
 
The results gained from our study are summarised in Table 5.2, with the significant results 
highlighted in red and bold. In summary, chRCC had higher CK7 overall expression 
intensity compared to RO and a difference in Cav-1 staining patterns between the two 
subtypes was recorded. RO recorded higher Ob nuclear expression and higher KIM-1 overall 
expression than chRCC. 
 
5.5.7 Clinicopathological data of Renal Tumour Biobank. 
As mentioned in Chapter 2, serum, urine and renal tumour and normal tissues have been 
collected from patients undergoing nephrectomy for suspected renal tumours and stored in 
the Renal Tumour Biobank. The clinicopathological data from these patients have also been 
collected to provide a comprehensive database. As seen in Table 2.1, 202 patients have been 
recruited and samples obtained. The ratio of male to female was 1.67 : 1, mean age of 57 
years, mean body mass index (BMI) of 28.9. Almost two thirds of patients had hypertension 
in their past medical history, with a mean eGFR of 72.7 ml/min/1.73m
2
. From this cohort, 
high BMI and hypertension are 2 of the risk factors known to be associated with RCC risk. 
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Mean tumour size was 4.5cm and not surprisingly most patients presented at clinical stage T1 
(78.2%), followed by T2 (7.9%), T3(8.5%), T4(2.9%) and 5 patients (2.5%) underwent 
cytoreductive nephrectomy due to M1 disease at presentation. The vast majority of patients 
seen at early T1 stage support the rise in early detection of incidental small renal masses due 
to increasing usage and availability of radiological scans. 
 
The majority of the renal tumours were ccRCC (64.8%), pRCC (10.9%), chRCC (9.9%), 
oncocytoma (4.5%), multilocular cystic RCC (2.5%), clear cell tubulopapillary RCC (2%) 
and others (benign and malignant) (5.4%). These proportions of renal tumour subtypes are 
typical of the representation of renal tumour pathology. With the ongoing collection of 
samples, these proportions of renal tumours will increase and provide a large comprehensive 
bank of samples for future research. 
 
Currently, two research projects from our group have started using data and samples collected 
in the Renal Tumour Biobank: 
(1) The development of a comprehensive clinical assessment tool that can be used to 
stratify patients into risk groups for developing adverse renal functional outcomes 
post-nephrectomy. The aim of the project is to evaluate the risk of CKD progression 
in patients following tumour nephrectomy, through evaluation of  blood, urine, tissue 
and clinical data on a short and long term follow up basis. 
(2) Identification of distinct metabolic changes that occur amongst RCC subtypes using 
magnetic resonance spectroscopy (MRS). The aim is to characterise metabolic 
patterns that occur across tumour, normal, urine and serum samples that are capable 
of accurately differentiate renal tumour subtypes. The results analysed will be 
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translated to clinical trials to assess feasibility of non-invasive MRS to accurately 
diagnose benign from malignant renal lesions, especially small renal masses.  
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Table 5.2 Summary of IHC biomarkers in differentiation of chRCC and RO 
Biomarker ChRCC RO  p 
value 
Cytokeratin 7  
Overall expression 
+++ - 0.03 
Caveolin-1 
Overall expression 
Membrane expression 
 
++ 
++ 
Diffuse cytoplasmic, peripheral 
enhancement, perinuclear halo 
 
+ 
+ 
Patchy cytoplasmic 
 
ns 
ns 
Leptin 
Overall expression 
Membrane expression 
Nuclear expression 
 
+ 
+ 
+ 
 
++ 
++ 
+++ 
 
ns 
ns 
0.02 
Leptin receptor 
Overall expression 
Membrane expression 
Nuclear expression 
 
+ 
+ 
+ 
 
++ 
++ 
++ 
 
ns 
0.08 
ns 
Kidney injury molecule-1 
Overall expression 
 
- 
 
+ 
 
0.002 
S100A1 
Overall expression 
Nuclear expression 
 
+ 
+ 
 
++ 
++ 
 
ns 
0.06 
Red bold = biomarkers with significant results which can differentiate chRCC and RO 
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CHAPTER 6 
CONCLUSION AND FUTURE DIRECTIONS 
 
6.1 OVERVIEW 
The incidence of renal tumours is on the rise in the last decade, largely due to diagnoses of 
incidental renal masses arising from widespread availability of radiological imaging. Despite 
advances in radiological imaging and improved techniques of renal lesion biopsy, accurate 
diagnosis often eludes clinicians and final pathological diagnoses are only made post-
operatively. A significant proportion of these renal lesions are benign, thus subjecting 
patients to unnecessary surgery and significant nephron loss. Accurate preoperative 
diagnostic non-invasive molecular biomarkers which can accurately distinguish benign from 
malignant renal tumours can potentially reduce unnecessary surgery, preserve nephron mass 
and subsequently reduce development of chronic renal insufficiency with its associated 
cardiovascular mortality. 
 
Another difficult diagnostic dilemma following surgery is the histopathological analyses of 
certain subtypes of renal tumours where morphological features overlap. The distinction of 
malignant chRCC from benign RO is one such diagnostic dilemma that can pose significant 
difficulties to pathologists as histological, morphological and histochemical features often 
overlap between the two entities. Accurate diagnosis of the pathological specimens is crucial 
and dictates further surveillance and potential management for malignant chRCC as 
compared to benign RO cases, where an expectant approach is sufficient. Therefore novel 
and reproducible effective biomarkers which can aid in the differential diagnoses of chRCC 
from RO are needed.  
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RCC still remain a lethal disease as 30% of patients still present with metastases and 30-40% 
will eventually die from their cancer due to tumour recurrence and progression (Lam et al. 
2008). In the last two decades, molecular targeted therapies like tyrosine kinase inhibitors and 
mTOR inhibitors have revolutionalised the management of metastatic RCC. Nevertheless, 
despite the numerous adverse effects of these agents, there is modest improvement in overall 
survival, but ultimately all patients succumb to this disease. Therefore newer therapeutic 
targets are required to achieve the utopian curative stage. 
 
Further characterisation of molecular signatures for renal tumour subtypes will help solve 
some of the diagnostic and therapeutic issues mentioned above. This will in turn lead to 
improved treatment algorithms with reduction of overtreatment of benign/indolent renal 
lesions leading to efficient management of healthcare costs. Therefore identification of such 
biomarkers which can aid in the differentiation of chRCC and RO is crucial and forms the 
basis of this research project. The relevance of this research result can then be translated to 
provide useful interventions into clinical urological day to day management of renal tumours. 
 
Gene expression profiling techniques have provided valuable information of the differential 
gene expression profiles of various renal tumour subtypes (Higgins et al. 2003; Takahashi et 
al. 2003; Tan et al. 2004). In two studies investigating the differential gene expression 
profiles between chRCC and RO, Rohan et al (2006) identified 5 target genes (AP1M2, 
MAL2, PROM2, PRSS8, and FLJ20171) that had differential expression patterns; and 
Yusenko et al (2009) identified CD82 and S100A1 as valuable markers for chRCC as well as 
AQP6 for RO, but found that these genes were expressed at the protein level in other types of 
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kidney cancers albeit at a low frequency and low intensity, and that none of the selected 
genes marked exclusively one type of kidney cancer. Nevertheless these gene expression 
profiling studies may lead to the discovery of useful biomarkers that can be used with IHC.  
In this research, we have concentrated on protein as the translated molecule and the technique 
used more-commonly by diagnostic pathologists, that of IHC, to assess useful biomarkers in 
differentiating chRCC from RO. 
 
This PhD research is centred upon the hypothesis that there are distinct differences in the 
molecular signatures between renal cancers that can be exploited to distinguish between 
malignant chRCC and benign RO phenotypes. The aims of this research included: 1) 
identification of panel of IHC biomarkers which can effectively differentiate chRCC from 
RO through a comprehensive meta-analysis approach; 2) assessment of the different 
molecular profiles of renal cancers via immunohistochemistry and morphometry techniques 
using selected biomarkers on renal tumour and normal tissue samples; 3) analyses of IHC 
biomarkers that are useful in differentiating chRCC from RO via IHC and Aperio 
Imagescope morphometry techniques; and 4) creation of comprehensive Renal Tumour 
Biobank from nephrectomy specimens. I believe I have managed to provide some valuable 
recommendations in regards to the utility of unique molecular signatures of chRCC and RO, 
which can be translated into urological clinical practice. 
 
6.2 SUMMARY OF MAJOR RESULTS 
6.2.1 Meta-analysis  
The clinical diagnostic dilemma and difﬁcult histopathological differentiation of RO from 
chRCC still persist. This systematic review and meta-analysis has revealed numerous IHC 
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biomarkers that have been investigated and regularly used across laboratories to aid in 
differentiating chRCC and RO. PubMed database was used to identify relevant literature. The 
primary end point was comparison of positive immunostaining of the biomarkers in chRCC 
and RO, with extracted data used to calculate OR and 95% CI and statistical I
2
 test of 
heterogeneity for multiple studies. This meta-analysis has provided us with a panel of the ten 
most relevant IHC biomarkers that may help to discriminate the two entities. This panel of 
biomarkers includes amylase α1A, Wnt-5a, FXYD2, ARPP, CD63, TGFβ1, CK7, S100A1, 
caveolin-1 and claudin-7. From these results, we studied the IHC expressions of CK7, Cav-1 
and S100A1 in our laboratory. Further large international collaborative studies are needed to 
validate the clinical usefulness and reproducibility of these IHC biomarkers.  
 
6.2.2 NF-κB 
NF-κB importantly affects target genes involved in immunity, cellular proliferation, pro- or 
anti-apoptotic functions and carcinogenesis. In addition, NF-κB is unique in RCC as it 
regulates all important aspects of RCC biology that pose challenge to conventional therapy: 
resistance to apoptosis; angiogenesis; and multi-drug resistance (Morais et al. 2011). NF-κB 
IHC analyses on a cohort of RCC patients provided interesting molecular NF-κB signatures. 
Most studies in the past have focussed on p65 and p50 subunits of NF-κB in human RCC 
tissue (Kankaya et al. 2015; Meteoglu et al. 2008; Oya et al. 2003; Ozbek et al. 2012). From 
our knowledge, this is the largest and most comprehensive series of IHC analyses on the 
subunits of NF-κB family in human RCC tissue. There was higher IHC expression of p65 
(overall, nuclear and membrane) and lower IHC expression of p52, p50 and cRel (overall, 
nuclear and membrane) in RCC tumour compared to normal counterparts. Higher p65 
nuclear, p50 overall and p52 overall and nuclear expressions were associated with worse 
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cancer specific survival; with higher p65 nuclear and p50 overall expressions shown to be 
independent prognostic factors in RCC survival. These results have provided us with new 
insights on the molecular profiles of NF-κB subunits in RCC tumourigenesis. This better 
understanding will encourage more research into the NF-κB family and pave way for future 
targeted NF-κB subunit specific therapeutic pathways. 
 
6.2.3 IHC results of various biomarkers 
The analyses of various IHC biomarkers in our human RCC and adjacent matched normal 
renal tissue and Aperio morphometry (overall, membrane and nuclear expression) assessment 
included CK7, Cav-1, Ob, ObR, KIM-1 and S100A1. Biomarkers CK7, Cav-1 and S100A1 
were selected based on the meta-analysis, while Ob, ObR and KIM-1 were novel biomarkers 
chosen to assess their ability in differentiating chRCC from RO. Most of results from this 
study for CK7, Cav-1 and S100A1 matched the previous published reports.  However, the 
positive IHC results that could aid in the differentiation of chRCC from RO include: higher 
CK7 overall expression in chRCC compared to RO; higher Ob nuclear expression; higher 
KIM-1 overall expression  in RO compared to chRCC; and diffuse cytoplasmic staining with 
peripheral enhancement and perinuclear halo Cav-1 pattern in chRCC compared to patchy 
cytoplasmic staining pattern in RO. Interestingly, 2 new findings were reported of increased 
Ob nuclear expression and KIM-1 overall expression in RO over chRCC. These new findings 
need to be validated with larger samples in future but, potentially, they could be used as 
differential IHC biomarkers in the differentiation of the two tumour subtypes. 
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6.3 FUTURE DIRECTIONS 
 
Future directions based on the results of this thesis have been discussed to some extent in 
each of the original research chapters. From the meta-analysis results, our ﬁndings 
recommended a panel 10 IHC biomarkers (amylase α1A, Wnt-5a, FXYD2, ARPP, CD63, 
TGFβ1, CK7, S100A1, Cav-1 and claudin-7) that have demonstrated their ability to 
differentiate chRCC and RO. It is hoped that further international large-scale studies will be 
performed on these 10 biomarkers in the future to further consolidate or afﬁrm the 
reproducibility of similar results in differentiation of RO from chRCC. Hopefully, there will 
also be further more specific novel biomarkers that can be discovered in this respect.  
 
In addition, further studies can delve into the correlation between sera and urine levels of 
these biomarkers in relation to these two renal tumour subtypes. Therefore, non-invasive 
serum or urine levels of these biomarkers can also be investigated to assess if they can 
discriminate a benign lesion like RO from malignant chRCCs or from other more aggressive 
RCCs.  
 
With respect to NF-κB, there is extensive research in targeting the NF-κB pathway for 
therapeutic purposes, especially in metastatic RCC. Recently, a study showed that targeting 
the phospholipase Cε (PLCε)/NF-κB/VEGF pathway may be a potential therapeutic strategy 
for preventing RCC progression (Du et al. 2014). Another study also indicated that p65 NF-
κB signalling pathway may be involved in osteopontin-mediated ccRCC progression, partly 
by anti-apoptotic effect; thus both molecules can be potential targets of therapeutic 
intervention in ccRCC (Matusan-Ilijas et al. 2011).  
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Our study showed the unique molecular expressions of various subunits of NF-κB (p65, p50, 
p52 and cRel), but further studies are needed to build upon targeting these subunits pathways 
(either singly or in combination) as potential therapeutic pathways. These studies could 
concentrate particularly on the roles of p65, p50 and p52 subunits, as these were shown to 
affect cancer specific survival outcomes in our cohort of patients. Based on these findings, it 
is worthwhile that these patients with increased expression of p65, p50 and p52 in their RCC 
tissue, will need closer surveillance and more aggressive targeted treatment if there was RCC 
progression. From another diagnostic perspective, further larger international studies could 
also assess the role of various NF-κB subunits in the differentiation of renal tumour subtypes, 
especially chRCC and RO.  
 
As shown in Chapter 5, where a panel of selected biomarkers was investigated, the results of 
IHC for CK7 concur with other previous published results that there was increased 
expression of CK7 in chRCC as opposed to only minimal patchy expression in RO. It has 
proven to be a reliable discriminatory IHC biomarker for chRCC from RO. Further work 
should focus on pathophysiology responsible for the increased expression of CK7 in chRCC 
compared to minimal or patchy in RO as both tumours originate from intercalated cells of 
collecting duct, which also expresses CK7. One study proposed that most biomarkers that are 
expressed in the collecting duct system may show decreased expression or disappear in many 
RO because cell-to-cell interactions of the majority of RO decrease during tumorigenesis 
(Ohe et al. 2012). In addition, the association of expression of CK7 in chRCCs with cancer 
specific survival should also be investigated. Perhaps expression intensity of CK7 could be a 
prognostic predictor for the smaller aggressive group of malignant chRCC phenotype which 
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will metastasise, unlike the majority of chRCC cases where risk of metastasis is low. Also, 
there is paucity of research investigating the utility of CK7 as a therapeutic target in RCC 
management. 
 
In the case of Cav-1, a different unique staining pattern of chRCC compared to RO was noted 
as the distinguishing feature of this biomarker. In fact, its role as a differential IHC biomarker 
with more intense positivity in chRCC over RO has been discussed in several previous 
studies. Also of note is the association of increased levels of Cav-1 with poorer prognosis in 
RCC, suggesting its use as not only a diagnostic but a prognostic biomarker (Campbell et al. 
2013; Joo et al. 2004; Liu et al. 2015). Therefore further research should also focus not only 
on its diagnostic function but also as a prognostic biomarker in serum and/or urine of RCC 
patients. 
 
One of the novel and interesting findings concerned Ob expression. Increased Ob nuclear 
expression in RO as compared to chRCC was identified. Further work should validate this 
finding on a larger scale and also investigate the mechanism behind this observed differential 
expression. As mentioned in Chapter 5 section 5.9.3, previous studies have investigated 
serum adipokines (leptin and adinopectin) and their relationship with obesity and RCC. In the 
study by Horigochi et al, serum leptin levels were higher in one group of renal tumours 
(granular cell carcinoma and papillary) compared to ccRCC (Horiguchi et al. 2006a). 
Perhaps, future study should focus on the serum Ob levels in a large cohort of RCC patients 
including chRCCs and ROs; as there might be differences in the serum levels of Ob in these 
various renal tumour subtypes. Furthermore, future studies should assess the association of 
serum leptin and Ob nuclear expression in RCC patients with respect to RCC progression and 
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cancer specific survival. Therefore, with funding support, we are planning to validate the IHC 
of Ob and ObR, and analyse the role and mechanistic pathway of Ob in obesity and RCC 
pathogenesis. We plan to characterise Ob and ObR amongst the RCC subtypes available in 
our Renal Tumour Biobank and correlate these with the serum leptin from these patients 
stored in the Biobank. 
 
KIM-1 immunostaining expression in RO was noted to be increased compared to chRCC in 
our study. This result is in contrast to most reported studies (Han et al. 2005; Zhang et al. 
2014). Nevertheless, we believe future larger international studies should be able to address 
this issue. Furthermore, urinary KIM-1 levels of patients with chRCCs and ROs should be 
investigated to assess if there are any significant differences. If there are reproducible 
significant different levels of urinary KIM-1, these can be correlated with the expression of 
KIM-1 in the RCC tissue. Urinary KIM-1 levels of patients with various renal tumours need 
to be further assessed to see whether there are any differences between tumour subtypes, 
(especially benign versus malignant phenotypes) and also if there are any changes in levels 
post resection of tumours. The utility of urinary KIM-1 can then be an invaluable non-
invasive diagnostic tool in workup of indeterminate renal lesions and also a surveillance 
technique in RCC patients following treatment. Since KIM-1 has been shown to be a useful 
urinary biomarker, we are planning to utilise the urine and renal tumour tissue samples stored 
in the Renal Tumour Biobank to compare the various urinary levels of these patients with 
different renal tumour subtypes and correlate with KIM-1 IHC expression in the tissue 
samples. We hypothesise that different renal tumour subtypes will have varying levels of 
urinary KIM-1 pre and post operatively. 
 
188 
 
One hypothesis is that different renal tumour subtypes will have different ratios of serum 
leptin to urinary KIM-1 levels. Future research from our laboratory will compare serum leptin 
and urinary KIM-1 from our stored samples and correlating them to the histology. This will 
hopefully pave way to non-invasive investigation of renal tumour subtypes, especially 
chRCC and RO, so that in the future, patients with radiological diagnoses of indeterminant 
small renal mass may only require serum leptin and urinary KIM-1 analyses to denote the 
renal tumour subtype, both benign and malignant. 
 
Following from this panel of results on the differentiation of chRCCs and ROs so far, a 
worthwhile study in near future that we will explore in our lab will be to analyse the efficacy 
of IHC on these panel of CK7, Cav-1, Ob, S100A1 and KIM-1 in ex vivo tissue core biopsy 
obtained from our nephrectomy renal tumour samples. One study has shown the 
improvement in diagnostic accuracy for 4 major renal tumour subtypes (ccRCC, pRCC, 
chRCC and RO) from following the utilisation of panel of IHC stains (CAIX, CD117, 
AMACR, CK7, and CD10) in ex vivo tissue core biopsy from renal tumours (Al-Ahmadie et 
al. 2011), however, that study did not fully qualify the distinction between chRCC from RO. 
It will be interesting to apply our panel of CK7, Cav-1, Ob, S100A1 and KIM-1 IHC and 
assess the diagnostic implications on tissue core biopsies. If this study on ex vivo tissue core 
biopsy is successful in differentiating renal tumour subtypes, especially chRCC from RO, 
then this will improve the diagnostic classification of renal tumours on needle biopsy. We 
have also started collecting ex vivo tissue core biopsies (18G) from the renal tumour 
immediately following nephrectomy; and will perform IHC from our panel (CK7, Cav-1, Ob, 
KIM-1, S100A1) to assess their diagnostic accuracies in differentiating renal tumour subtypes 
especially chRCC from RO. Therefore, hopefully future diagnostic accuracies of renal mass 
biopsies can further be enhanced from our panel of IHC biomarkers. 
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Another future study planned will be the assessment of serum Ob and urinary KIM-1 levels 
in RCC and its association with their respective IHC expressions in RCC patients with 
various subtypes. Serum Ob and urinary KIM-1 levels might correlate well with their tumour 
IHC results, thus leading to the utility of sera and urine analyses instead of tissue analyses. 
Perhaps a non-invasive diagnostic algorithm incorporating serum leptin and urinary KIM-1 
levels could be predictive of renal tumour subtypes. If successful, this will definitely improve 
the sensitivity and specificity of diagnostic tests when combined with radiological 
characteristics of renal tumours and help clinicians discern benign from malignant renal 
lesions. 
 
Last but not least, the comprehensive creation and management of the Renal Tumour 
Biobank in CKDR in TRI will serve as invaluable source of clinicopathological data and 
serum, urine, renal tumour and normal renal tissue samples for further research projects. As 
mentioned in Chapter 5, serum, urine and tissue samples from the Biobank are being analysed 
with MRS to characterise molecular fingerprints of various renal tumours. Hopefully these 
results can be translated to clinical urological practice into distinguishing benign from 
malignant renal tumours. Numerous and important clinical and longitudinal follow up data 
can be obtained and analysed in this cohort of renal tumour patients. Furthermore, approved 
research projects locally and internationally involving renal tumours in the future can utilise 
the stored patient samples from the Biobank. Hopefully this future research work into RCC 
will further enhance our discovery and knowledge in this humbling disease of renal cancers. 
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 6.4 CONCLUSION 
The increasing detection of asymptomatic incidental renal tumours due to the widespread use 
of high resolution abdominal imaging for other indications is providing a significant clinical 
challenge. There is emerging concern regarding overdiagnosis, unnecessary treatment and 
treatment related harm including CKD. Current clinical practice dictates treatment of all solid 
lesions on the presumption they are malignant and contemporary surgical series continue to 
report significant numbers of unnecessary surgical and ablative procedures for benign and 
low malignant potential lesions.  Advances in imaging and renal lesion biopsy have not 
provided sufficient certainty in the preoperative diagnosis of indolent lesions to arrest this 
trend. There is an urgent need for ongoing development of molecular biomarkers that 
accurately distinguish benign and low malignant potential lesions.  
 
The application of these biomarkers to preoperative functional imaging techniques, urine and 
serum assessment and renal mass biopsy will ultimately result in the reliable characterization 
of lesions with no or limited malignant potential such as oncocytoma and chromophobe RCC. 
This will have a major clinical impact in reducing unnecessary intervention and treatment 
related harm. 
The results gained from this PhD research have provided insight to the expressions of various 
IHC biomarkers in different renal tumour subtypes. In addition, discriminatory IHC 
biomarkers have been shown to be useful in the differentiation of chRCC from RO. Further 
research can be built upon these results and will hopefully encourage the development of 
better diagnostic and therapeutic pathways for patients with renal tumours.  
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Consent Form 
 
 
Urological Diseases and Urological Cancer Research Now and in the Future 
 
 
1. I, the undersigned .......................................................... hereby consent to  
 my involvement in the above study. 
 
2. Include here the details of the procedure proposed including the anticipated length of time it will take, the 
frequency with which the procedure will be performed, and an indication of any discomfort, which may 
be expected. 
 
3. I acknowledge that the nature, purpose and contemplated effects of the study so far as it affects me 
have been fully explained to me by the research worker and my consent is given voluntarily.   I have 
also read and understand the Patient Information Sheet. 
 
4. Although I understand that the purpose of this research project is to improve the quality of medical care, 
it has also been explained that my involvement may not be of any benefit to me. 
 
5. I have been given the opportunity to have a member of my family or a friend present while the study was 
explained to me. 
  
6. I am informed that no information regarding my medical history will be divulged and the  results of any 
tests involving me will not be published so as to reveal my identity.  
 
7. I understand that my involvement in the study will not affect my relationship with my  medical 
advisers in their management of my health.   I also understand that I am free to  withdraw from the 
study at any stage without my future treatment being affected. 
 
8.* “I understand that where biological material is collected, it may be stored and used for future research 
purposes either with my further consent or (in circumstances where my further consent cannot be 
obtained or is impractical to obtain) with the further specific approval of a hospital ethics committee set 
up in accordance with the NHMRC guidelines”. 
 
9.* I give permission for the release of information regarding progress in this study to the study centre, on 
the understanding that while the study centre will keep confidential results under my name, no published 
study will identify me in any way. 
 
10.* I authorise the Greenslopes Private Hospital to allow access to relevant medical records to the 
investigators from Urology Department, Princess Alexandra Hospital.and Centre for Kidney Disease 
Research, School of Medicine, University of Queensland............................................ 
 
11. I have been told that this study has been approved by the Ethics Committee at Greenslopes Private 
Hospital. 
 
 
 
 
 Signed .................................................. Date ...................................... 
 
  
 
Greenslopes Private Hospital Consent Form - Version 1  - Formulated - 28.09.98 
 
 
* If applicable (eg No.9 is usually applicable to clinical trials.)   
* No. 10 applies when investigators from other institutions are involved. 
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PATIENT INFORMATION SHEET 
 
 Urological Disease and Urological Cancer Research Now and in the Future  
 
Principal Investigators:  Dr Keng Lim Ng                 Ph:- (07) 34437937  
 Research members:     Dr Simon Wood                 Ph:- (07) 3176 6946 
                                       Assoc Prof Glenda Gobe  Ph: (07) 31765655 
                                       Dr Cristudas Morais          Ph: (07) 34438012 
                                       Mr David Small                  Ph: (07) 34437938 
 
We would like to invite you to be involved with the Urology Department of 
Greenslopes Private Hospital by donating kidney and other urological tissue 
samples. Please read through all the documentation supplied before making your 
decision.  
 
Purpose of Tissue Collection.  
Scientific, medical and genetic research using human tissue, blood, urine and bodily 
fluid samples has played a significant role in advancing the knowledge and 
understanding of the causes and management of urological diseases. From this 
research, we are able to advise patients with particular urological diseases including 
cancers which treatment or combination of treatments is best for them. The success 
of this research relies heavily upon donations of kidney tissue, blood and urine 
samples for current research and for storage in a tissue bank for future research. 
 
Types of Research Projects  
There are several groups of doctors and scientists involved in research using 
donated tissue samples from patients. The small amount of kidney tissue, blood and 
urine stored in the tissue bank that we are asking you to donate can be used in a 
variety of ways in the:-  
 Development of new techniques to diagnose urological diseases and 
urological cancers  
 Identification of novel markers that can aid in diagnosis of kidney cancers 
 Development of new treatments and drugs to treat urological diseases and 
cancers  
 Determining the effects of new treatments and drugs on the growth of the 
cancer cells. This may also involve studies on laboratory animals.  
 Identification of viruses that may be implicated in the development of cancer  
 Establishment of Primary cell lines:- Cancer cells are cultured (grown) in the 
laboratory. Once the cells are successfully growing, the genes can be studied. 
This may involve adding or removing genes to the cells to determine if this 
produces changes to how the cells grow or behave  
 Production of Tissue Micro-arrays (TMAs) from specimens archived within 
diagnostic pathology laboratories. TMAs are a new investigative tool that will 
allow examination of multiple tissue samples under the microscope. 
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Further detailed information regarding current individual research projects and future 
projects using your donated tissue samples will be provided by the researchers 
mentioned above unless you specifically indicate that you do not want to receive this 
information. 
                                                                             
 What is involved in Donating Tissue and Information?  
 
Tissue Donation  
The kidney tissue removed during a diagnostic procedure or surgical procedure 
(operation) will be sent to the pathology department for routine tests. The results of 
these tests will be given to your doctor and will be used to plan your post-operative 
care.  
It is usual that not all of the kidney tissue removed at the time of your procedure is 
required for your diagnosis. We would like to collect and store small portions of fresh 
kidney tissue, already removed during your diagnostic or surgical procedure, for the 
purpose of research. This kidney tissue is collected in such a way that it will not 
interfere with your surgery, subsequent treatment or the pathologists’ examination of 
the specimen. We would also like to access any “left over tissue” that is not required 
for examination by the pathology department which is stored in the pathology 
department following routine testing.  
According to current legislation your tissue samples that are sent to pathology for 
routine analysis are retained for a period of up to 30 years. We would also like your 
permission to access these specimens.  
 
Additional Donation of Blood and Urine.  
We would also ask your consent to collect a small amount of blood (30mls or 
approximately 2 table spoons) and a urine sample from you, either at a routine 
hospital clinic visit, at the time of your surgery or during your hospital admission. 
These will be processed and stored in tissue bank for future biomedical and genetic 
research.  
It is possible that your blood and urine samples will be used in developing tests to 
determine genes or markers that may be involved in relation to particular types of 
new or developing therapies. This research may also look at genes that can predict 
the likelihood of your kidney tumour being benign or malignant. 
 
Information collection from your health records  
Information may be collected from you directly in the form of a questionnaire or from 
your medical records. We request your permission to collect information from your 
medical records about your past and present medical history, such as the names of 
any medication that you are currently taking, and for what medical condition, the 
results of any investigations, pathology reports from your operation and hospital 
admission and other ongoing information about your progress. All information will be 
collected, coded and stored for an indefinite period of time in accordance with the 
relevant State and Federal Privacy legislation.  
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Does the decision to Participate affect my care in any way?  
Deciding to donate tissue samples is voluntary and that refusal to participate will 
involve no penalty or loss of benefits to which you are otherwise entitled, and you 
may discontinue participation at any time without comment or penalty. If you do not 
wish your donated tissue samples to be used in certain types of research all you 
have to do is let us know and precautions will be taken so that your donated sample 
is not used.  
                                                                                     
Benefits of Participating  
It is not possible to predict whether any personal benefits to you will result from 
participation in these research projects. Research using your tissue may have the 
potential to provide invaluable information about the progression of kidney diseases 
and may provide information that will assist in studies of therapeutic treatments and 
the people it afflicts, improving the quality of medical care in the future.  
 
Possible Risks Associated with the Donation of Tissue Samples  
Tissue Collection  
This tissue is collected in such a way that it will not interfere with your surgery, 
subsequent treatment or the pathology department’s examination of the specimen. 
However, if the pathologist feels that there is potentially important information related 
to your diagnosis or treatment within the samples we have stored, then we will return 
the tissue for further examination by the pathologist. In most situations this will not be 
the case and we will be able to use this tissue for research. 
Blood Collection  
If blood is collected you might feel a slight pinch in your arm when the blood is taken 
and you could develop a small bruise.  
Urine collection 
If urine is collected, there are no possible risks associated with donation of this 
sample. 
By donation of the above samples, it will not jeopardise the treatment in anyway and 
if there were adverse events, then the providing team of doctors will provide the 
appropriate assistance. 
 
What is a Tissue Bank or BioBank?  
Tissue that may not be required for current research may be banked in a Tissue 
Bank or BioBank. A  BioBank is a large not-for-profit repository established for the 
collection of tissue samples from multiple sources for the purposes of use in future 
for biomedical, genetic analysis and genetic testing research projects.  
The term “tissue” includes the substance, structure and texture of which the human 
body or any part or organ of it is composed. The term “tissue” includes kidney 
tumour or healthy kidney samples, blood, and urine. It also includes tissue 
derivatives such as DNA, RNA and proteins obtained from human beings. Tissue 
samples that are banked will be banked in the Princess Alexandra Hospital and 
BioBank at Centre for Kidney Disease Research at Translational Research Institute.  
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Future Implications of donating Tissue Samples  
Every stored tissue is a potential source of genetic information (DNA). It is possible 
that future research using your sample may result in new genetic information about 
your risk of getting cancer or disease. If after extensive testing and validation, it is 
determined that the research findings may have significant implications for your 
family, and you have indicated you wish to receive further information, then this will 
be arranged with the help of appropriate counselling. It is your choice whether or not 
you wish to know any important results and we will ask you if you want us to tell you 
if we do find any information that has significant implications for you or your family. 
We will also ask you if you want the information to be given to a member of your 
family if we cannot contact you. We will not give any information about you to 
members of your family without your permission.  
 
How is My Privacy Protected?  
To maintain your privacy each participant is given a unique code that is used to track 
all tissue samples and data. All information that could possibly identify you, such as 
your name and date of birth, is removed and replaced with this code. However, this 
code can be potentially identifiable and traced back to you for the purpose of linking 
important medical information that can be of a benefit to you. Only authorised staff 
involved in this research will be able to de-identify the code and link this code with 
your information. These authorised staff are the members of the research team 
above. If your tissue sample is stored for the purpose of future research, researchers 
accessing these samples are only supplied with coded samples and data. This 
ensures that nothing that can identify you or your family will ever be sent to other 
researchers, or appear on any public or published reports.  
 
What are the Financial Implications of Donating Tissue?  
You will not receive any financial reward for donating tissue samples and 
information. In order to achieve our aims, we will seek to use the most advanced 
technology available and on some occasions this will only be possible through 
collaboration with other institutions or commercial companies. If new discoveries of 
potential diagnostic or therapeutic importance are made, we will protect this 
“intellectual property” through the filing of appropriate patents. The development of 
diagnostic agents and new medicines for cancer patients is likely to be very 
expensive and may require us to license our “intellectual property” to commercial 
companies. Such companies would be asked to undertake costly and complicated 
analyses and, in return, may require commercial rights to benefits arising from any 
discoveries. In this context, it should be noted that it is the whole collection of 
hundreds of samples that is of value and that each individual sample has in reality no 
value of its own. To allow such collaborations to proceed, you are asked to waive 
any future claim to financial benefit through participation in this research.  
 
Who will use my tissue?  
Your tissue sample may be used by local, interstate and international medical 
researchers for biochemical and genetic studies of kidney diseases. Prior to the use 
of tissue samples and associated information in current projects and the release of  
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tissue samples and associated information for future research release, these studies 
must have been approved by a Human Research Ethics Committee as required by 
the principles set out in the National Health and Medical Research Council of 
Australia (NHMRC) National Statement on Ethical Conduct in Research involving 
Humans, and the reporting Scientific Committee.  
 
Will I find out the results of the research using my donation?  
The results of any research done with your tissue are not likely to be available in the 
immediate future. This is because research can take a long time and must use tissue 
samples from many people before results are known. The researchers will not be 
able to give you the individual results from your samples except in exceptional 
circumstances.  
 
Information to other doctors or investigators 
That the subjects should advise the investigator of any other studies in which they 
are participating in. 
 
What if I change my mind?  
At any stage following tissue sample donation you have the right to withdraw any 
banked tissue samples. If you wish to have your tissue or blood or other samples 
withdrawn from this tissue bank or to stop access to your health information, please 
notify any member of the research team. A letter confirming removal of your tissue 
and or health information will be sent to you.  
 
Who can I contact if I have more questions?  
For further information: please contact Dr Keng Lim Ng (07 34437937) or you may 
also contact any research members mentioned above.  
 
Ethical Considerations  
All work undertaken on your donated tissue samples will comply with the NHMRC 
National Statement on Ethical Conduct in Research involving Humans and will have 
approval from the Greenslopes Hospital Research and Ethics Committee. 
 
Thank you for your time and contribution. 
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Please refer to the publication: Ng KL, Morais C, Bernard A, Saunders N, Samaratunga H, 
Gobe G, Wood S. 2016. A systematic review and meta-analysis of immunohistochemical 
biomarkers that differentiate chromophobe renal cell carcinoma from renal oncocytoma. 
Journal of Clinical Pathology 0 :1-11 at hyperlink :-  DOI:10.1136/jclinpath-2015-203585 
 
 
 
 
 
 
 
 
 
 
 
